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Recent research suggests that amino acids, such as leucine and isoleucine, can 
improve glucose tolerance in vivo and in vitro animal models by accelerating glucose 
uptake in peripheral tissues and stimulate glycogen synthesis in vitro in the absence of 
insulin. Our laboratory recently found that gavaging normal Sprague-Dawley rats with an 
amino acid mixture, composed of isoleucine, leucine, cystine, methionine, and valine, 
improved blood glucose response during an oral glucose challenge without an increase in 
the plasma insulin response. The blood glucose-lowering effect of the amino acid mixture 
was due to an increase in skeletal muscle glucose uptake. These results suggest that this 
amino acid supplement acutely improves muscle insulin sensitivity and blood glucose 
homeostasis. However, the effect of this amino acid mixture on glucose tolerance and 
muscle glycogen synthesis in humans has not been investigated. Some studies have also 
shown that daily supplementation or acute ingestion of amino acids may prevent muscle 
damage that occurs as a result of a prolonged, intense endurance exercise or strength 
training and therefore improves force production and exercise performance. However, the 
effects of the addition of an amino acid mixture to carbohydrate supplement on muscle 
damage after a prolonged endurance exercise, as well as on the subsequent anaerobic 
 vii 
exercise performance, have not been characterized. Therefore, in this series of two 
studies, the effects of an amino acid mixture, composed of isoleucine, leucine, cyctine, 
methionine, and valine, on glucose tolerance, muscle glycogen resynthesis, muscle 
damage, and anaerobic exercise performance were investigated. Study 1 demonstrated 
that our amino acid mixture lowered the glucose response to an OGTT in healthy 
overweight/obese subjects in an insulin-independent manner. Study 2 demonstrated that 
both high and low dosages of amino acid mixture were effective in lowering blood 
glucose response to a carbohydrate bolus in athletes postexercise. High dosage of amino 
acid mixture was more potent in glucose regulation by providing a higher insulin 
response and amino acid effect. However, our amino acid mixture had no effects on post 
exercise muscle glycogen synthesis, exercise-induced muscle damage or subsequent 
anaerobic performance. Taken together, the results of this research series suggest that an 
amino acid mixture, composed of isoleucine and 4 additional amino acids, attenuates the 
glucose response to a glucose bolus in an insulin-independent manner, but does not 
enhance muscle glycogen restoration following exercise or prevent exercise-induced 
muscle damage.  
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Chapter I: General Introduction 
 
Amino acids are the building blocks of proteins, and as such they are essential for 
the synthesis of structural proteins, enzymes, some hormones and neurotransmitters. 
Moreover, amino acids are also involved in numerous metabolic pathways. One of these 
metabolic pathways mediated by amino acids is for glucose transport. Recent in vivo and 
in vitro animal studies suggest that amino acids, such as leucine and isoleucine, may 
lower the blood glucose level by accelerating glucose uptake in skeletal muscle, which is 
insulin-independent (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007; Kalogeropoulou 
et al., 2008; Morifuji et al., 2009; Nishitani et al., 2002). The hypoglycemic effect of 
isoleucine holds great clinical significance for individuals with impaired glucose 
tolerance. The ability of isoleucine to lower blood glucose independently of insulin may 
provide a non-pharmaceutical therapy in the fight against insulin resistance and type 2 
diabetes mellitus.    
One possible factor that may have contributed to the potential hypoglycemic 
effect of amino acids is an acceleration on peripheral tissue glucose uptake. It is well-
known that skeletal muscle is the predominate tissue for the clearance of blood glucose 
and 70 to 80% of an oral glucose challenge is cleared by skeletal muscle (DeFronzo et al., 
1981; Katz et al., 1983; Willems et al., 1991). The storage form of glucose in the 
muscles, glycogen, is an important fuel source for moderate to high intensity exercise. It 
has been clearly demonstrated that aerobic endurance is directly related to the initial 
muscle glycogen stores (Bergstrom et al., 1967; Bergstrom and Hultman, 1966) and that 
strenuous exercise cannot be maintained once these stores are depleted (Bergstrom et al., 
1967; Bergstrom and Hultman, 1966; Hermansen et al., 1967). During intense physical 
training and tournament competitions, it is very important to speed up the recovery 
process when recovery time is limited and achieve optimal performance in up coming 
exercise. The faster the muscle glycogen can be replenished post-exercise, the greater 
ability to achieve optimal performance in the subsequent exercise. Therefore, amino acid 
supplementation during the recovery period may be beneficial for rapid and effective 
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replenishment of muscle glycogen and subsequent exercise performance, taking account 
of the hypoglycemic effects of amino acids. 
Another important aspect of endurance exercise recovery is muscle damage 
repair. Muscle damage not only limits performance due to delayed onset muscle soreness 
(DOMS), but it also compromises the muscle glycogen replenishment and limits muscle 
training adaptations (Costill et al., 1990; O'Reilly et al., 1987). This damage does not just 
occur during exercise, but can continue after exercise for many hours. It is well known 
that immediately after prolonged, intense endurance exercise, the body is in a catabolic 
physiological state in which blood insulin is low and cortisol and the catecholamines are 
high. Although there is an increase in muscle protein synthesis, its rate is exceeded by the 
rate of protein degradation such that there is a negative net protein balance. During the 
catabolic physiological state, considerate muscle tissue damage can occur. Proper nutrient 
supplementation post-exercise can shift a catabolic physiological state to an anabolic 
state. The ingestion of carbohydrate and protein or amino acids following exercise has 
been reported to promote protein synthesis and hasten recovery post-exercise, taking 
advantage of an enhanced insulin response, energy availability, and substrate for protein 
synthesis (Biolo et al., 1997; Koopman et al., 2005; Levenhagen et al., 2001; Tipton et 
al., 1999). Based on these studies in which an anabolic response was promoted by 
carbohydrate-protein/amino acids supplementation, it could be predicted that such 
supplementation would also reduce exercise-induced muscle damage.  
During intense physical training and tournament competitions, rapid recovery 
from the previous exercise is essential for achieving optimal performance in the 
subsequent exercise bout. Muscle damage that occurs as a result of a prolonged, intense 
endurance exercise could affect force production and result in a reduction in the 
subsequent anaerobic exercise performance. Some studies also suggest that muscle 
glycogen status influences anaerobic power generation and capacity for high-intensity 
exercise (Lacombe et al., 2001; Langfort et al., 1997). Therefore, anaerobic performance 
during a subsequent exercise bout maybe highly influenced by nutrient supplementation.  
Therefore, this series of studies aimed to investigate the effects of an amino acid 
mixture on glucose metabolism and exercise recovery in humans. Study 1 investigated 
whether the amino acid mixture attenuates blood glucose response during a glucose 
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challenge in healthy overweight/obese adults. An overweight/obese population was 
chosen because weight is considered the single strongest predictor of type 2 diabetes. 
After we found a significant effect of the amino acid mixture on blood glucose 
regulation, we continued to investigate the effects of the same amino acid mixture on 
blood glucose homeostasis, muscle glycogen synthesis, muscle damage markers, and 
subsequent anaerobic performance post prolonged exercise in trained athletes. In 
addition, we examined whether this amino acid mixture can better activate cellular 
signaling proteins that regulate glucose transport and glycogen synthesis. Because it has 
been reported that amino acids cause gastrointestinal (GI) distress in some individuals, 
we compared the effects of half dosage with full dosage of amino acid mixture as used in 
Study 1 and investigated whether half dosage had the same effect on glucose tolerance 
but without any GI distress.  
OBJECTIVES 
 Study 1: to determine whether the ingestion of an amino acid mixture, composed of 
isoleucine and 4 additional amino acids, could improve the blood glucose response of 
healthy overweight/obese men and women following an oral glucose tolerance test. 
 Study 2: to determine whether an amino acid mixture, composed of isoleucine and 4 
additional amino acids, ingested with a carbohydrate beverage, could improve the blood 
glucose response of healthy active men and women postexercise. We also investigated 
whether the rate of muscle glycogen synthesis following strenuous exercise is increased 
with this amino acid+carbohydrate beverage (CHO/AA) given post-exercise, as 
compared to a carbohydrate only beverage (CHO). Furthermore, we investigated the 
activation states of signaling proteins that control both muscle glucose uptake and 
glycogen synthesis, the effect of the CHO/AA supplement on exercise-induced muscle 
damage, and subsequent anaerobic exercise performance. Two different doses of the 
amino acid mixture in combination with carbohydrate supplementation (CHO/HAA, 







1. In comparison with a placebo, an amino acid mixture, composed of isoleucine and 
4 additional amino acids, will significantly reduce the blood glucose response to a 
glucose challenge in healthy overweight/obese subjects, and this blood glucose-
lowering effect would be insulin independent. 
Study 2:  
1.  In comparison with a CHO supplement, a CHO/AA supplement provided post-
exercise will: (a) reduce the blood glucose response in healthy active subjects, and 
this blood glucose-lowering effect would be insulin independent, and (b) increase 
the rate of muscle glycogen resynthesis after a prolonged aerobic exercise bout 
that depletes the muscle glycogen stores. 
2. In comparison with a CHO supplement, a CHO/AA supplement provided post-
exercise will: (a) decrease protracted muscle damage as assessed by creatine 
kinase (CK) and myoglobin levels; and (b) improve the subsequent anaerobic 
exercise performance as assessed by a 30-sec sprint (Wingate test). 
3. In comparison with a CHO supplement, a CHO/AA supplement will better 
phosphorylate cellular signaling proteins that control both muscle glucose uptake 
and glycogen synthesis.  
4. The effects of the high and low AA mixtures on blood glucose homeostasis and 
recovery will not differ. 
SIGNIFICANCE 
The first study was set to test the effectiveness of an amino acid mixture, 
composed of isoleucine and 4 additional amino acids, in improving the blood glucose 
clearance of healthy overweight/obese subjects following an oral glucose tolerance test. 
According to data from the National Center for Health Statistics 2010 (2011), it is 
estimated that two-thirds of the adult population and a growing number of children in the 
United States are overweight or obese. Weight is considered the single strongest predictor 
of type 2 diabetes (Laaksonen et al., 2009), which is a metabolic disorder primarily 
characterized by insulin resistance and hyperglycemia.  
 5 
Our laboratory recently found that gavaging Sprague-Dawley rats with this amino 
acid mixture improved the blood glucose response during an oral glucose challenge 
without an increase in the plasma insulin response (Bernard et al., 2011). The blood 
glucose-lowering effect of the amino acid mixture was due to an increase in skeletal 
muscle glucose uptake. These results suggest that our amino acid supplement acutely 
improves muscle insulin sensitivity and blood glucose homeostasis in rats. However, the 
effect of this supplement on blood glucose homeostasis has not been evaluated in 
humans. To our knowledge, Study 1 is the first to investigate the effect of amino acid 
supplementation on blood glucose homeostasis in response to an oral glucose tolerance 
test in humans. If we are able to show a significant improvement in glucose tolerance in 
overweight/obese subjects with this amino acid mixture, this mixture could be used to 
benefit individuals with impaired glucose tolerance and type 2 diabetics.  
Study 2 continued to test the effectiveness of this amino acid mixture on the blood 
glucose response of healthy active subjects after an oral glucose load post prolonged 
aerobic exercise. Likewise, this study would be the first study to test the hypoglycemic 
effect of amino acids in healthy subjects. Furthermore, this study determined whether the 
rate of muscle glycogen resynthesis following prolonged aerobic exercise is increased 
with CHO/AA supplementation. This would further support the hypothesis that the amino 
acid mixture can improve blood clearance by increasing muscle glucose uptake and 
muscle glycogen synthesis in humans.   
Several studies have demonstrated that carbohydrate–protein beverages can 
attenuate exercise-induced muscle damage (EIMD) (Baty et al., 2007; Romano-Ely et al., 
2006; Saunders et al., 2004; Saunders et al., 2007). However, much less is known about 
the potential benefits of adding amino acids to a carbohydrate supplement post-exercise 
on muscle damage. Therefore, based on studies in which an anabolic response was 
promoted by carbohydrate-protein/amino acids supplementation post-exercise (Biolo et 
al., 1997; Koopman et al., 2005; Levenhagen et al., 2001; Tipton et al., 1999), we 
hypothesized that CHO/AA would also reduce exercise-induced muscle damage to a 
greater extent than CHO alone. If our hypothesis is shown to be correct, then this might 
be reflective of a better subsequent anaerobic exercise performance with AA/CHO 
supplementation.  
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Some studies have demonstrated that consuming a carbohydrate and protein 
supplement improved endurance performance in time-to-fatigue or time trial settings (Ivy 
et al., 2003; Saunders et al., 2004; Saunders et al., 2007) and improved muscle strength 
(Andersen et al., 2005; Coburn et al., 2006; Willoughby et al., 2007) when compared to a 
carbohydrate-only supplement. However, the effect of an amino acid mixture with 
carbohydrate supplement on anaerobic performance has not been investigated. If we were 
able to show a significant improvement in muscle glycogen replenishment, muscle tissue 
damage repair as well as the subsequent anaerobic exercise performance with CHO/AA 
supplementation, this could provide scientific evidence for coaches and trainers who 
recommend recovery supplements for aerobic and anaerobic athletes.  
Taken together, the goals of these studies were to demonstrate more effective 
ways to improve blood glucose control as well as recovery from prolonged, intense 
endurance exercise, including increasing the rate of muscle glycogen resynthesis, 
reducing muscle tissue damage, and improving subsequent anaerobic exercise 
performance. Moreover, we tested two dosages of the amino acid mixture to determine 
the potency of the mixture. If we are able to show a similar effect on blood glucose 
control and recovery measures with CHO/LAA, this would dramatically reduce the 
amount of amino acids needed for the desired effects, but without the risk of possible 
gastrointestinal stress symptoms that have been observed with the high dosage. 
LIMITATIONS AND DELIMITATIONS 
These studies may have some limitations. First, large numbers of participants may 
not be possible due to the large time commitment by subjects and limited funding.  
Second, while all effort was made to recruit subjects with similar BMI (body mass 
index), life style (Study 1), and fitness levels (Study 2), it is possible that there is 
variation in their body composition, fitness levels and training status which might affect 
their responses to different treatments in the study. In both studies, we required each 
subject to eat normally and consume his/her same diet for 48-72 hrs before each 
experimental trial. We also requested all the subjects to be fasting for 12 hrs before each 
experiment trial so that starting levels of blood glucose would be similar for all trials. We 
provided a nutrition drink to subjects to consume at 12 hrs before each trial during Study 
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1. Nevertheless, we did not control the diet throughout the course of the studies. 
Therefore, variations in subjects’ day-to-day diets could affect their substrate metabolism 
during the experimental trials. We also required subjects to keep their exercise level 
consistent for 48-72 hrs and refrain from intense exercise for 24 hrs before each 
experimental trial, so that starting levels of muscle glycogen would not be affected by 
variations in activity or exercise performed the days before the trials. However, variations 
in the diet and training across the entire study period might affect the muscle metabolism 
during the experimental trials. 
Third, both studies used a crossover design so that subjects served as their own 
controls. In Study 2, subjects conducted one familiarization trial, which was designed to 
help them be comfortable with the exercise protocol and equipment and minimize any 
novel components of the experimental trial. Nevertheless, a learning effect may still 
occur after the first experimental trial, and their experiences and perceptions in the first 
trial may influence their psychological approach to the second experimental trial. We 
randomly assigned the subjects to a sequence of different experimental treatments, which 
should have minimized the impact of any learning effect. 
Other possible limitations lie in techniques and measurement methods. During 
Study 2, when taking muscle biopsies, small sample size (~50 mg) may have limitation in 
extrapolating to whole muscle, which might affect the accuracy to assess the muscle 
glycogen amount and the signaling protein activation status. For measuring creatine 
kinase (CK) from the serum, we collected the blood samples from subjects 24 hrs after 
the exercise bout for each trial. However, most studies have noted that CK levels may not 
increase for 2 days post-exercise and the peak values may not occur until 4 days post-
exercise (Newham et al., 1986). Due to the difficulty to control the exercise level of 
subjects for 4 days post trials and then collect blood samples from subjects, we might not 
be able to observe the peak values of CK.  
Our subjects were all in the age range of 20-45 (Study 1) or 19 – 35 (Study 2) 
who reside in Austin, Texas. Therefore, our results may not be generalizable to younger 
or older individuals or to other urban populations. Also, the fitness levels of subjects were 
selected as sedentary overweight/obese individuals for Study 1 or healthy trained athletes 
for Study 2, and therefore the results may not be generalizable to other populations. 
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During Study 2, we used cycling on a mountain bike as the mode of endurance exercise, 
which is composed of concentric and eccentric contractions. It is possible that substrate 
metabolism and muscle damage may differ from what could be found in other exercise 
modes. Therefore, the results of Study 2 may not be generalizable to other types of 
athletes or exercise. 
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Chapter II: Review of the Literature 
 
Recent research suggests that the addition of protein to a carbohydrate supplement 
can have greater benefits on muscle metabolism and exercise recovery than 
supplementing carbohydrate alone. It is also reported that the components of protein, 
amino acids, such as leucine and isoleucine, can improve glucose tolerance in vivo and in 
vitro animal models by accelerating glucose uptake in peripheral tissues. Additionally, 
amino acids can stimulate glycogen synthesis in vitro in the absence of insulin. Our 
laboratory recently found that an amino acid mixture, composed of isoleucine, leucine, 
cysteine, methionine, and valine, improved the blood glucose response during an oral 
glucose challenge without an increase in the plasma insulin response in rats. Some studies 
have also shown that daily supplementation or acute ingestion of amino acids may 
prevent muscle damage that occurs as a result of prolonged intense endurance exercise or 
strength training and therefore improve force production and exercise performance. 
Therefore, in this review I will discuss the relevant literature regarding the effects of 
amino acids or carbohydrate/protein/amino acids supplement on glucose tolerance, 
muscle glycogen resynthesis, muscle damage, and the subsequent anaerobic exercise 
performance. 
EFFECTS OF CARBOHYDRATE PLUS PROTEIN/AMINO ACIDS ON 
GLUCOSE TRANSPORT AND POST-EXERCISE MUSCLE GLYCOGEN 
RESYNTHESIS  
The Amount and Timing of Post-Exercise Carbohydrate Supplementation on Muscle 
Glycogen Resynthesis  
During intense physical training and tournament competitions, it is very important 
to speed up recovery in a limited time and achieve optimal performance in up coming 
exercise. Muscle glycogen is an important fuel source for moderate- to high-intensity 
exercise. It has been clearly demonstrated that aerobic endurance is directly related to the 
initial muscle glycogen stores (Bergstrom et al., 1967; Bergstrom and Hultman, 1966) 
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and that strenuous exercise cannot be maintained once these stores are depleted 
(Bergstrom et al., 1967; Bergstrom and Hultman, 1966; Hermansen et al., 1967). 
Therefore, the faster the muscle glycogen can be replenished post-exercise, the greater 
ability to achieve optimal performance in the subsequent exercise. In recent years, many 
researchers have investigated different methods of rapidly increasing muscle glycogen 
recovery, including type and amount of supplement to ingest (Blom et al., 1987; Burke et 
al., 1993; Ivy, 1998; Ivy et al., 1988b; Piehl Aulin et al., 2000; Reed et al., 1989; van 
Loon et al., 2000; Zawadzki et al., 1992), and the timing (Ivy et al., 1988a; Levenhagen 
et al., 2001) and frequency (Ivy, 1998) of supplementation. Ingestion of carbohydrate 
increases the blood glucose level and stimulates pancreatic insulin release, which results 
in a coordinated increase in glucose transport in peripheral tissues and an activation of 
insulin signaling for glycogen synthesis. It has been suggested that the rate of muscle 
glycogen synthesis post-exercise is maximized when a carbohydrate supplement in 
excess of 1.0 g/kg body weight is consumed immediately post-exercise (Ivy, 1998; Ivy et 
al., 1988a; Levenhagen et al., 2001). The rapid rate of glycogen recovery can be 
maintained up to six hours post-exercise when the carbohydrate supplement is ingested at 
two hour intervals (Ivy, 1998). Some studies demonstrated that the rate of glycogen 
resynthesis post-exercise could be further increased when the supplement is provided at a 
rate of ~0.25 to 0.4 g CHO/kg every 15 min or ~1.0 g CHO/kg every 30 min (total ~2.0 
to 4.2g CHO/kg/2hr) (Doyle et al., 1993; Piehl Aulin et al., 2000; van Hall et al., 2000). 
However, the amount of CHO they used is too large to consume post-exercise, especially 
for those who must maintain body weight within a weight class and who are exercising to 
reduce weight. The frequent ingestion rate (every 15-30 min) is also not practical for 
most athletes, especially during limited recovery intervals between intense exercise bouts. 
Therefore, the search for means to reduce the carbohydrate content of a sports drink, 
while maintain or even enhance performance is desired.  
Effects of Carbohydrate/Protein Supplementation on Post-Exercise Muscle Glycogen 
Resynthesis 
Recent studies suggested that the inclusion of small amounts of protein in a 
carbohydrate-electrolyte beverage may enhance muscle glycogen recovery post-exercise 
 11 
over traditional carbohydrate-only beverages (Berardi et al., 2006; Ivy et al., 2002; van 
Loon et al., 2000; Zawadzki et al., 1992). This has been credited, in part, to the ability of 
protein and carbohydrate to act synergistically on insulin secretion (van Loon et al., 2000; 
Zawadzki et al., 1992). In a study by Zawadzki et al. (Zawadzki et al., 1992), 
carbohydrate (112g) or carbohydrate (112g) plus protein (40.7g) was provided 
immediately and 2 hours after exercise. It was found that adding protein to a 
carbohydrate supplement caused a greater insulin response, a significantly lower plasma 
glucose response and a faster rate of muscle glycogen recovery, compared with a 
carbohydrate treatment of similar amount.  
Several subsequent studies ascribed the benefit of carbohydrate-protein 
supplementation to the greater calorie content contained in the feedings. These studies 
with isocaloric supplementation showed no extra effect of carbohydrate-protein on 
muscle glycogen recovery relative to carbohydrate-only supplementation (Carrithers et 
al., 2000; Jentjens et al., 2001; van Loon et al., 2000). However, a more recent research 
employing natural abundance 13C-nuclear magnetic resonance (NMR) spectroscopy to 
measure muscle glycogen confirmed that the muscle glycogen resynthesis rate is 
enhanced when a carbohydrate-protein supplement is consumed post-exercise, compared 
to an isocaloric carbohydrate-only supplement (Berardi et al., 2006; Ivy et al., 2002). 13C-
NMR spectroscopy is a noninvasive, highly sensitive technique, providing continuous 
and more precise measurement of muscle glycogen content compared with the muscle 
biopsy technique (Price et al., 1999). The use of the noninvasive 13C-NMR spectroscopy 
technique might be one important factor for detecting a statistical difference in glycogen 
storage compared with studies using the muscle biopsy technique.  
There are other differences in the methodologies of these studies that may account 
for the conflicting findings. Different amount of macronutrients and the timing/frequency 
of supplementation provided during the recovery period might be one possibility. The 
ability of protein to improve glycogen resynthesis rate might be restricted to the 
conditions when protein is added to low or moderate amounts of carbohydrate (0.6-0.8 
g/kg/h) and provided at intervals of 1-2 hours or greater (Berardi et al., 2006; Ivy et al., 
2002). The previous studies, which found no additional effect of isocaloric carbohydrate-
protein supplements on glycogen resynthesis, gave their subjects large amount of CHO 
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(1.0-1.2g/kg/h) at more frequent intervals (every 30min) (Carrithers et al., 2000; Jentjens 
et al., 2001; van Loon et al., 2000). The large amount of carbohydrate mixed with protein 
might have altered the absorption rate of carbohydrate and protein and possibly limited 
the advantage of adding protein to a carbohydrate supplement. 
Another possible reason for the conflicting findings in these studies may have 
been the exercise protocol used to deplete the muscle glycogen. It was indicated that 
insulin-independent glucose uptake and glycogen synthesis happens when glycogen 
concentrations are lower than 120-150 mmol/kg dry muscle (Berardi et al., 2006; Price et 
al., 1999). Therefore, when the glycogen concentration is below this threshold level, there 
is a high physiological drive for muscle glucose uptake and muscle glycogen resynthesis 
independent of insulin (Berardi et al., 2006). Previous studies which found no effect of 
isocaloric carbohydrate-protein supplementation on glycogen resynthesis employed 
strenuous exercise protocols, which resulted in a very low post-exercise muscle glycogen 
content (~100mmol/kg dry muscle) (Berardi et al., 2006; Carrithers et al., 2000; Ivy et al., 
2002; Jentjens et al., 2001; van Loon et al., 2000). In these studies, CHO supplement 
alone might be sufficient to stimulate maximal muscle glycogen replenish rate. The more 
recent studies using 13C-NMR spectroscopy employed less strenuous protocols, which 
resulted in moderate extent of muscle glycogen depletion and post-exercise 
concentrations are ~160-200mmol/kg dry muscle. They found enhanced muscle glycogen 
storage when adding protein to a carbohydrate supplement (Berardi et al., 2006; Ivy et al., 
2002). Thus, the severe exercise protocol might conceal the benefit of protein added to a 
carbohydrate supplement.  
The Signaling Pathway Underlying the Effects of Carbohydrate plus Protein on Post-
Exercise Muscle Glycogen Resynthesis 
The underlying signaling pathway responsible for the beneficial effect of CHO-
PRO on muscle glycogen resynthesis was investigated recently (Fig. 2.1). Ivy et al. (Ivy 
et al., 2008) found that a CHO-PRO supplement post-exercise alters the phosphorylation 
levels of the enzymes involved in muscle glycogen synthesis, like protein kinase B 
(Akt/PKB), the mammalian target of rapamycin (mTOR), ribosomal protein S6 (rpS6), 
glycogen synthase kinase 3 (GSK-3) and glycogen synthase (GS). Another study from 
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our laboratory also demonstrated in the rat that post-exercise CHO-PRO supplementation 
was more effective in activating the mTOR-dependent signaling pathway, especially rpS6 
and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) in red and white 
skeletal muscles, compared to either CHO or PRO supplementation (Morrison et al., 
2008). More recently, we investigated the effects of cereal with nonfat milk (Cereal) post 
prolonged exercise on muscle glycogen resynthesis and associated enzyme activation, 
compared with a traditional carbohydrate-electrolyte sports drink (Drink) (Kammer et al., 
2009). Plasma insulin was significantly increased after Cereal although plasma glucose 
was similar between treatments. Muscle signaling proteins, like mTOR, GS, and 
Akt/PKB, were significantly activated during recovery after Cereal. Cereal also blunted 
the increase in plasma lactate post-exercise, which suggests that a higher percentage of 
glucose transported into muscle was converted to muscle glycogen after Cereal. 
Effects of Amino Acids on Muscle Glycogen Synthesis and the Underlying Signaling 
Pathway 
The benefits of addition of protein to carbohydrate supplement post-exercise have 
been widely studied in recent years. However, whether the components of protein, amino 
acids, have a similar effect on muscle recovery is not clear. Physiological concentrations 
of amino acids in vitro have been found to stimulate glycogen synthesis directly in the 
absence of insulin (Armstrong et al., 2001; Peyrollier et al., 2000). It was suggested that 
amino acids, specially leucine, in vitro stimulate glycogen synthesis via activating mTOR 
and/or the 70 kDa ribosomal S6 kinase (p70S6K) in the absence of insulin, without 
paralleled activation of Akt/PKB (Fig. 2.1) (Armstrong et al., 2001; Peyrollier et al., 
2000). It was presumed that activated p70S6K might induce transient inactivation of 
GSK-3, which triggers the initial activation of GS, and amino acids could further 
maintain the activation of GS via the rapamycin-sensitive pathway without the 
involvement of GSK-3 (Armstrong et al., 2001). However, the effects of amino acids in 
vivo on GSK-3 and/or GS activities are not obviously like that of insulin, partly due to 
the fact that insulin also can stimulate Akt/PKB phosphorylation and subsequently 
phosphorylates GSK-3 via a p70S6K-independent mechanism.  
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A study by Ruby et al. (Ruby et al., 2005) found that the addition of 4-
hydroxyisoleucine (4-OH-Ile), an amino acid extract purified from fenugreek seeds, to a 
carbohydrate supplement has been found to increase muscle glycogen synthesis post-
exercise. Research indicated that 4-OH-Ile, combined with a moderate carbohydrate 
supplement (0.9 g/kg/h) and provided immediately and 2 hours after exercise in trained 
male cyclists, was able to stimulate greater post-exercise muscle glycogen synthesis 
compared with carbohydrate-only without any difference in plasma insulin concentration 
between the two trials (Ruby et al., 2005). These results suggest that 4-OH-Ile in 
combination with a moderate amount of carbohydrate might improve the rate of muscle 
glycogen synthesis post-exercise via an alternative mechanism independent of an 
enhanced plasma insulin response. However, the underlying signaling pathway for the 
effect of 4-OH-Ile on muscle glycogen synthesis is not clear. 
Effects of Amino Acids Alone or Combined with Carbohydrate on Glucose Transport 
and the Underlying Signaling Pathway 
Amino acids might also enhance glycogen synthesis indirectly by stimulating 
glucose transport. Several studies have reported that leucine and/or isoleucine might 
stimulate glucose transport independently of insulin/Akt/PKB, possibly via an mTOR-
independent phosphatidylinositol 3-kinases (PI3K)/ atypical isoforms of protein kinase C 
(aPKC) pathway (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007; Nishitani et al., 
2002). Nashitani et.al. (Nishitani et al., 2002) reported that 1ml of 2mM leucine promoted 
glucose transport in isolated rat soleus muscles (0.1-0.2g). The leucine-stimulated 
glucose transport in rat muscle was maintained at high rates from 15-45 minutes and 
declined thereafter. This stimulating effect on glucose transport of leucine was 
suppressed by 10 µM LY294002 or 6 µM GF109203X, which are specific inhibitors for 
PI3K and aPKC, respectively (Uberall et al., 1999). PI3K is essential for insulin-
regulated GLUT4 translocation and glucose uptake (Clarke et al., 1994; Haruta et al., 
1995; Katagiri et al., 1996; Kotani et al., 1995; Tanti et al., 1996; Thong et al., 2005). 
aPKCs are downstream proteins of insulin receptor substrate (IRS)/PI3K and have been 
suggested to be able to increase glucose transport in skeletal muscle by vesicle-associated 
membrane protein 2 (VAMP2) serine phosphorylation in the glucose transporter type 4 
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(GLUT-4) compartment (Nishitani et al., 2002; Thong et al., 2005). It is known that 
leucine has no effect on Akt/PKB (Greiwe et al., 2001), which is another downstream 
protein of IRS/PI3K and contributes to insulin regulation of GLUT4 traffic and glucose 
uptake (Thong et al., 2005). Furthermore, pre-treatment of 1 µM rapamycin did not 
significantly affect increased glucose transport by leucine and this study was conducted 
under insulin-free conditions. Taken together, leucine might stimulate glucose transport 
differently from insulin, possibly via an mTOR-independent PI3K/aPKC pathway.  
However, the combination of carbohydrate and leucine appears to have no 
additive effect on glucose transport.  Baum et al. (Baum et al., 2005) evaluated the impact 
of a physiological oral dose of leucine and/or carbohydrate on glucose uptake in rats. 
Rats were fed oral doses of carbohydrate (CHO) (1.31g glucose, 1.31g sucrose), leucine 
(270mg), or CHO plus leucine (CHO/Leu) after 12 hours fasting. It was shown that 
during the first 60 minutes after oral administration, CHO/Leu did not cause any 
difference in glucose uptake when compared with CHO alone. However, the activity of 
PI3K in skeletal muscle was suppressed at 30, 60, and 90 minutes following CHO/Leu 
supplement. It was proposed that the decreased PI3K activity while maintaining normal 
levels of glucose transport might be due to increased degradation of the IRS1/PI3K 
complex rather than inhibition of the IRS1/PI3K complex formation. Therefore, the 
initiated signal is still able to activate physiological events, such as glucose transport. The 
blunting effect on the IRS1/PI3K pathway may result from the overactivation of 
mTOR/p70S6K by leucine, which might serves as a component of the feedback 
regulation of PI3K signaling pathway (Baum et al., 2005; Iwanaka et al., 2010; Tremblay 
et al., 2005a; Tremblay and Marette, 2001).  
Isoleucine has also been found to increase glucose uptake in an insulin-
independent manner (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007). In an oral 
glucose tolerance test in normal rats, a single dose of 0.3 g/kg body wt isoleucine 
significantly reduced plasma glucose levels 30 and 60 min after the glucose bolus (Doi et 
al., 2003). In an in vivo study in food-deprived rats, 1.35 g/kg body wt isoleucine 
significantly increased skeletal muscle glucose uptake (Doi et al., 2005). In the absence 
of insulin, 1 mM isoleucine also significantly increased glucose consumption in C1C2 
myotubes (Doi et al., 2003). The signaling pathway analysis using several inhibitors 
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found that the potent hypoglycemia effect of isoleucine in vitro was mediated by PI3K 
and aPKC, which was independent of mTOR, similar to leucine-mediated glucose uptake 
in isolated muscle (Nishitani et al., 2002). It is also found that glucose uptake by skeletal 
muscle might be the major mechanism by which isoleucine lowers blood glucose levels 
in vivo (Doi et al., 2005; Doi et al., 2007). 
It has been found that isoleucine has no effects on mTOR/p70S6K (Atherton et 
al., 2010). Therefore, the addition of isoleucine to carbohydrate supplement might be 
more efficient on glucose transport than carbohydrate/leucine combination. Our 
laboratory recently found that gavaging both normal Sprague-Dawley rats and insulin-
resistant obese Zucker rats with an amino acid mixture, composed of isoleucine and 4 
other amino acids, improved the blood glucose response during an oral glucose challenge 
without an increase in the plasma insulin response (Bernard et al., 2011). We also found 
that the amino acid mixture significantly elevated phosphorylation of Akt substrate of 
160 kDa (AS160) and markedly decreased GS phosphorylation without altering Akt/PKB 
activation stimulated by carbohydrate in Sprague-Dawley rat skeletal muscles. AS160 is 
one potential candidate of downstream targets of Akt/PKB and has been suggested to 
regulate GLUT-4 translocation in response to either insulin or contractile activity (Bruss 
et al., 2005; Cheng et al., 2005; Eguez et al., 2005; Kane et al., 2002). Another recent in 
vitro study from our laboratory also found that an amino acid mixture increases glucose 
uptake in isolated rat epitrochlearis muscle in the absence of insulin (Kleinert et al., 
2011). This effect is associated with an increased phosphorylation of AS160 without 
significant changes in mTOR or Akt/PKB. These results suggested that the amino acid 
mixture improves glucose tolerance by increasing skeletal muscle glucose uptake in rats 
through an as yet undefined intracellular signaling cascade (Fig.2.1). 
The findings of the many studies discussed above indicate that combined 
ingestion of protein/amino acids and carbohydrate further increases the rate and amount 
of muscle glycogen resynthesis when taken immediately and 1-2 hours post-exercise. 
This would be more practical for those who have only limited time to recovery between 
training sessions or competitive events and would be beneficial for those who must limit 
their carbohydrate intake and maintain or reduce body weight while maintaining or even 
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enhancing performance. The potential hypoglycemic effect of amino acids, especially 
isoleucine, might be also beneficial for those glucose intolerant individuals.  
EFFECTS OF CARBOHYDRATE PLUS PROTEIN/BCAA ON MUSCLE 
DAMAGE AND THE SUBSEQUENT EXERCISE PERFORMANCE 
Following prolonged strenuous exercise, the body is in a catabolic state in which 
blood insulin is low and the catecholamines and cortisol are high. Although there is an 
increase in muscle protein synthesis, its rate is exceeded by the rate of protein 
degradation such that there is a negative net protein balance. The ingestion of 
carbohydrate and protein following exercise has been reported to promote protein 
synthesis and hastens recovery (Koopman et al., 2005; Levenhagen et al., 2001).  
Supplementation with a mixture of essential amino acids will also increase protein 
synthesis and suppress protein degradation (Biolo et al., 1997; Blomstrand and 
Newsholme, 1992; Tipton et al., 1999). Blomstrand et al. (Blomstrand and Newsholme, 
1992) supplied BCAA to well-trained endurance athletes during two types of sustained, 
intensive running exercise, a 30 km cross-country race and a full marathon. The total 
amount of BCAA ingested by each subject during the cross-country race was 7.5g and 
composed of 35% leucine, 50% valine, and 15% isoleucine. During the full marathon, 
each subject ingested 12g BCAA, which was composed of 35% leucine, 40% valine, and 
25% isoleucine. In the placebo group, the amount of the aromatic amino acids, tyrosine 
and phenylalanine, in the muscle was increased by 20-40% after both types of exercise, 
and the plasma concentration of these amino acids was increased after the marathon. 
However, when BCAA were supplied during both types of exercise, the increases in 
tyrosine and phenylalanine concentrations in both plasma and muscle were inhibited. 
Since tyrosine and phenylalanine are neither taken up nor metabolized by                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
skeletal muscle, the increased concentrations of them in muscle might indicate net protein 
degradation during exercise. Therefore, these results suggest that BCAA supplementation 
during exercise may prevent or decrease the net rate of protein degradation caused by 
prolonged intense exercise. 
Furthermore, adding amino acids to a carbohydrate supplement could provide an 
efficient intervention to optimize net skeletal muscle protein balance during post-exercise 
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recovery (Koopman et al., 2005), taking advantage of an enhanced insulin response, 
energy availability, and substrate for protein synthesis. In addition, Miller et al. (Miller et 
al., 2003) evaluated the combined effects of essential amino acids and carbohydrate 
administered after resistance exercise on muscle protein metabolism. Subjects ingested 
one of three drinks (~6 g amino acids (AA), ~35 g carbohydrate (CHO), or AA and CHO 
(MIX)) at 1 and 2 h after leg resistance exercise. Total net uptake of phenylalanine across 
the leg over 3 h was greatest in MIX and least in CHO, which was due to increased 
muscle protein synthesis in MIX.  The results showed that the combined effects of amino 
acids and carbohydrate supplementation on muscle protein synthesis are additive, and 
roughly equivalent to the sum of the independent effects of either given alone.  
These studies indicate that carbohydrate-protein/amino acids supplementation 
promoted the anabolic response and inhibited the catabolic response post exercise, 
resulting in a positive net protein balance. Improved protein balance might result in a 
protection or a faster repair of muscle damage. It could be interesting to know whether 
carbohydrate-protein/amino acids supplementation would also reduce exercise-induced 
muscle damage (EIMD).  
Exercise-induced Muscle Damage and its Effects on Exercise Performance 
EIMD occurs following either unaccustomed physical activity, or activity of great 
intensity or duration. Many studies reported that muscle damage mainly occurred in 
exercise involving a large amount of eccentric muscle contractions, such as plyometric 
jumps (Marginson et al., 2005), downhill backward walking (Nottle and Nosaka, 2005), 
marathon running (Asp et al., 1999; Asp et al., 1997; Tuominen et al., 1996), resistance 
training (Baty et al., 2007), and bench stepping (Vickers, 2001). This damage is mainly 
associated with damage to the excitation-contraction coupling system and disruption at 
the level of the sarcomeres (Byrne et al., 2004; Clarkson and Hubal, 2002; Proske and 
Morgan, 2001). Other studies, however, reported that muscle damage also occurs in 
prolonged intense exercise involving concentric actions such as cycling but in a lesser 
degree (Bessa et al., 2008; Greer et al., 2007; Koller et al., 1998; Millet and Lepers, 2004; 
Romano-Ely et al., 2006; Saunders et al., 2004; Saunders et al., 2007). 
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EIMD does not just occur during exercise, but can continue after exercise for 
many hours. Muscle damage could cause an immediate and prolonged reduction in 
muscle function, including reductions in muscle force production and power generation. 
It was suggested that the measurement of muscle function provides the most effective 
means of evaluating the magnitude and time course of damage caused by exercise 
(Warren et al., 1999). A number of studies have quantified the declines in isometric 
strength (Avela et al., 1999; Byrne and Eston, 2002; Clarkson et al., 1992; Howell et al., 
1993; Komi and Viitasalo, 1977; Sayers and Clarkson, 2001), isokinetic concentric and 
eccentric strength (Byrne et al., 2001; Deschenes et al., 2000; Michaut et al., 2002), 
vertical jump performance (Avela et al., 1999; Byrne and Eston, 2002; Horita et al., 
1999), and endurance performance (Gleeson et al., 1998; Gleeson et al., 1995). However, 
few studies have examined the effect of muscle damage on power generation. Muscular 
power is the product of force and velocity. Therefore, a similar reduction in power and 
strength resulting from muscle damage would be expected. Sherman et al. (Sherman et 
al., 1984) employed a maximal work capacity test consisting of 50 maximal leg 
extensions at 3.2 rad/sec and found 47% reduction in work capacity immediately after a 
marathon race. Byrne et al. (Byrne and Eston, 2002) reported immediate and prolonged 
reductions (up to 3 days) in dynamic peak power during a 30-second Wingate cycle test 
after 100 repetitions of the eccentric phase of the barbell squat exercise. The Wingate 
cycle test has been shown to be a highly reliable and applicable test for predicting 
performance in both individual and team sporting events (Nottle and Nosaka, 2007; 
Sinnett et al., 2001). Because the external load during the Wingate test remains constant, 
a reduction in Wingate peak power is the direct result of an inability to achieve a high 
pedal frequency against a constant resistance. Another study by Nottle et al. (Nottle and 
Nosaka, 2007) also reported an immediate reduction in peak and average power during 
the 30-second Wingate test following a 40-minute down hill run on a treadmill.  
Effects of Carbohydrate plus Protein/Amino Acids Supplementation on Muscle 
Damage and the Subsequent Exercise Performance 
Carbohydrate–protein beverages have been reported to attenuate exercise-induced 
muscle damage and maintain exercise performance (Baty et al., 2007; Romano-Ely et al., 
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2006; Rowlands et al., 2008; Saunders et al., 2004; Saunders et al., 2007). A recent study 
from our lab found that ingestion of a carbohydrate-protein supplement before and during 
a resistance exercise session significantly reduced muscle damage, as evidenced by 
decreased responses of both plasma myoglobin and creatine kinase (CK), which are 
blood markers of muscle damage (Baty et al., 2007). Saunders et al. (Saunders et al., 
2004; Saunders et al., 2007) reported that ingestion of a carbohydrate-protein supplement, 
in both beverage- and gel-forms, during and after exercise significantly reduced muscle 
damage in endurance cyclists, accompanied with lower plasma CK concentration. 
Moreover, these cyclists rode 13%-29% longer in timed cycle-trials at 75% VO2 peak to 
volitional exhaustion when consuming CHO/PRO beverage or gel during exercise than 
CHO only beverage. They also performed 40% longer in a second ride to exhaustion at 
85%VO2 peak at 12-15h later when consuming CHO/PRO beverage than consuming 
CHO only beverage. 
In recent years, some studies have shown that BCAA supplementation are 
beneficial for reducing EIMD and fatigue, maintaining muscle force and exercise 
performance (Blomstrand and Newsholme, 1992; Coombes and McNaughton, 2000; 
Greer et al., 2007; Jackman et al., 2010; Negro et al., 2008; Shimomura et al., 2010; 
Skillen et al., 2008). The effects of BCAA supplementation on serum indicators of 
muscle damage after prolonged exercise were investigated in a study by Coombes et al. 
(Coombes and McNaughton, 2000). Sixteen male subjects took 12 g/day BCAA in 
addition to their normal diet or only took the normal diet for 14 days. There was no 
difference in the baseline serum CK and lactate dehydrogenase (LDH), both of which are 
shown to be accurate indicators of muscle damage. On day 7, subjects cycled on an 
ergometer at ~70% VO2max for 2 hrs. Both serum CK and LDH concentrations were 
significantly increased thereafter until 5 days post-exercise in the placebo group, while 
the BCAA supplementation significantly reduced the increase in serum LDH from 2 hrs 
to 5 days, and serum CK from 4 hrs to 5 days post-exercise. These results indicate that 
daily supplementation of BCAA may reduce the serum concentrations of intramuscular 
enzymes CK and LDH associated with EIMD.   
Shimomura et al. (Shimomura et al., 2010) examined the acute effect of three 
BCAA supplementation (isoleucine:leucine:valine = 1:2.3:1.2) taken before exercise on 
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muscle damage. The subjects ingested BCAA or dextrin at 100 mg/kg body weight 
before a series of squat exercise, which consisted of 7 sets of 20 squats/set with 3-min 
intervals between sets. Serum myoglobin concentration was increased post-exercise in 
the placebo trial but not in the BCAA trial. In both trials, exercise-induced delayed-onset 
muscle soreness (DOMS) showed a peak on Day 2 and 3, but the level of soreness was 
significantly lower in the BCAA trial compared with the placebo trial. Leg-muscle force 
during maximal voluntary isometric contractions was significantly decreased on Day 2 in 
the placebo trial but not in the BCAA trial. These results suggest that BCAA 
supplementation before strength training exercise may suppress EIMD and maintain 
muscle force. 
The effect of BCAA supplementation on muscle damage caused by endurance 
exercise involving concentric actions was investigated in a study by Greer et al. (Greer et 
al., 2007).  Nine untrained subjects cycled at 55% VO2peak for 90 min and consumed 
BCAA or CHO beverage before and at 60 min of exercise. CK activities and ratings of 
perceived soreness were significantly lower during the BCAA trial than the CHO trial at 
24 h post-exercise. Leg-flexion torque was higher during the BCAA trial at 48 h post-
exercise. These results suggest that BCAA supplementation attenuates muscle damage 
and prevents muscle torque drop post prolonged concentric exercise. 
Furthermore, Skillen et al. (Skillen et al., 2008) examined the effect of amino 
acids in a carbohydrate beverage on muscle damage and cycling performance. Twelve 
male athletes took 3.6% carbohydrate plus 1% amino acids (AA) or 4.6% carbohydrate-
only (CHO) beverages for 2 weeks. They cycled at 75% VO2 peak for 90 min followed 
by a ride to exhaustion at 85% VO2 peak before (T1) and on 2 consecutive days (T2 and 
T3) after 2 weeks of supplementation. Plasma CK levels were significantly lower for AA 
in T3. Time to exhaustion decreased from T2 to T3 only in CHO but not in AA. Changes 
in vertical-jump pre- to post-exercise were greater in T3 for the CHO treatment. 
Supplementation with AA significantly decreased total fatigue score and mood 
disturbance in T3. These data suggest that the addition of AA to a carbohydrate beverage 
reduced muscle damage as indicated by CK levels, decreased muscle fatigue, and 
maintained the subsequent endurance exercise performance compared with consuming 
carbohydrate alone.  
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The findings of the studies discussed above indicate that daily supplementation or 
acute ingestion of protein and/or BCAA may prevent muscle damage that occurs as a 
result of a prolonged, intense endurance exercise or strength training. Moreover, some 
studies have demonstrated that consuming protein/amino acids supplement improved 
muscle strength when compared to a carbohydrate only supplement (Andersen et al., 
2005; Coburn et al., 2006; Shimomura et al., 2010; Willoughby et al., 2007). 
Furthermore, consuming the combined supplement of carbohydrate and protein has been 
shown to improve endurance performance in time-to-fatigue or time trial settings (Ivy et 
al., 2003; Saunders et al., 2004; Saunders et al., 2007). The effects of amino acids in a 
carbohydrate beverage on muscle damage and cycling performance have also been 
examined in a study by Skillen et al. (Skillen et al., 2008). However, much less is known 
about the effect of carbohydrate plus amino acids supplement on anaerobic exercise 
performance. Based on the fact that amino acids have been found to prevent exercise-
induced muscle damage, it is reasonable to hypothesize that supplementing post-exercise 
with carbohydrate plus amino acids will lead to a faster post-exercise recovery and 
improve subsequent anaerobic exercise performance. 
CONCLUSION 
During intense physical training and tournament competitions, it is very important 
to speed up recovery when time is limited to achieve optimal performance in subsequent 
exercise. Recovery from exercise involves the integration of multiple systems and many 
components which are directly affected by post-exercise nutrition. Compared to 
carbohydrate supplements alone, carbohydrate plus protein/amino acids further increased 
the rate and amount of muscle glycogen resynthesis when taken immediately and 1-2 
hours post-exercise. This provides a more practical method for those who have only 
limited time to recovery and those who must limit their carbohydrate intake and maintain 
or reduce body weight while maintaining or even enhancing performance. The 
components of protein, amino acids, have also been shown to stimulate glycogen 
synthesis via activating mTOR and/or p70S6K in the absence of insulin. Amino acids 
might also enhance glycogen synthesis indirectly by stimulating glucose transport via an 
mTOR-independent PI3K/aPKC pathway. Moreover, the potential hypoglycemic effect 
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of amino acids, especially isoleucine, might be also beneficial for those insulin intolerant 
individuals. In addition, protein and/or BCAA supplements may prevent exercise-induced 
muscle damage and maintain muscle strength, compared to a carbohydrate only 
supplement. The combination of carbohydrate and protein/amino acids has been shown to 
improve endurance performance in time-to-fatigue or time trial settings, but much less is 
known about anaerobic exercise performance. A summary for the previous studies about 
the effects of protein/amino acids supplementation on glucose metabolism and muscle 
damage is listed in Table 2.1. While it has not previously been investigated, we 
hypothesize that a carbohydrate plus amino acid mixture supplement can lower blood 
glucose levels, increase muscle glycogen resynthesis, suppress exercise-induced muscle 













FIGURE 2.1. INSULIN AND MTOR SIGNALING PATHWAYS IN GLUCOSE TRANSPORT AND 
MUSCLE GLYCOGEN SYNTHESIS. –––►, ·····►, Activating steps; ⎯|, inhibitory steps in 
the pathway. ·····, Incompletely-defined links. CHO, carbohydrate; PRO, protein; IRS, 
insulin receptor substrates; PDK, phosphatidylinositol phosphate-dependent protein 
kinase; Akt/PKB, protein kinase B. AS160, Akt substrate of 160kDa; αPKC-λ/δ, atypical 
protein kinase C; GSK-3, glycogen synthase kinase-3; GS, glycogen synthase; p70S6K, 
70kDa ribosomal protein (rp) S6 kinase; See text for further details.    
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et al. 1992 
male 
cyclists 
CHO-PRO 112 g CHO + 
40.7 g PRO 
immediately 
and 2 hrs 
post exercise 
decrease increase N/A increase N/A N/A 




CHO-PRO 80 g CHO + 
28 g PRO 
immediately 




N/A increase N/A N/A 
van Loon 









every 30 min 
until 270 min 
post exercise 
N/A increase N/A increase N/A N/A 
Hara et al. 
2011 
rats CHO-PRO 0.9 g CHO + 
0.3 g PRO/kg 
body wt.  
N/A N/A N/A N/A increase N/A N/A 
Armstrong 





amino acids See 
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N/A N/A N/A N/A increase N/A N/A 






























2 mM N/A N/A N/A increase N/A N/A N/A 
Doi et al. 
2003 
rats isoleucine 0.3 g/kg 
body wt. 
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before OGTT  
decrease decrease N/A N/A N/A N/A 
 rats leucine 0.3 g/kg 
body wt. 
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before OGTT  
increase decrease N/A N/A N/A N/A 
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before OGTT  











leucine 1 mM N/A N/A N/A no 
change 
increase N/A N/A 
 C2C12 
myotubes 
valine 1 mM N/A N/A N/A no 
change 
increase N/A N/A 
Doi et al. 
2005 
rats isoleucine 1.35 g/kg 
body wt. 















increase N/A N/A 
Doi et al. 
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N/A N/A N/A 











isoleucine 300 mg/kg 
body wt. 
N/A decrease no 
change 




isoleucine 300 mg/kg 
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N/A decrease increase N/A N/A N/A N/A 
 Type 2 
diabetes 
mice 
isoleucine 500 mg/kg 
body wt. 
N/A decrease no 
change 







1 mM  N/A N/A N/A increase increase N/A N/A 
Bernard et 
al. 2011 
rats CHO-AA mixture see reference N/A decrease no 
change 





AA mixture see reference N/A N/A N/A increase N/A N/A N/A 
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increase N/A N/A N/A N/A 
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lean body 
mass + 
glucose 25 g 
N/A decrease 
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isoleucine 1 mmol/kg 
lean body 
mass 
N/A decrease no 
change 
N/A N/A N/A N/A 




mass + 25 g 
glucose 
N/A decrease increase N/A N/A N/A N/A 
Baty et al. 
2007 
male CHO-PRO vs. 
Placebo 





N/A increase N/A N/A decrease N/A 
Saunders 
et al. 2004 
male 
cyclists 
CHO-PRO 7.3% CHO + 
1.8% PRO 





N/A N/A N/A N/A decrease N/A 
Coombes 
et al. 2000 
male 
adults 
BCAA 12g per day 14 days N/A N/A N/A N/A decrease N/A 




BCAA 200 kcal of 
energy via 
the CHO or 
BCAA 
beverage 
before and at 
60 min of 
exercise 
N/A N/A N/A N/A decrease N/A 
Shimomura 
et al. 2010 
untrained 
females 









CHO-BCAA 3.6% CHO + 
1% BCAA per 
day 
for 2 weeks N/A N/A N/A N/A decrease N/A 
Blomstrand 
et al. 1992 
trained 
athletes 
BCAA 7.5-12 g during 
exercise 
N/A N/A N/A N/A N/A decrease 
Table 2.1 Summary for the previous studies about the effects of protein/amino acids on glucose metabolism and muscle  damage.
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Chapter III: Amino Acid Mixture Acutely Improves the Glucose 
Tolerance of Healthy Overweight/Obese Adults 
 
ABSTRACT 
Certain amino acids have been reported to influence carbohydrate metabolism and 
blood glucose clearance, as well as improve the glucose tolerance in animal models. The 
aim of the present study was to investigate the effect of an amino acid mixture on the 
glucose response of healthy overweight/obese men and women to an oral glucose 
tolerance test (OGTT). Twenty-two overweight/obese healthy subjects completed two 
OGTT after consuming two different test beverages. The amino acid mixture beverage 
(CHO/AA) consisted of 0.088 g cystine 2HCl, 0.043 g methionine, 0.086 g valine, 12.094 
g isoleucine, 0.084 g leucine and 100 g dextrose. The control beverage (CHO) consisted 
of 100 g dextrose, only. Venous blood samples were drawn 10 min before the start of 
ingesting the drinks, and 15, 30, 60, 120 and 180 min after the completion of the drinks. 
During the OGTT, the plasma glucose response for the CHO/AA treatment was 
significantly lower than that of the CHO treatment, as was the plasma glucose area under 
the curve (CHO/AA 806 ± 31 mmol/L•3h vs. CHO 942 ± 40 mmol/L•3h). Differences in 
plasma glucose between treatments occurred at 30, 60, 120, and 180 min after 
supplement ingestion. Plasma glucagon during the CHO/AA treatment was significantly 
higher than during the CHO treatment. However, there were no significant differences in 
plasma insulin or c-peptide responses between treatments.  These results suggest that our 
amino acid mixture lowers the glucose response to an OGTT in healthy overweight/obese 
subjects in an insulin-independent manner. 
INTRODUCTION 
Type 2 diabetes is a metabolic disorder that is primarily characterized by insulin 
resistance and hyperglycemia. Skeletal muscle is the predominate tissue for the clearance 
of blood glucose and 70 to 80% of an oral glucose challenge is cleared by skeletal muscle 
(DeFronzo et al., 1981; Katz et al., 1983; Willems et al., 1991). Recent research has 
demonstrated that certain amino acids, such as leucine and isoleucine, can improve blood 
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glucose clearance and uptake in skeletal muscles in vivo and in vitro (Doi et al., 2003; 
Doi et al., 2005; Doi et al., 2007; Kalogeropoulou et al., 2008; Morifuji et al., 2009; 
Nishitani et al., 2002). It is currently suggested that the potent hypoglycemic effect of 
amino acids is mediated by phosphoinositide 3-kinase (PI3K) and atypical isoforms of 
protein kinase C (aPKC) (Doi et al., 2003; Morifuji et al., 2009; Nishitani et al., 2002). 
Therefore, it may be possible to develop an amino acid supplement as a potent non-
pharmaceutical approach to improve glucose tolerance. 
Our laboratory recently found that gavaging Sprague-Dawley rats with an amino 
acid mixture, composed of isoleucine, leucine, cystine, methionine, and valine, improved 
the blood glucose response during an oral glucose challenge without an increase in the 
plasma insulin response (Bernard et al., 2011). The blood glucose-lowering effect of the 
amino acid mixture was due to an increase in skeletal muscle glucose uptake. These 
results suggest that this amino acid supplement acutely improves muscle insulin 
sensitivity and blood glucose homeostasis in rats.  
Although our previous results support the hypoglycemic effect of an amino acid 
supplement in rats, the effect of this supplement on blood glucose homeostasis has not 
been evaluated in humans. According to data from the National Center for Health 
Statistics 2010 (2011), it is estimated that two-thirds of the adult population and a 
growing number of children in the United States are overweight or obese. Weight is 
considered the single strongest predictor of type 2 diabetes (Laaksonen et al., 2009). 
Therefore, the objective of the present investigation was to study whether the ingestion of 
an amino acid mixture, composed of isoleucine and 4 additional amino acids, could 
improve the blood glucose clearance of healthy overweight/obese men and women during 
an oral glucose tolerance test. We hypothesized that the amino acid mixture would 
significantly reduce the blood glucose response to a glucose challenge in healthy 
overweight/obese subjects, and this blood glucose-lowering effect would be insulin 
independent.  
EXPERIMENTAL PROCEDURES 
This study was registered as a clinical trial with http://www.ClinicalTrials.gov/ 
NCT00974831.  
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Subjects.  Twenty-two healthy overweight/obese men and women (3 men and 19 
women) between 20 and 45 years old volunteered for the study. Subject characteristics 
are presented in Table 3.1. The subjects habitually engaged in recreational exercise less 
than 3 hrs per week and were considered sedentary. They were not engaged in any 
exercise programs over the course of the experiment. A body mass index (BMI) of more 
than 25 kg/m2 was required for all subjects. A waist circumference of at least 101 cm was 
required for all male subjects and 88 cm for female subjects. All subjects’ fasting blood 
glucose levels were between 4.16 and 6.99 mmol/L (75 and 126 mg/dL), and their blood 
pressures were less than 140/90 mm Hg. The subjects were first screened via phone to 
determine if they met the requirements of age, exercise level, and health status, and were 
not on a low carbohydrate diet before they came for the screening visit. During the 
screening visit, the experimental procedures and potential risks of the study were fully 
explained to the subjects, and all subjects signed the Informed Consent to Participate in 
Research and filled out the Participation Health Research Screening Form. The 
experimental protocol was approved by The University of Texas at Austin Institutional 
Review Board.   
Physical Activity and Nutritional Controls.  Subjects were asked to keep their 
habitual exercise pattern and normal dietary intake as constant as possible over the course 
of the experiment. They were instructed to consume their last meal at least 14 hrs prior to 
their trial appointment, during which they were allowed to consume only water and an 8 
oz can of Ensure (Abbott Nutrition, Columbus, OH). The 8 oz can of Ensure was 
consumed 12 hrs prior to each of the trials. All subjects were required to bring a 3-day 
food record for analysis of their daily average intake of carbohydrate and they were 
advised to eat the same diet 3 days prior to each trial. The subjects were also refrained 
from exercise for 24 hrs before each of the trials. On reporting to the laboratory, the 
three-day food record was analyzed to ensure that subjects had consumed a minimum of 
150 g of carbohydrate per day. All subjects were in compliance with these instructions. 
Experimental Design.  Upon reporting to the laboratory, the subjects were 
weighed and a finger prick glucose test was performed to ensure the blood glucose level 
of each subject was between 4.16 mmol/L and 6.99 mmol/L. After the subject sat quietly 
for at least 5 min, a catheter was inserted into a forearm vein, fitted with a three-way 
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stopcock with a catheter-extension, and taped in place. Each subject completed two 
glucose tolerance tests after consuming two different test beverages using a double-
blinded, random ordered experimental design. Tests were separated by at least 1 week but 
not more than 2 weeks. All beverages were provided by Abbott Nutrition (Columbus, 
OH). The CHO/AA beverage consisted of an amino acid mixture in a 355 ml orange-
flavored solution. The amino acid mixture consisted of 0.088 g cystine 2HCl, 0.043 g 
methionine, 0.086 g valine, 12.094 g isoleucine and 0.084 g leucine per 355 ml solution. 
The CHO beverage consisted of a 355 ml orange-flavored placebo drink. Before each 
trial, both beverages were mixed with a 296 ml orange-flavored drink containing 100 g 
dextrose (SUN-DEX, Fisher Healthcare, Houston, TX) to make a drink totaling 651 ml. 
The experimental drinks were provided to subjects every 5 min in 207 ml, 237 ml and 
207 ml increments. All subjects were instructed to finish the drinks within a total of 15 
min. Subjects rested quietly in a room with dimmed lighting during each trial. Venous 
blood samples (7 ml) were drawn 10 min before the start of ingesting the drinks. Once 
the drinks were ingested, subsequent blood samples (7 ml) were taken at 15, 30, 60, 120 
and 180 min.  
Blood Analysis.  Each blood sample was transferred into two 12 x 75 mm 
polypropylene culture test tubes cooled on ice, containing ethylenediaminetetraacetic acid 
solution (EDTA, 24 mg/ml, pH 7.4). From all blood samples, 0.3 ml of the anticoagulated 
blood was transferred to tubes containing 0.6 ml 10% perchloric acid (PCA). All tubes 
were centrifuged for 10 min at 3,000 rpm at 4℃ in a Sorvall RC-6 centrifuge (Thermo 
Fisher Scientific Inc. Waltham, MA). Following centrifugation, the PCA extracts were 
transferred to 12 x 75 test tubes and stored for later analysis of blood lactate. The plasma 
was transferred to five new 12 x 75 test tubes. Three tubes received 0.6 ml plasma each 
and were stored for later analysis of insulin, c-peptide, and glucagon. A protease 
inhibitor, Trasylol (aprotinin), was added to the glucagon test tubes to prevent 
proteolysis. A fourth test tube received 0.5 ml plasma and was stored for later analysis of 
glucose, free fatty acids (FFA), and triglycerides (TG). The remaining plasma was placed 
in a fifth test tube and saved as a backup. All test tubes were immediately stored at -80℃. 
Each subject’s blood samples were analyzed in duplicate and concurrently after 
completion of all trials.  
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Plasma glucose was determined using a colorimetric method, which employs 
glucose oxidase (GOD) and a modified Trinder color reaction (Trinder, 1969). The 
absorbance of the reaction solution was measured using a Beckman DU 640 
spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) at a wavelength of 500 nm. 
The intensity of the color in the reaction solution was proportional to the concentration of 
glucose in the blood sample. Duplicate samples were measured and the intra-assay 
coefficient of variance was 2.20%. 
Plasma insulin, c-peptide, and glucagon were measured using commercially 
available 125I radioimmunoassay (RIA) kits (MP biomedicals, LLC. Solon, OH). The 
radioactivity of antibody-bound 125I-labeled hormone was counted in a Wallac 1470 
Wizard™ automatic gamma counter (Perkin Elmer life Sciences, Turku, Finland). The 
concentrations of plasma hormones were calculated based on prepared standards. 
Duplicate samples were measured and the intra-assay coefficient of variances for insulin, 
c-peptide, and glucagon assays were 4.46%, 4.20%, and 8.10%, respectively. 
FFA was measured using a modified colorimetric method stemming from those 
devised by Ayers (Ayers, 1956) and Iwayama (Iwayama, 1959). The absorbance of the 
reaction solution was measured using a Beckman DU 640 spectrophotometer at a 
wavelength of 436 nm. Duplicate samples were measured and the intra-assay coefficient 
of variance was 5.52%. 
Lactate was determined spectrophotometrically as described by Hohorst (Hohorst, 
1965). The reaction can be monitored by the changes in the fluorescence of NADH, 
which was measured using a Beckman DU 640 spectrophotometer at a wavelength of 340 
nm. Duplicate samples were measured and the intra-assay coefficient of variance was 
1.31%. 
TG was measured using triglyceride GPO reagent (Cliniqa corporation, San 
Marcos, CA). The absorbance of the reaction solution was measured using a Cary 50 
MPR microplate reader (Varian Australia Pty Ltd, Victoria, Australia) at a wavelength of 
520 nm. The absorbance of quinoneimine dye in the reaction solution was proportional to 
the concentration of TG in the blood sample. Duplicate samples were measured and the 
intra-assay coefficient of variance was 10.07%. 
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Statistics.  Statistical analyses were performed by using SPSS software (SPSS 
Inc, Chicago, IL). The data were analyzed using a two-way ANOVA (treatment x time) 
with repeated measures. When a significant F-ratio was obtained, a Bonferroni post hoc 
test was made to identify significant differences between means. Paired t-tests were 
performed to determine if significant differences in the area under the curve (AUC) for 
glucose, insulin, c-peptide, and glucagon occurred between treatments. A power analysis 
was conducted using MANOVA per  D’Amico (D'Amico et al., 2001) using a correlation 
matrix obtained from a previous rat study data (power = 0.88). Effect sizes were derived 
from correlation matrices from a previous rat study data. A MANOVA per  D’Amico 
(D'Amico et al., 2001) was then run to project sample size using repeated measures. 
Sensitivity analysis was performed to determine minimum and maximum sample sizes 
(max. sample size = 14, min. sample size = 10). A sample of 22 was chosen as a 
conservative estimate to maintain power over 0.9. Statistical significance was set at 
p<0.05. All data are displayed as mean ± standard error (SE). 
RESULTS 
The mean fasting blood glucose values were not significantly different between 
the two treatments (CHO/AA 4.18±0.07 mmol/L, CHO 4.16±0.06 mmol/L) (Fig. 3.1A). 
However, there was a significant treatment effect with the blood glucose response for the 
CHO/AA treatment significantly lower than that of the CHO treatment. This result was 
supported by the finding that the glucose AUC for the CHO/AA treatment was 
significantly lower than that for the CHO treatment (Fig. 3.1B). Statistical analysis also 
identified a treatment by time interaction with blood glucose during the CHO/AA 
treatment lower than the CHO treatment at 30, 60, 120, and 180 min after supplement 
ingestion. It was further noted that blood glucose returned to the fasting level after 120 
min during the CHO/AA treatment, but during the CHO treatment this required 180 min.  
The mean fasting plasma insulin values were not significantly different between 
the two treatments (CHO/AA 161.34±13.66 pmol/L, CHO 163.80 ± 14.53 pmol/L) (Fig. 
3.2A). Furthermore, there was no significant difference between the CHO and CHO/AA 
treatments, nor was there a significant difference in the insulin AUC between the two 
treatments (Fig. 3.2B). After ingestion of the beverage, blood insulin increased 
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immediately and remained higher than the fasting value for the next 180 min after both 
treatments, and there were no significant differences in plasma insulin concentration 
between the two treatments at any time point.  
Similar to the plasma insulin responses, plasma c-peptide concentrations did not 
differ between the treatments at any time point (Fig. 3.3A). There was also no significant 
difference in the c-peptide AUC between the two treatments (Fig. 3.3B). After ingestion 
of either treatment, plasma c-peptide increased and remained higher than the fasting 
value for the next 180 min. The maximal c-peptide concentration was reached at 60 min 
in both treatments.  
The mean fasting plasma glucagon values were not significantly different between 
the two treatments (CHO/AA 63.85±5.91 ng/L, CHO 67.70±6.52 ng/L) (Fig. 3.4A). 
There was, however, a significant treatment effect found between the CHO and CHO/AA 
treatments. There was also a significant difference in the glucagon AUC between the two 
treatments (Fig. 3.4B). As expected, the plasma glucagon concentration significantly 
decreased at 30 min during the CHO treatment and remained below the fasting value for 
the next 180 min. During the CHO/AA treatment, the plasma glucagon concentration 
fluctuated around the fasting value during the OGTT, but never became significantly 
lower than the fasting value. The plasma glucagon concentration was significantly higher 
in CHO/AA than CHO at 60 min post treatment (p<.05).  
 The mean fasting plasma FFA concentration was significantly lower in CHO/AA 
treatment as compared to CHO treatment (CHO/AA 0.224±0.014 mmol/L, CHO 
0.257±0.014 mmol/L, p<.05) (Fig. 3.5A). There was no significant difference between 
the CHO and CHO/AA treatments. However, there was a significant treatment by time 
interaction with plasma FFA during the CHO/AA treatment lower than the CHO 
treatment at 15 min after supplement ingestion. There were no significant differences in 
plasma FFA concentration between the two treatments at any other time point post 
beverage ingestion. Plasma FFA concentration significantly decreased at 30 min and 
reached a plateau at 120 min during both treatments.  
No treatment effect was found for plasma TG (Fig. 3.5B) or blood lactate (Fig. 
3.6). Moreover, there were no significant differences in plasma TG or blood lactate 
concentrations at any time point between the two treatments.  
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DISCUSSION 
In the present study, we investigated the acute effect of an amino acid mixture on 
glucose tolerance in healthy overweight/obese adults. We found that the amino acid 
mixture, composed of isoleucine, cystine, methionine, valine, and leucine, can improve 
the glucose response to an oral glucose challenge. In addition, we found that the blood 
glucose response was significantly reduced within 30 min of ingesting the glucose/amino 
acid mixture (Fig. 3.1A). Moreover, blood glucose returned to the fasting level more 
rapidly during the CHO/AA treatment than the CHO treatment. These results are 
consistent with our previous study, which shows that amino acid mixture can reduce 
blood glucose responses to an oral glucose challenge in Sprague-Dawley rats (Bernard et 
al., 2011). Ikehara et al. (Ikehara et al., 2008) also reported a hypoglycemic effect of 
isoleucine, the primary amino acid in our mixture. In their study, mice fasted for 18h 
were given isoleucine or distilled water orally. During the following oral glucose 
tolerance test, the blood glucose level was significantly reduced by isoleucine 
administration in normal mice, as well as in diet-induced glucose-intolerant mice and 
db/db mice, a model of severe type 2 diabetes.  
Some studies ascribe the hypoglycemic effects of amino acids to an increased 
insulin response (Kalogeropoulou et al., 2008). It is known that protein and certain amino 
acids, such as leucine, isoleucine, arginine, and methionine, are insulin secretagogues 
(Boden and Tappy, 1990; Bolea et al., 1997; Broca et al., 1999; Broca et al., 2000; Fajans 
et al., 1967; Milner, 1970; Sener and Malaisse, 1981; Sener et al., 1981; Spiller et al., 
1987). Protein and amino acids have been reported to increase the blood insulin response 
and reduce the blood glucose response when ingested with carbohydrate (Kalogeropoulou 
et al., 2008; Spiller et al., 1987; van Loon et al., 2000; Zawadzki et al., 1992). 
Kalogeropoulou et al. (Kalogeropoulou et al., 2008) reported that 1 mmol/kg lean body 
mass leucine (a mean of 7 g) provided with 25 g glucose attenuated the blood glucose 
response and strongly stimulated additional insulin secretion in healthy subjects, 
compared with a 25 g glucose only treatment. Moreover, Nuttall et al. (Nuttall, 2008) 
reported that 1 mmol/kg lean body mass isoleucine (a mean of 7.4 g) reduced the blood 
glucose response without a significant rise in plasma insulin concentration. Several 
animal studies have also suggested the insulin-independent hypoglycemic effect of amino 
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acids in vivo (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007; Ikehara et al., 2008) and 
in vitro (Doi et al., 2003; Nishitani et al., 2002). Our results are consistent with an 
insulin-independent effect of amino acids on control of blood glucose. Although 
CHO/AA significantly reduced the blood glucose response, the plasma insulin responses 
were similar between CHO/AA and CHO treatments. This was further confirmed by the 
similar c-peptide responses in both treatments. Therefore, the improved glucose tolerance 
by the amino acid mixture in the present study was not likely due to an increased plasma 
insulin response.  
Aside from an increased insulin response, there are several other possibilities that 
might account for the reduced glucose response to the glucose challenge during the 
CHO/AA treatment. One is that the amino acid mixture slowed gastric emptying, 
resulting in a smaller blood glucose response. Dietary protein before or with a meal 
generally slows gastric emptying (Bowen et al., 2006) and produces greater satiety 
(Latner and Schwartz, 1999; Ma et al., 2009; Poppitt et al., 1998; Porrini et al., 1995). 
However, the similar insulin and c-peptide responses for both treatments in the present 
study suggest that the appearance rate of glucose from the gastrointestinal system to the 
circulation should be similar. Furthermore, it is unlikely the small amount of amino acids 
ingested during the OGTT would have the same effect on gastric emptying as dietary 
protein.  
Another possibility is that the amino acid mixture suppressed hepatic glucose 
output. Doi et al. (Doi et al., 2007) reported that under insulin-free conditions, isoleucine 
significantly inhibited hepatic gluconeogenesis when alanine was used as a glucogenic 
substrate in isolated hepatocytes. This was accompanied by a reduction in mRNA levels 
for phosphoenolpyruvate carboxykinase (PEPCK), a key gluconeogenic enzyme, and a 
decrease in PEPCK activity. A reduction in mRNA levels for glucose-6-phosphatase 
(G6Pase) and a decreased activity of G6Pase were also found in both isoleucine-
incubated hepatocytes and isoleucine-administered rats. These findings suggest that the 
hypoglycemic effect of amino acids could be due, in part, to a reduced hepatic glucose 
output subsequent to inhibition of gluconeogenesis. However, with plasma insulin levels 
reaching 1200 pmol/L in both the CHO/AA and CHO treatments, it is likely that 
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gluconeogenesis was completely suppressed, and any effect amino acids could have on 
hepatic glucose output was negated (Ader and Bergman, 1990; Sindelar et al., 1997). 
A third possibility for the hypoglycemic effect of the amino acid mixture in the 
present study was an acceleration in peripheral tissue glucose uptake. Several in vivo 
animal studies have reported that certain amino acids increase skeletal muscle glucose 
uptake (Bernard et al., 2011; Doi et al., 2005; Doi et al., 2007; Kleinert et al., 2011). For 
example, Doi et al. (Doi et al., 2007) found that oral administration of isoleucine 
(0.45g/kg body weight) with a bolus intravenous administration of 2-deoxyglucose 
significantly decreased the plasma glucose level by 20% and enhanced skeletal muscle 
glucose uptake by 71% in rats without a significant rise in plasma insulin. In contrast, no 
significant changes in glucose uptake were identified in the liver or adipose tissue. 
Likewise, Bernard et al. (Bernard et al., 2011) reported that our amino acid mixture 
increased muscle glucose uptake in both fast-twitch red and white muscles with no 
difference in insulin response among treatments. These results suggest that the 
hypoglycemic effect of our amino acid mixture is due to an increased glucose uptake in 
skeletal muscle.  
The mechanism by which amino acids increase muscle glucose uptake is not 
immediately clear. The possible underlying signaling pathway for amino acid-stimulated 
glucose uptake in skeletal muscle was investigated in several in vitro studies (Doi et al., 
2003; Doi et al., 2005; Doi et al., 2007; Kleinert et al., 2011; Morifuji et al., 2009; 
Nishitani et al., 2002). Doi et al. (Doi et al., 2003) found that isoleucine increased glucose 
uptake of C2C12 myotubes in an insulin-independent manner. Nishitani et al. (Nishitani 
et al., 2002) also found that 2 mM leucine significantly increased 2-deoxyglucose uptake 
in isolated rat soleus muscle under insulin-free conditions. It has been reported that PI3K 
was transiently activated in myotubes by leucine (Peyrollier et al., 2000), which is a key 
enzyme related to the translocation of GLUT4 to the plasma membrane and glucose 
uptake in skeletal muscle. However, the phosphorylation of Akt/PKB, which is an 
intermediate in the insulin signaling pathway and lies downstream of PI3K, was 
unchanged in myotubes by incubation with leucine or isoleucine (Atherton et al. 2010; 
Kimball et al., 1999; Peyrollier et al., 2000). Analysis of the intracellular signaling 
pathway via enzyme inhibitors found that the PI3K inhibitor LY294002 and aPKC 
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inhibitor GF 109203X independently suppressed glucose uptake stimulated by isoleucine 
or leucine (Doi et al., 2003; Nishitani et al., 2002). Inhibition of the mammalian target of 
rapamycin (mTOR) with rapamycin, however, had no effect on amino acid-stimulated 
glucose transport (Doi et al., 2003; Nishitani et al., 2002). A recent study from our 
laboratory found that our amino acid mixture significantly increased glucose uptake in 
isolated epitrochlearis muscle in the absence or presence of a submaximal and maximal 
insulin concentration (Kleinert et al., 2011). Western blotting analysis revealed that the 
amino acid mixture increased phosphorylation of Akt substrate of 160 kDa (AS160) 
under these conditions. AS160 is one potential candidate of downstream targets of 
Akt/PKB and has been suggested to regulate GLUT-4 translocation in response to either 
insulin or contractile activity (Bruss et al., 2005; Cheng et al., 2005; Eguez et al., 2005). 
However, our amino acid mixture had no effect on Akt/PKB or mTOR phosphorylation. 
These results were confirmed with an in vivo study from our laboratory. Intubation of our 
amino acid mixture significantly elevated muscle glucose uptake in Sprague-Dawley rat 
independently of insulin (Bernard et al., 2011). The increased muscle glucose uptake was 
accompanied by an increased phosphorylation of AS160 without altering Akt/PKB 
activation. These findings suggest that certain amino acids may enhance muscle glucose 
transport through an as yet undefined intracellular signaling pathway.  
Although previous studies and our findings suggest improved glucose tolerance 
by protein and amino acid supplementation, others have reported that amino acids inhibit 
muscle glucose uptake rather than improve glucose tolerance (Abumrad et al., 1982; 
Baum et al., 2005; Flakoll et al., 1992; Patti et al., 1998; Pisters et al., 1991; Tessari et al., 
1985). It is proposed that amino acids activate mTOR/p70S6K signaling, which mediates 
the phosphorylation of insulin receptor substrate 1 (IRS-1) and suppresses IRS-1-
dependent PI3K/Akt signaling for glucose transport (Iwanaka et al., 2010; Patti et al., 
1998; Tremblay and Marette, 2001; Tzatsos and Kandror, 2006). Of all the essential 
amino acids, leucine has been suggested as the most potent and unique in stimulating 
mTOR/p70S6K signaling (Anthony et al., 2000; Atherton et al., 2010; Blomstrand et al., 
2006; Patti et al., 1998; Tzatsos and Kandror, 2006). However, the amino acid mixture 
investigated in the present study was predominately composed of isoleucine, which has 
been shown to have no effect on mTOR and p70S6K (Atherton et al., 2010; Tremblay 
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and Marette, 2001). Therefore, the different compositions of amino acids utilized may be 
responsible for the observed conflicting effects of amino acids on blood glucose 
regulation. 
Other possibilities for the conflicting effects of amino acids on blood glucose may 
be the different amounts, exposure time, and methods of administering the amino acids. It 
was found that in vitro muscle glucose uptake was optimal with 2 mM leucine but 
decreased with 4 mM leucine under insulin-free conditions (Nishitani et al., 2002). 
Therefore, there may be an optimal concentration range of amino acids, which can 
stimulate muscle glucose uptake. Below or above this optimal range may limit the 
glucose lowering effect of amino acids. Moreover, Nishitani et al. (Nishitani et al., 2002) 
found that muscle glucose uptake in vitro increased when the muscle was incubated with 
2 mM leucine for 15-45 min but not with 60 min incubation. Therefore, over exposure to 
high concentrations of amino acids could result in insulin resistance and limit blood 
glucose uptake. In addition, Tremblay et al. (Tremblay et al., 2005b) found that amino 
acid infusion rapidly increased the plasma amino acid concentration and decreased the 
whole body rate of glucose disappearance in response to peripheral hyperinsulinemia. 
The resulting hyperaminoacidaemia may suppress glucose transport via the 
overactivation of mTOR/p70S6K, which can suppress the IRS-1-dependent PI3K/Akt 
signaling cascade. Therefore, hyperaminoacidaemic infusion may also be partially 
contributing to the conflicting effects of amino acids on blood glucose regulation. 
The present study found that the plasma glucagon concentration was significantly 
decreased after 30 min of CHO ingestion. However, when amino acid mixture was 
ingested with glucose, the plasma glucagon concentration fluctuated around the fasting 
value for the entire 3 hrs and was significantly higher than CHO at 60 min. The relative 
higher glucagon concentration in CHO/AA, as compared to the CHO treatment, may be 
due to the reduced glucose concentration by the amino acid mixture. The blood glucose 
concentration was significantly lower in CHO/AA compared with the CHO treatment 
(CHO/AA 4.71 mmol/L, CHO 5.95 mmol/L) at 60 min post supplement, which 
corresponded with the significantly higher plasma concentration of glucagon at 60 min in 
CHO/AA.  
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Another reason for the higher glucagon level in CHO/AA may be the amino acid 
mixture itself. It has been reported that protein and amino acids stimulate an increase in 
circulating glucagon concentration (Unger and Orci, 1976; Westphal et al., 1990). Nuttall 
et al. (Nuttall, 2008) reported a small, transient increase in glucagon in subjects given 
isoleucine at a concentration of 1 mmol/kg lean body mass. Kalogeropoulou et al. 
(Kalogeropoulou et al., 2008) also recently reported an increase in glucagon 
concentration with orally administrated leucine. Glucagon is known to stimulate the liver 
to release glucose and raise blood glucose levels (Samols et al., 1966; Vranic et al., 
1976). However, in the present study, the blood glucose concentration was significantly 
lower in CHO/AA compared with the CHO treatment, even though the plasma glucagon 
level was significantly higher in CHO/AA. These results, therefore, further support the 
hypoglycemic effect of the amino acid mixture. 
Although the mean fasting plasma FFA concentration was significantly lower in 
CHO/AA trial compared to CHO, there were no significant differences in plasma FFA 
concentration between the two treatments at any time point except at 15 min post 
beverage ingestion. This difference in FFA concentration at 15 min between the two 
treatments was likely caused by the initial difference in mean fasting FFA concentrations. 
Likewise, there were no significant differences in plasma TG at any time between the two 
treatments. Therefore, the amino acid mixture appeared to have little effect on plasma 
FFA or TG metabolism during the oral glucose challenge.  
It is well known that blood lactate concentration increases after an oral glucose 
load (Bratusch-Marrain et al., 1980; Doar et al., 1970; Prando et al., 1988). The rise in 
blood lactate is caused by an inhibition of splanchnic lactate uptake and an increase in 
hepatic and muscle lactate production. However, the contribution to a rise in blood lactate 
is mainly a result of enhanced glycolysis in muscle, rather than a reduced lactate uptake 
by the liver (Bratusch-Marrain et al., 1980; Prando et al., 1988). In the present study, as 
expected, the plasma lactate concentration increased and peaked at 60 min after both 
supplements. There was no significant difference in blood lactate between the two 
treatments at any time point. This may suggest that an increased glucose clearance via the 
amino acid supplement is directed more to glucose storage than glycolysis, if in fact the 
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lower blood glucose level during the CHO/AA treatment was due to an increase in 
glucose uptake by skeletal muscle.  
In summary, an amino acid mixture, composed of isoleucine and 4 additional 
amino acids, lowered the glucose response to an OGTT in healthy overweight/obese 
subjects. Insulin was not likely responsible for the smaller increase in blood glucose 
concentration during the CHO/AA treatment since the plasma insulin and c-peptide 
responses were similar in both treatments. There was a small increase in plasma glucagon 
during the CHO/AA treatment, as compared with the CHO treatment, which was most 
likely due to the lower blood glucose response during the CHO/AA treatment. There 
were no differences in plasma FFA, TG, or blood lactate between the two treatments at 
any time point. This study suggests that a mixture of amino acids may be effective in 
improving the control of blood glucose in individuals at risk of developing type 2 
diabetes. Further research is needed to determine if type 2 diabetics will respond 

























  Male Female 
Number 3 19 
Age (yr)       25 + 1.53   31.79 + 1.75 
Weight (kg) 103.31 + 6.77   91.02 + 2.65 
Height (cm) 180.87 + 0.62 161.19 + 2.03 
BMI (kg/m2)   31.53 + 2.15   35.04 + 1.16 
Waist circumference (cm) 105.67 + 1.20 105.58 + 2.27 
Screen Fasting blood glucose 
(mmol/L) 
   4.92 + 0.46    5.52 + 0.13 
Values are expressed as means + SE. BMI, body mass index. Fasting blood glucose was 
measured during screening visit.  
 




FIGURE 3.1A. BLOOD GLUCOSE DURING OGTT.  22 subjects ingested 100 g dextrose 
(CHO) or 100 g dextrose plus a 5 amino acid mixture (CHO/AA). Blood was taken 
before the ingestion and 15, 30, 60, 120 and 180 min after. Values are means + SE. *, p < 
0.05 CHO/AA vs. CHO. #, p<0.001 CHO/AA vs. CHO. 
 
FIGURE 3.1B. BLOOD GLUCOSE AREA UNDER THE CURVE (AUC) DURING OGTT.  AUC was 
calculated with baseline (pre). Values are means + SE. #, p < 0.001 CHO/AA vs CHO.
  *    * 
     # 
     # 




FIGURE 3.2A. PLASMA INSULIN DURING OGTT. 22 subjects ingested 100 g dextrose (CHO) 
or 100 g dextrose plus a 5 amino acid mixture (CHO/AA).  Blood was taken before the 
ingestion and 15, 30, 60, 120 and 180 min after. Plasma insulin was determined by 
radioimmunoassay.  Values are means + SE. 
 
FIGURE 3.2B. PLASMA INSULIN AREA UNDER THE CURVE (AUC) DURING OGTT. AUC was 
calculated with baseline (pre). Values are means + SE. 
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FIGURE 3.3A. PLASMA C-PEPTIDE DURING OGTT. 22 subjects ingested 100 g dextrose 
(CHO) or 100 g dextrose plus a 5 amino acid mixture (CHO/AA).  Blood was taken 
before the ingestion and 15, 30, 60, 120 and 180 min after. Plasma C-peptide was 
determined by radioimmunoassay. Values are means + SE. 
 
FIGURE 3.3B. PLASMA C-PEPTIDE AREA UNDER THE CURVE (AUC) DURING OGTT. AUC 
was calculated with baseline (pre). Values are means + SE. 
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FIGURE 3.4A. PLASMA GLUCAGON DURING OGTT. 22 subjects ingested 100 g dextrose 
(CHO) or 100 g dextrose plus a 5 amino acid mixture (CHO/AA).  Blood was taken 
before the ingestion and 15, 30, 60, 120 and 180 min after. Plasma glucagon was 
determined by radioimmunoassay.  Values are means + SE. *, p< 0.05 CHO/AA vs. CHO. 
§, p<0.05 vs baseline (time 0). 
 
FIGURE 3.4B. PLASMA GLUCAGON AREA UNDER THE CURVE (AUC) DURING OGTT. AUC 
was calculated with baseline (pre). Values are means + SE. *, p < 0.05 CHO/AA vs. CHO.
§ § § § 
*     
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FIGURE 3.5A. PLASMA FFA DURING OGTT. 22 subjects ingested 100 g dextrose (CHO) 
or 100 g dextrose plus a 5 amino acid mixture (CHO/AA). Blood was taken before the 
ingestion and 15, 30, 60, 120 and 180 min after. Values are means + SE. *, p < 0.05 
CHO/AA vs. CHO.  
 
FIGURE 3.5B. PLASMA TRIGLYCERIDES DURING OGTT. 22 subjects ingested 100 g 
dextrose (CHO) or 100 g dextrose plus a 5 amino acid mixture (CHO/AA).  Blood was 








FIGURE 3.6. PLASMA LACTATE DURING OGTT. 22 subjects ingested 100 g dextrose (CHO) 
or 100 g dextrose plus a 5 amino acid mixture (CHO/AA).  Blood was taken before the 
ingestion and 15, 30, 60, 120 and 180 min after. Values are means + SE
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Chapter IV: The Effect of an Amino Acid Beverage on Glucose 
Response, Glycogen Replenishment, Muscle Damage, and Anaerobic 
Performance after Strenuous Exercise 
 
ABSTRACT 
In the present study, we tested whether an amino acid mixture, composed of 
isoleucine and 4 other amino acids, would affect blood glucose and muscle glycogen 
replenishment when a carbohydrate supplement was provided after strenuous exercise. 
The effects of the amino acid mixture on muscle damage and subsequent anaerobic 
performance were also evaluated. After an intense glycogen-depleting cycling bout, 
subjects received a CHO/HAA (1.2g/kg bw CHO, 13 g amino acid mixture), CHO/LAA 
(1.2g/kg bw CHO, 6 g amino acid mixture), or CHO (1.2g/kg bw CHO) supplement 
immediately after exercise and 2 hr postexercise. Muscle biopsies were performed 
immediately post exercise and 4 hr postexercise. After the second biopsy, a Wingate 
Anaerobic Test (WAnT) was performed to evaluate anaerobic performance. The 
CHO/HAA and CHO/LAA treatments significantly decreased glucose response compared 
with CHO. The CHO/HAA caused a significantly higher insulin response compared with 
CHO treatment. Glycogen storage rate was significantly lower in the CHO/HAA 
compared with CHO while it did not differ significantly between the CHO/LAA and 
CHO treatments (CHO/HAA 15.4 ± 2.0 µmol/g wet muscle•4h-1, CHO/LAA 18.1 ± 2.0 
µmol/g wet muscle•4h-1, CHO 21.5 ± 1.4 µmol/g wet muscle•4h-1). There were no 
significant differences in the blood lactate, creatine kinase, or myoglobin responses among 
treatments. The CHO/HAA had a greater effect on phosphorylation of mTOR and 
Akt/PKB compared with CHO treatment. No significant differences in AS160 or GS 
phosphorylation were identified between treatments. The results suggest that the small 
dosage of amino acid mixture is effective in controlling blood glucose. The higher dosage 
of amino acid mixture also may stimulate insulin secretion and activate insulin-induced 
signaling.    
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INTRODUCTION 
Several studies have reported that leucine and/or isoleucine can stimulate glucose 
transport independently of insulin, possibly via an mTOR-independent PI3K/aPKC 
pathway (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007; Nishitani et al., 2002). 
Glucose uptake by skeletal muscle may be the major mechanism by which leucine and/or 
isoleucine lowers blood glucose levels (Bernard et al., 2011; Doi et al., 2005; Doi et al., 
2007; Kleinert et al., 2011). The storage form of glucose in the muscles, muscle 
glycogen, is an important fuel source for moderate to high intensity exercise. The faster 
the muscle glycogen can be replenished, the greater ability to achieve optimal 
performance in subsequent exercise. Therefore, faster clearance of blood glucose by 
skeletal muscle caused by amino acids may enhance muscle glycogen synthesis and be 
beneficial for subsequent exercise. 
Recent studies have shown that daily supplementation or acute ingestion of 
branched-chain amino acids (BCAAs) may prevent muscle damage that occurs resulting 
from prolonged, intense endurance exercise or strength training (Coombes and 
McNaughton, 2000; Greer et al., 2007; Jackman et al., 2010; Shimomura et al., 2010; 
Skillen et al., 2008). Muscle damage could affect force production and result in a 
reduction in the subsequent anaerobic exercise performance. Based on the fact that amino 
acids have been found to prevent exercise-induced muscle damage, it is reasonable to 
hypothesize that supplementing post-exercise with carbohydrate plus amino acids will 
lead to a faster post-exercise recovery and improve subsequent anaerobic exercise 
performance. 
Our laboratory recently found that gavaging normal Sprague-Dawley rats with an 
amino acid mixture, composed of isoleucine, leucine, cystine, methionine, and valine, 
improved the blood glucose response during an oral glucose challenge without an 
increase in the plasma insulin response (Bernard et al., 2011). The blood glucose-
lowering effect of the amino acid mixture was due to an increase in skeletal muscle 
glucose uptake. Correspondingly, it was also found that the amino acid mixture enhanced 
glucose uptake in rat epitrochlearis muscle in the absence of insulin, and augmented 
insulin-stimulated glucose uptake in an additive manner when the muscle was treated 
with physiological and maximally-stimulating concentrations of insulin (Kleinert et al., 
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2011).  The hypoglycemic effect of the amino acid mixture appears to be mediated by a 
molecular pathway that is independent from the insulin signaling cascade. Moreover, we 
have recently found that the similar amino acid mixture lowered the blood glucose 
response and improved glucose tolerance during an OGTT in overweight/obese subjects, 
without differences in insulin response (Study 1).  
Although our previous results support the hypoglycemic effect of an amino acid 
supplement in rats and human, the effects of this supplement on blood glucose response, 
muscle glycogen resynthesis, muscle damage, and subsequent anaerobic performance 
post strenuous exercise have not been evaluated in athletes. Therefore, the objective of 
the present investigation was to study the effects of an amino acid mixture, composed of 
isoleucine and 4 additional amino acids, on blood glucose homeostasis and recovery in 
athletes after strenuous exercise. In addition, we investigated whether the amino acid 
mixture activates cellular signaling proteins that regulate glucose transport and glycogen 
synthesis. Moreover, we tested the effects of two different doses of the amino acid 
mixture in combination with carbohydrate supplementation.  
EXPERIMENTAL PROCEDURES 
Subjects.  Ten healthy active adults (7 men, 3 women) volunteered for the study. 
Subject characteristics are presented in Table 4.1. Subjects were 27.5±2.0 yr of age, 
175.2±2.6 cm in height, and weighed 71.6±2.8 kg. All subjects were accustomed to 
cycling for prolonged periods of 3-5 hours. Before testing, subjects were given a detailed 
explanation of the procedures to be used and the potential risks of the study. During the 
initial visit, volunteers completed the Informed Consent to Participate in Research and 
filled out the Participation Health Research Screening Form. The experimental protocol 
was approved by The University of Texas at Austin Institutional Review Board. 
Maximum oxygen uptake (VO2max) was measured in all subjects on a cycle ergometer by 
using a TrueOne 2400 metabolic measurement system (ParvoMedics, Sandy, UT) to 
verify adequate aerobic fitness levels. The average VO2max was 51.9±1.6 ml•kg-1•min-1 in 
men and 46.4±3.0 ml•kg-1•min-1 in women.  
Experimental protocol. Two to three days after the VO2max test, the subjects 
reported to the laboratory to perform a practice ride to familiarize them with the 
 52 
laboratory environment and the experimental protocol. The practice ride was also used to 
adjust and verify appropriate workloads for the experimental trials. The practice rides 
simulated the protocol ride but without blood samples being taken. The ride consisted of 
cycling at 70% VO2max for 2 hr, which was followed by two 1-min sprints at maximal 
effort at 85% VO2max. The sprints were separated by 1 min cycling at 45% VO2max. 
During the first 15 min of each hour, oxygen uptake was measured for 5 min by using the 
same metabolic measurement system as used during the VO2max test, which was used to 
verify workload. Water (250 ml) was provided every 20 min of exercise. Heart rate (HR) 
was monitored and ratings of perceived exertion (RPE) were collected every 30 min of 
exercise. The practice ride and each of the following three experimental trials were 
separated by a minimum of 7 days. The subjects performed each trial in a room of 19-21
℃ at the same time of the day over a 3-week period. 
The experimental protocol is presented in Fig. 4.1. On the day of each 
experimental trial, the subjects reported to the lab in the morning after a 12 hr fast during 
which time they were allowed to consume only water. On reporting to the laboratory, 
body weight was obtained and a heart rate monitor (Cardiosport, Deer Park, NY) was 
secured in place around their chest. A Teflon catheter was inserted into a forearm vein, 
fitted with a three-way stopcock, extended with a catheter-extension, and taped in place. 
The catheter was kept patent with regular sterile saline washes. After sitting quietly for 2 
min, a resting heart rate was recorded and a blood sample was drawn. The subjects then 
mounted the ergometer and started a glycogen-depleting cycling bout, consisting of 
cycling at 70% VO2max for 2 hr, followed by five 1-min sprints at maximal effort at 85% 
VO2max. Each sprint was separated by 1 min of rest during which time the subject cycled 
at approximately 45% VO2max. During the exercise trial, the laboratory temperature was 
maintained at 19-21℃ and two floor fans were directed towards the subject to reduce 
thermal stress. Water (250 ml) was provided every 20 min of exercise. HR and RPE were 
recorded every 30 min and at the end of the sprint bout. Constant verbal encouragement 
was given to the subjects during each trial. Blood sampling and a muscle biopsy were 
performed immediately on cessation of exercise. After the muscle biopsy, subjects were 
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given the first of two supplement doses. The timing for recovery was started immediately 
after complete ingestion of the first supplement. At 120 min into the recovery period, 
subjects were given the second dose of the supplement. A second muscle biopsy was 
performed after 240 min of recovery to assess muscle glycogen resynthesis. A 
questionnaire was completed during recovery to rate the effects of the test supplements 
on stomach feeling and gastrointestinal distress. 
Within 30 min of the second muscle biopsy, subjects performed a Wingate 
Anaerobic Test (WAnT). The subjects mounted the ergometer and cycled at a self-
selected leisurely rate. After a 30 second warm up, subjects began pedaling as fast as 
possible without any resistance. Within 5 seconds, a fixed resistance (0.098 kg/kg body 
weight for men, 0.095 kg/kg body weight for women) was applied to the flywheel and 
subjects continued to pedal "all out" for 30 seconds. An electrical counter continuously 
recorded flywheel revolutions in 5 second intervals. Twenty hours after WAnT, each 
subject returned to the lab for the last blood draw. 
Nutritional supplementation. Subjects received either a 1.2 g CHO/kg body 
weight (CHO), 1.2 g CHO/kg body weight plus 6.5 g amino acid mixture (CHO/LAA) or 
1.2 g CHO/kg body weight plus 13 g amino acid mixture (CHO/HAA) immediately after 
the first muscle biopsy and at 120 min into the recovery period in a double-blinded, 
counter-balanced order. Carbohydrate was obtained as 100 g dextrose in a 10 oz orange 
flavored drink (SUN-DEX, Fisher Healthcare, Houston, TX) and the amount of drink was 
calculated according to each subject’s body weight in order to provide 1.2 g CHO/kg body 
weight. CHO/LAA consisted of 0.046g cystine 2HCl, 0.023g methionine, 0.045g valine, 
6.342g isoleucine and 0.044g leucine per person and was added to the dextrose drink. 
CHO/HAA was twice CHO/LAA. The test beverages (CHO, CHO/LAA or CHO/HAA) 
were similar in color, taste, and texture to allow a double-blinded and counter-balanced 
study design. A laboratory technician who was not involved in the data collection 
supplied the drinks to each subject. 
Dietary/training control. The subjects were instructed to maintain the same 
dietary intake and activity during the 48 hr period before each trial. They were also asked 
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to refrain from intense exercise and alcohol for 24 hr before each trial. In addition, the 
subjects were asked to fast for 12 hr before reporting to the laboratory, during which they 
could not eat or drink anything except water. They were also instructed to provide a copy 
of their training and dietary logs for the 2 days before each experimental trial. 
Physiological measures. Using Cardiosport heart rate monitor units (Deer Park, 
NY), HR was recorded at the beginning of exercise, every 30 min of exercise, at the end of 
the sprints, and at the end of WAnT. Subjective RPE on a Borg-scale (ranging from 6 to 
20) was obtained at the same time points as HR obtained during exercise. 
Anaerobic performance. WAnT was used to measure anaerobic leg power. 
Anaerobic power is defined simply as peak power relative to the subject’s body mass. 
Peak power was ideally measured during the first 5 second interval of WAnT, expressed 
in Watts. The decline in power divided by test duration is defined as the fatigue index. 
Anaerobic capacity is estimated as mean power during 30 seconds of the test relative to 
the subject’s body mass. Total work is the total amount of work accomplished in 30 
seconds of the test, expressed in Joules. The test occurred after 4 hr recovery from the 
initial fatiguing exercise bout on the same day. 
Blood sample collection and analysis. To quantify the effects of the supplements 
on glucose metabolism and muscle damage, we assessed the levels of blood glucose, 
insulin, lactate, creatine kinase (CK), and myoglobin. Blood samples (6 ml) were collected 
from a catheter inserted in a forearm vein, before the onset of the 2 hr cycling bout, on the 
cessation of sprint bouts, periodically during recovery and at the end of WAnT. During 
recovery, blood samples were collected at 30, 120, 150, and 240 min of recovery. Twenty 
hours after WAnT, each subject returned to the lab for the last blood draw. Five milliliters 
of each blood sample was put into one 5 ml gold top vacutainer tube containing clot 
activator and gel for serum separation. A 0.5 ml sample was transferred to another 12x75 
mm chilled culture tube containing 1 ml of 10% perchloric acid. Vacutainer tubes were 
centrifuged for 15 min at 1,300 g and culture tubes were centrifuged for 10 min at 3,000 
rpm at 4℃ with a HS-4 rotor in a Sorvall RC-6 centrifuge (Thermo Fisher Scientific Inc. 
Waltham, MA). Serum and perchloric acid extracts were transferred to separate 
 55 
eppendorf microcentrifuge tubes and stored at -80℃ . Each subject’s samples were 
analyzed in duplicate and concurrently after completion of all trials. Serum extracts were 
used for analysis of glucose, insulin, CK and myoglobin. Perchloric acid extracts were 
used for enzymatic analysis of blood lactate.  
Plasma glucose was determined using a colorimetric method, which employs 
glucose oxidase (GOD) and a modified Trinder color reaction (Trinder, 1969). The 
modified Trinder reagent contains the enzyme peroxidase (HPOD), 4-aminoantipyrine (4-
AAP) and p-hydroxybenzene sulfonate (p-HBS). Glucose is oxidized to D-gluconate by 
GOD with production of equal amount of hydrogen peroxide. Catalyzed by HPOD, 4-
AAP and p-HBS are oxidized by hydrogen peroxide and form a quinoneimine dye, 
intensely colored in red. The absorbance of the reaction solution was measured using a 
Beckman DU 640 spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) at a 
wavelength of 500 nm. The intensity of the color in the reaction solution is proportional 
to the concentration of glucose in the blood sample. Duplicate samples were measured 
and the intra-assay coefficient of variance was 2.2%. 
Serum insulin was measured using commercially available 125I radioimmunoassay 
(RIA) kits (MP biomedicals, LLC. Solon, OH). In a radioimmunoassay, the serum insulin 
competes with its 125I-labeled counterpart for a limited and constant number of binding 
sites on the antibody. The amount of antibody-bound 125I-labeled insulin decreases as the 
concentration of the serum insulin increases. After incubation, antibody-bound insulin 
was separated from free 125I-labeled insulin by precipitation and centrifugation. The 
radioactivity of antibody-bound 125I-labeled insulin was counted in a Wallac 1470 
Wizard™ automatic gamma counter (Perkin Elmer life sciences, Turku, Finland). The 
concentrations of serum insulin were calculated based on prepared standards. Duplicate 
samples were measured and the intra-assay coefficient of variances for insulin assay was 
4.5%. 
Lactate was determined spectrophotometrically as described by Hohorst (Hohorst, 
1965). Coupled with β-NAD and hydrazine, lactate was oxidized by lactate 
dehydrogenase (LDH) to generate pyruvate hydrazone and β-NADH. The reaction can be 
monitored by the changes in the fluorescence of NADH, which was measured using a 
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Beckman DU 640 spectrophotometer at a wavelength of 340 nm. Duplicate samples were 
measured and the intra-assay coefficient of variance was 1.3%. 
Serum CK was measured spectrophotometrically using a Creatine Kinase Reagent 
Set (Pointe Scientific, Inc. Canton, MI). CK catalyzes the reversible phosphorylation of 
ADP to form ATP and creatine in the presence of creatine phosphate.  Coupled with the 
formed ATP, glucose is phosphorylated by hexokinase(HK) to generate ADP and 
glucose-6-phosphate (G-6-P). The G-6-P is then oxidized by G6PDH to form 6-
phosphogluconate with the concomitant production of NADH. This reaction can be 
monitored by the changes in the fluorescence of NADH, which was measured using a 
Beckman DU 640 spectrophotometer at a wavelength of 340 nm. Duplicate samples were 
measured and the intra-assay coefficient of variance was 3.6%. 
Myoglobin was measured spectrophotometrically using a Myoglobin Enzyme 
Immunoassay Test Kit (Bio Check, Inc., Foster City, CA). This test is based on the 
principle of a solid phase enzyme-linked immunosorbent assay (ELISA). The absorbance 
of the reaction solution was measured using a Bio-Tek ELx800 microplate reader (Bio-
Tek Inc., Winooski, VT) at a wavelength of 450 nm. The intensity of the color in the 
reaction solution is proportional to the concentration of myoglobin in the blood sample. 
Duplicate samples were measured and the intra-assay coefficient of variance was 8.0%. 
Tissue processing. Muscle biopsies (~50 mg wet wt) were taken immediately 
after exercise and after 4 hr of recovery according to Bergstrom (Bergstrom et al., 1967) 
from the vastus lateralis, a muscle highly recruited during cycling. The biopsies were 
frozen in liquid nitrogen and stored at -80℃ for subsequent determination of glycogen and 
protein. The muscle samples were weighed and homogenized in 9X volume of ice-cold 
buffer (pH 7.4), containing 20 mM Hepes, 2 mM EGTA, 50 mM NaF, 100 mM KCl, 0.2 
mM EDTA, 50 mM glycerolphosphate, 1 mM DTT, 0.1 mM PMSF, 1 mM 
Benzamidine, and 0.5 mM Na vanadate. The muscle homogenate was then centrifuged at 
1,000 rpm for 2 min at 4℃ to collect the entire sample. Half of the homogenate was used 
for muscle glycogen analysis and the other half for western blotting. 
Muscle glycogen analysis. The muscle homogenate samples were transferred and 
added to 1 ml of ice-cold 1N KOH, which were then incubated at 60℃ for 30 min. After 
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cool down to room temperature, a 100 µl aliquot of the KOH-digested muscle homogenate 
was added to 250 µl of 0.3 M sodium acetate (pH 4.8) and 10 µl of 50% of glacial acetate 
acid. The KOH-digested muscle homogenate was then incubated overnight in 250 µl of 0.3 
M sodium acetate buffer (pH 4.8) containing 10 mg/ml amyloglucosidase. After overnight 
incubation, 25 µl of 1 N NaOH was added to terminate the reaction. Liberated glucose 
was then measured using a spectophotometric Trinder color reaction (Cliniqa 
Corporation, San Marcos, CA) (Trinder, 1969). Duplicate samples were measured and 
the intra-assay coefficient of variance was 0.7%. 
Western blotting. Proteins investigated included mTOR, Akt/PKB, Akt substrate 
of 160 kDa (AS160) and glycogen synthase (GS). The muscle homogenate samples were 
centrifuged at 14,000 g for 10 min at 4℃ and supernatant then aliquoted to several test 
tubes for western blotting. A modified version of the Lowry assay (Lowry et al., 1951) 
was used to determine the protein concentration of the homogenate. The phosphorylation 
of mTOR, Akt/PKB, AS160 and GS were used as an indirect measurement of their 
activity. The phosphorylation of a structural protein, α-Tubulin, was used as an internal 
control. Sample protein (100 µg) was combined with an equal amount (1:1) of sample 
buffer (1.25M tris, 20% glycerol, 20% SDS, 0.25% bromophenol, β-mercaptoethanol, pH 
6.8) and boiled at 95℃ for 5 min. Next, sample proteins were subject to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins were separated 
on a 10% polyacrylamide resolving gel for 2 hr. The resolved proteins were then 
transferred to a nitrocellulose membrane using a wet transfer unit and blocked in 7% 
nonfat dry milk in Tris-Tween-buffered saline (NFDM/TTBS) for 30 min at room 
temperature. The membranes were then incubated with either affinity purified anti-
phospho-Akt/PKB (Ser-473), anti-phospho-AS160 (Thr-642), anti-phospho-GS (Ser-
641), anti-phospho-mTOR (Ser-2448), or anti-α-Tubulin (Cell Signaling Technology, 
Inc., Danvers, MA) overnight at 4℃. These phosphorylation sites were chosen as an 
indirect measurement of activity because they represent the primary sites of 
phosphorylation of the respective protein under insulin-stimulated conditions. The 
primary antibodies were diluted to either 1:1000 (phospho-AKT/PKB), 1:800 (phospho-
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AS160), 1:1000 (phospho-GS), 1:900 (phosphor-mTOR) or 1:1000 (phosphor-α-
Tubulin) in TTBS containing 2% NFDM. Following overnight incubation, the membranes 
were washed for three, 5-min washes in TTBS then incubated for 1 hr at room 
temperature with species-specific (anti-rabbit) immunoglobulin G (IgG) secondary 
antibodies (Cell Signaling Technology, Inc., Danvers, MA). The secondary antibodies 
were diluted to 1:800 in TTBS containing 2% NFDM. The membranes were washed again 
for three, 5-min washes with TTBS and the anti-body-bound proteins were visualized 
using Western Lightning Plus-ECL Enhanced Chemiluminescence Reagent (PerkinElmer, 
Inc., Waltham, MA) according to the manufacturer’s protocol. Images were detected and 
quantified using Quantity One analysis software (Bio-Rad, Hercules, CA). All samples 
were run with a control from insulin-stimulated rat skeletal muscle and molecular ladder. 
The amount of phosphorylated target protein on the membrane was normalized to α-
tubulin as a control between samples. 
Statistical analysis. Statistical analyses were performed by using SPSS 13.0 
software (SPSS Inc, Chicago, IL). The data was analyzed using a two-way ANOVA 
(treatment x time) with repeated measures. Post hoc analysis was performed when 
significance was found using Fisher’s Least Square Difference (LSD). Paired t-tests were 
performed to determine if significant differences in the area under the curve (AUC) for 
glucose and insulin occurred between treatments. Statistical significance was set at p<.05. 
All data was displayed as mean ± standard error (SE). 
RESULTS 
The mean fasting blood glucose values were not significantly different among the 
three treatments (CHO 4.6±0.1 mmol/L, CHO/LAA 4.8±0.2 mmol/L, CHO/HAA 4.7±0.1 
mmol/L). Immediately post 2 hr strenuous exercise, there was no significant difference in 
the mean blood glucose values between the treatments (CHO 4.4±0.3 mmol/L, 
CHO/LAA 4.3±0.3 mmol/L, CHO/HAA 4.2±0.3 mmol/L)  (Fig. 4.2A). Within 30 min 
after ingestion of the first supplement, blood glucose increased significantly regardless of 
the treatments. However, there was a significant treatment effect with the blood glucose 
response for the CHO/HAA treatment significantly lower than that of the CHO treatment 
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during the 4 hr recovery. This result was supported by the finding that the glucose AUC 
for the CHO/HAA treatment was significantly lower than for the CHO treatment (Fig. 
4.2B). Statistical analysis also identified a treatment-by-time interaction with blood 
glucose during the CHO/HAA treatment lower than the CHO treatment at 150 and 240 
min during the recovery. No significant treatment effect was detected between the CHO 
and the CHO/LAA treatments. However, the glucose AUC for the CHO/LAA treatment 
was significantly lower than for the CHO treatment. Also, a treatment-by-time interaction 
was identified with blood glucose during the CHO/LAA treatment lower than the CHO 
treatment at 240 min during the 4 hr recovery. There was no significant difference 
between the CHO/HAA and CHO/LAA treatments, nor was there a significant difference 
in the glucose AUC between the two treatments. There was also no significant difference 
in the blood glucose post WAnT between all three treatments. 
The mean fasting plasma insulin values were not significantly different among  
the three treatments (CHO 108.8±12.0 pmol/L, CHO/LAA 133.4±26.9 pmol/L, 
CHO/HAA 111.7±10.3 pmol/L). Immediately post 2 hr strenuous cycling exercise, blood 
insulin decreased dramatically in all three treatments with no significant difference 
between the treatments (CHO 62.6±5.8 pmol/L, CHO/LAA 65.6±7.3 pmol/L, CHO/HAA 
66.4±11.0) (Fig. 4.3A). After ingestion of the first supplement, insulin levels rose 
significantly at 30 min and then declined until the second supplement was ingested. 
Insulin levels then significantly increased again during the next 30 min and declined 
steadily thereafter. There was a significant treatment effect with the blood insulin 
response for the CHO/HAA treatment significantly higher than that of the CHO and 
CHO/LAA treatments during the 4 hr recovery. This result was supported by the finding 
that the insulin AUC for the CHO/HAA treatment was significantly higher than for the 
CHO and CHO/LAA treatments (Fig. 4.3B). Statistical analysis also identified a 
treatment-by-time interaction with blood insulin during the CHO/HAA treatment higher 
than the CHO treatment at 30, 120 and 150 min, and higher than the CHO/LAA treatment 
at 30 and 150 min during the recovery. There was no significant difference between the 
CHO and the CHO/LAA treatments, nor was there a significant difference in the insulin 
AUC between the two treatments (Fig. 4.3B). There was also no significant difference in 
the blood insulin post WAnT between all three treatments. 
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Plasma lactate rose significantly after the first 2 hr cycling bout and post WAnT 
without significant differences between treatments (Fig. 4.4). During recovery, plasma 
lactate significantly decreased in all three treatments. There were no differences in 
plasma lactate between the three treatments at any time point during recovery. 
There were no significant differences in muscle glycogen concentration among 
the three treatments immediately after exercise (CHO 26.3±4.6 µmol/g wet muscle, 
CHO/LAA 33.5±4.8 µmol/g wet muscle, CHO/HAA 28.5±5.9 µmol/g wet muscle) or 
after 4 hr recovery (CHO 47.8±4.5 µmol/g wet muscle, CHO/LAA 51.7±5.0 µmol/g wet 
muscle, CHO/HAA 43.9±5.1 µmol/g wet muscle). After ingestion of the beverages 
immediately post exercise and 2 hrs post exercise, muscle glycogen concentration 
significantly increased in all three treatments (Fig. 4.5). Muscle glycogen synthesis rate 
during 4 hr recovery was significantly greater during the CHO treatment compared with 
the CHO/HAA treatment. There was no difference in glycogen synthesis rate between the 
CHO and CHO/LAA treatments, and between the CHO/LAA and CHO/HAA treatments. 
The phosphorylation status of insulin-signaling proteins for glucose uptake 
(AS160, Akt/PKB) and glycogen synthesis (GS, mTOR) was assessed as an indirect 
measurement of activity level. A structural protein, α-tubulin, was used to normalize the 
amount of target protein on the membrane as a control between samples. There were no 
significant differences in AS160 phosphorylation at Thr642 (Fig. 4.6) and in GS 
phosphorylation at Ser641 (Fig. 4.7) in all three treatments immediately post 2 hr 
strenuous exercise or post 4 hr recovery. Phosphorylation of AS160 at Thr642 was 
significantly decreased and phosphorylation of GS at Ser641 was significantly increased 
post 4 hr recovery regardless of the supplement ingested. Although the phosphorylation 
of mTOR at Ser2448 did not differ between treatments immediately post 2 hr strenuous 
exercise, it was significantly higher in the CHO/HAA than the CHO treatment at the end 
of 4 hr recovery (Fig. 4.8). Meanwhile, the phosphorylation of mTOR at Ser2448 
significantly increased in the CHO/HAA treatments, but not in the CHO and CHO/LAA 
treatments. There were no significant differences in Akt/PKB phosphorylation at Ser473 
in all three treatments immediately post 2 hr strenuous exercise or post 4 hr recovery 
(Fig. 4.9). The phosphorylation of Akt/PKB at Ser473 was significantly increased in the 
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CHO/HAA at the end of 4 hr recovery, but not in the other two treatments, compared 
with immediately post exercise. 
No differences in serum CK occurred between treatments immediately post 2 hr 
strenuous exercise or after 24 hr recovery (Fig, 4.10A). Serum CK increased significantly 
24 hr post exercise in all three treatments. Similar to the serum CK responses, serum 
myoglobin concentrations did not differ between the treatments at any time point (Fig. 
4.10B). Serum myoglobin levels rose immediately post 2 hr strenuous exercise and 
continued to increase during the first 2 hours in all three treatments. Immediately after 
WAnT, serum myoglobin declined slightly regardless of the treatment ingested. 
WAnT results are presented in Table 4.2. Total work accomplished within 30 sec 
sprint was presented in Fig. 4.11. There were no significant differences identified in mean 
power, peak power, anaerobic capacity, anaerobic power, fatigue index or total work 
among the three treatments.  
DISCUSSION 
Amino acid mixture reduces blood glucose response to a carbohydrate supplement 
postexercise 
In the present study, we investigated the acute effect of an amino acid mixture 
supplement after strenuous exercise on glucose tolerance, muscle glycogen resynthesis, 
muscle damage markers, subsequent anaerobic exercise performance, and activation 
states of insulin-signaling proteins involved in glucose uptake and glycogen synthesis. 
The key finding of the present study is that the amino acid mixture, composed of 
isoleucine, cystine, methionine, valine, and leucine, can lower the glucose response to a 
carbohydrate supplement given immediately and 2 hr post strenuous exercise in trained 
athletes. This result was supported by the finding that the glucose AUC for the 
CHO/HAA and CHO/LAA treatments was significantly lower than that for the CHO 
treatment. In addition, we found that the blood glucose response was significantly 
reduced within 30 min of ingesting the second supplement in the CHO/HAA treatment, 
and also at 120 min in both the CHO/HAA and CHO/LAA treatments compared with the 
CHO only treatment. These results are consistent with our previous studies, which show 
that the amino acid mixture can reduce blood glucose responses to an oral glucose 
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challenge in Sprague-Dawley rats (Bernard et al., 2011) and in healthy overweight/obese 
adults (Study 1).  
 
Increased insulin response is partly responsible for the hypoglycemic effect of an 
amino acid mixture 
Some studies ascribe the hypoglycemic effects of amino acids to an increased 
insulin response (Kalogeropoulou et al., 2008). It is known that protein and certain amino 
acids, such as leucine, isoleucine, arginine, and methionine, are insulin secretagogues 
(Boden and Tappy, 1990; Bolea et al., 1997; Fajans et al., 1967; Milner, 1970; Sener and 
Malaisse, 1981; Sener et al., 1981). Milner et al. (Milner, 1970) reported that both leucine 
and isoleucine stimulated insulin release from rabbit pancreas incubated in a medium 
containing 1.5 mg glucose/ml. Leucine has been reported to increase the blood insulin 
response and reduce the blood glucose response in humans when ingested with 
carbohydrate (Kalogeropoulou et al., 2008; van Loon et al., 2000). Kalogeropoulou et al. 
(Kalogeropoulou et al., 2008) reported that 1 mmol/kg lean body mass leucine (a mean of 
7 g) provided with 25 g glucose attenuated the blood glucose response and strongly 
stimulated additional insulin secretion in healthy subjects, compared with a 25 g glucose 
only treatment. In contrast, Nuttall et al. (Nuttall, 2008) reported that 1 mmol/kg lean 
body mass isoleucine (a mean of 7.4 g) significantly reduced blood glucose in non-
diabetic subjects without changes in plasma insulin compared with placebo. When 
ingested with 25 g glucose, isoleucine reduced the blood glucose response without a 
significant rise in plasma insulin area response compared with glucose only treatment. 
However, they found that the mean insulin concentration was greatly increased when 
isoleucine was ingested with glucose. The mean insulin concentration increased 8-fold 
when isoleucine was ingested with glucose, but only increased 5-fold when glucose was 
ingested alone. When compared to that resulting from glucose only ingestion, the mean 
insulin concentration increased 49% with isoleucine/glucose. The insulin response 
increased more rapidly and also decreased more rapidly with isoleucine/glucose 
compared with glucose only treatment, which caused a similar plasma area response 
between two treatments. Therefore, it is possible that isoleucine per se has no effect on 
insulin response but it may synergistically stimulate glucose-induced insulin secretion. In 
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the present study, the CHO/HAA treatment significantly increased blood insulin response 
compared with the CHO and CHO/LAA treatments. The amino acid mixture in the 
CHO/HAA supplement is mainly composed of isoleucine (12.684g/2hr), which is about 
1.35 mmol/kg body mass (about 1.72 mmol/kg lean body mass). Leucine is only a small 
portion (0.088g/2hr), which is about 9.36 µmol/kg body mass. Moreover, it was found 
that the plasma concentration of isoleucine was over threefold that of leucine 1 hr after 
oral administration of the same amount of individual amino acid in rats (Doi et al., 2003). 
Therefore, the higher insulin response during the CHO/HAA treatment should be due to 
the insulin-secretion effect of isoleucine but not leucine. Nevertheless, the mechanisms 
involved for the insulin-secretion effect of isoleucine remain to be determined. 
In Study 1, one dose of a high amino acid mixture also decreased the blood 
glucose response during an oral glucose tolerance test in overweight/obese adults. 
However, no additional insulin secretion was identified with the amino acid mixture 
treatment in Study 1. The conflicting findings in Study 1 and the present study may be 
due to the experimental design. Study 1 gave the amino acid mixture with 100 g-
carbohydrate supplement to sedentary overweight/obese adults. The present study gave 
the amino acid mixture with 1.2g/kg body weight carbohydrate to healthy active adults 
immediately and 2 hr post a strenuous exercise. The blood insulin levels post 
supplements are strikingly different in these two studies. The highest insulin levels 
reached were 1000-1300 pmol/L at 30 min post supplement in Study 1, but only reached 
300-400 pmol/L at 30 min after the first supplement and reached 400-600 pmol/L at 30 
min after the second supplement in the present study. The reduced insulin response to a 
carbohydrate supplement post exercise is consistent with many studies, which found that 
insulin levels are frequently reduced after exercise (Cinar et al., 2008; Jurimae et al., 
1990). The lower insulin response post exercise is thought to be a control mechanism to 
prevent further decrease in blood glucose. Isoleucine may be only capable of stimulating 
insulin release when the circulating insulin level is low. This is also supported by the 
study done by Nuttall et al. (Nuttall, 2008). They found that isoleucine ingested with 
glucose greatly increased the insulin response. The mean circulating insulin concentration 
increased from 63 pmol/L to a maximum of 333 pmol/L at 40 min after ingestion of 
glucose. Addition of isoleucine to glucose increased insulin to a maximum of 486 pmol/L 
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at 40 min. The much higher insulin levels found in Study 1 may conceal the insulin-
secretion effect of isoleucine.     
 
Amino acid mixture reduces blood glucose response independently of insulin 
As discussed above, the higher insulin response caused by isoleucine may be 
partly responsible for the lower blood glucose levels during the CHO/HAA treatment. 
Amino acid mixture also may decrease blood glucose responses independently of insulin. 
Several animal studies have suggested the insulin-independent hypoglycemic effect of 
amino acids in vivo (Bernard et al., 2011; Doi et al., 2003; Doi et al., 2005; Doi et al., 
2007; Ikehara et al., 2008) and in vitro (Doi et al., 2003; Kleinert et al., 2011; Nishitani et 
al., 2002). Nuttall et al. (Nuttall, 2008) reported that 1 mmol/kg lean body mass 
isoleucine significantly reduced blood glucose in non-diabetic subjects without changes 
in plasma insulin, indicating an insulin-independent hypoglycemic effect of isoleucine. 
Bernard et al. (Bernard et al., 2011) from our laboratory recently found that gavaging 
Sprague-Dawley rats with a similar amino acid mixture reduced blood glucose response 
to an oral glucose challenge without additional effect on insulin response. Their results 
indicate that our amino acid mixture lowers blood glucose independently of insulin. In 
the present study, our results in the CHO/LAA treatment are consistent with an insulin-
independent effect of amino acids on control of blood glucose. The glucose AUC for the 
CHO/LAA treatment was significantly lower than that for the CHO treatment; however, 
no significant difference in the plasma insulin response was identified between the 
CHO/LAA and CHO treatments. Therefore, the improved glucose tolerance by the amino 
acid mixture in the present study may be partly due to amino acid mixture itself and 
partly due to an increased plasma insulin response. 
 
Amino acid mixture decreased glucose response by inhibiting hepatic glucose output 
and increasing muscle glucose uptake  
There are several possible explanations for the lower blood glucose response after 
an amino acid mixture ingested with carbohydrate. One is that the gastric emptying may 
be slowed down by the amino acid mixture, resulting in a smaller blood glucose response. 
Dietary protein before or with a meal generally slows gastric emptying (Bowen et al., 
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2006) and produces greater satiety (Latner and Schwartz, 1999; Ma et al., 2009; Poppitt 
et al., 1998; Porrini et al., 1995). However, when the amount of supplement ingested is 
concerned, it is unlikely the small amount of amino acids provided during the present 
study (13g/2hr for CHO/HAA or 6.5g/2hr for CHO/LAA) would have the same effect on 
gastric emptying as dietary protein.  
Another possibility is that the amino acid mixture suppressed hepatic glucose 
output. After prolonged exercise, the hepatic glucose output is elevated to maintain 
overall glucose homeostasis (Ahlborg et al., 1986; Roy and Parker, 2007). The increased 
glucose output from liver is mainly due to an increase in hepatic gluconeogenesis rather 
than glycogenolysis since the liver glycogen stores are depleted substantially during the 
prolonged exercise. The ability of insulin to suppress hepatic glucose output is well 
accepted (Ader and Bergman, 1990; De Bodo et al., 1959; Rizza et al., 1981; Steele et al., 
1965). Several studies suggested that a higher than 600 pmol/L insulin concentration is 
required to suppress gluconeogenesis completely in human (Adkins et al., 2003; Chiasson 
et al., 1980; Gastaldelli et al., 2001). In the present study, the highest insulin level 
observed after supplements is about 400-600 pmol/L. Therefore, the significantly higher 
insulin levels found in the CHO/HAA treatment may inhibit the hepatic glucose output to 
a greater extent than the CHO only treatment, resulting in a smaller blood glucose 
response. Moreover, amino acid mixture itself also may inhibit hepatic glucose output 
directly. Doi et al. (Doi et al., 2007) reported that under insulin-free conditions, 
isoleucine significantly inhibited hepatic gluconeogenesis when alanine was used as a 
glucogenic substrate in isolated hepatocytes. This was accompanied by a reduction in 
mRNA levels for phosphoenolpyruvate carboxykinase (PEPCK), a key gluconeogenic 
enzyme, and a decrease in PEPCK activity. A reduction in mRNA levels for glucose-6-
phosphatase (G6Pase) and a decreased activity of G6Pase were also found in both 
isoleucine-incubated hepatocytes and isoleucine-administered rats. These findings 
suggest that the hypoglycemic effect of amino acids could be due, in part, to a reduced 
hepatic glucose output. 
A third possibility for the hypoglycemic effect of the amino acid mixture in the 
present study was an acceleration in peripheral tissue glucose uptake. Insulin-stimulated 
glucose uptake has been well recognized. The higher insulin response in the CHO/HAA 
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treatment may cause a greater muscle glucose uptake. Moreover, several in vivo and in 
vitro animal studies also reported that amino acids improved glucose tolerance 
independent of insulin, which was associated with an increase in skeletal muscle glucose 
uptake (Bernard et al., 2011; Doi et al., 2005; Doi et al., 2007; Kleinert et al., 2011). Doi 
et al. (Doi et al., 2007) found that oral administration of isoleucine (0.45g/kg body 
weight) with a bolus intravenous administration of 2-deoxyglucose (2-DG) significantly 
decreased the plasma glucose level by 20% and enhanced skeletal muscle glucose uptake 
by 71% in rats without a significant elevation of the plasma insulin level compared with 
controls. In contrast, no significant changes in glucose uptake were identified in the liver 
or adipose tissue. Moreover, Bernard et al. (Bernard et al., 2011) from our laboratory 
gavaged Sprague-Dawley rats with either glucose (CHO) or glucose plus a similar amino 
acid mixture (CHO-AA) as used in the present study. A bolus containing [3H] 2-DG and 
[U-14C] mannitol was infused via a tail vein 15 min after gavage. They found that muscle 
glucose uptake was significantly higher in CHO-AA compared with CHO in both fast-
twitch red and white muscle with no difference in insulin between treatments. Another 
recent study from our laboratory also confirmed that the amino acid mixture increased 2-
DG uptake in the isolated rat epitrochlearis muscle in the absence of insulin (Kleinert et 
al., 2011). Furthermore, when the amino acid mixture was combined with a submaximal 
or maximal insulin concentration, 2-DG uptake was further increased significantly. These 
results suggest that an increase in skeletal muscle glucose uptake may be contributing to 
the hypoglycemic effect of the amino acid mixture independently of insulin and its 
signaling pathway. 
 
The underlying mechanism for isoleucine-induced glucose uptake in skeletal muscles  
The mechanism by which amino acids increase muscle glucose uptake is not 
immediately clear. The possible underlying signaling pathway for amino acid-stimulated 
glucose uptake in skeletal muscle was investigated in several animal studies (Doi et al., 
2003; Doi et al., 2005; Doi et al., 2007; Kleinert et al., 2011; Morifuji et al., 2009; 
Nishitani et al., 2002). A recent in vivo study from our laboratory found that an amino 
acid mixture significantly elevated phosphorylation of AS160 without altering insulin 
secretion and Akt/PKB activation stimulated by carbohydrate in Sprague-Dawley rat 
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skeletal muscles during an oral glucose challenge (Bernard et al., 2011). AS160 is a 
potential candidate of downstream targets of Akt/PKB and has been suggested to regulate 
GLUT-4 translocation in response to either insulin or contractile activity (Bruss et al., 
2005; Eguez et al., 2005; Larance et al., 2005; Treebak et al., 2006). Another recent study 
from our laboratory also found that an amino acid mixture significantly increased 2-DG 
uptake in isolated rat epitrochlearis muscle in the absence or presence of insulin (Kleinert 
et al., 2011). The amino acid mixture increased phosphorylation of AS160 under these 
conditions. Moreover, the phosphorylation of Akt/PKB was not affected by the amino 
acid mixture in the absence or presence of submaximal concentration of insulin. These 
data suggest that the amino acid mixture may increase glucose uptake in the absence of 
insulin via AS160 signaling.  
In comparison with CHO treatment, insulin was significantly elevated in the 
CHO/HAA treatment at 120 and 150 min of recovery. This would suggest a greater 
phosphorylation of AS160 during the CHO/HAA treatment since AS160 is regulated by 
insulin. Moreover, we found that Akt/PKB phosphorylation was significantly increased 
after 4 hr recovery in the CHO/HAA treatment but not in the other two treatments. This 
change in Akt/PKB phosphorylation may be due to the higher insulin response in the 
CHO/HAA treatment, since isoleucine was found to have no effect on Akt/PKB 
(Atherton et al., 2010; Bernard et al., 2011; Kimball et al., 1999; Peyrollier et al., 2000). 
Akt/PKB is suggested to be the upstream protein for insulin simulated phosphorylation 
of AS160 (Dreyer et al., 2008); however, we did not see a difference in AS160 
phosphorylation between treatments in the present study. The reason for the lack of 
effects of amino acid mixture and insulin on AS160 phosphorylation is not clear. One 
might be that AS160 phosphorylation was significantly increased and then reversed in the 
CHO/HAA treatment before the end of 4 hr recovery. Bernard et al. (Bernard et al., 2011) 
gavaged Sprague-Dawley rats with either 22.5% glucose or our amino acid mixture in 
22.5% glucose and sacrificed them 60 min after gavage. AS160 phosphorylation in 
skeletal muscle was significantly increased at 60 min after the amino acid mixture 
treatment; however, how long the higher phosphorylation of AS160 can be sustained is 
unknown. Unfortunately, we only had biopsies immediately post exercise and at the end 
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of the 4 hr recovery, which may have missed the optimal time frame to detect the effect 
of the amino acid mixture on AS160 phosphorylation. Regardless, the significantly lower 
glucose responses during the CHO/HAA and CHO/LAA treatments compared with the 
CHO treatment, but similar AS160 phosphorylation, may suggest the hypoglycemic 
effect of the amino acid mixture was mainly due to inhibition of hepatic glucose output 
and not muscle glucose clearance. 
 
Amino acid mixture directs increased glucose flux in the muscle to pyruvate oxidation 
rather than glycogen synthesis 
Once glucose enters muscle cells, it is rapidly converted to glucose-6-phosphate 
(G-6-P) by hexokinase. It may then undergo glycolysis to pyruvate or can enter the 
glycogen synthetic pathway depending on the prevailing conditions (Mandarino et al., 
1993). In the present study, the average muscle glycogen synthesis rate during 4 hr 
recovery was 5.4 µmol/g wet muscle•h-1 in the CHO treatment. This rate is similar to the 
one reported in a study by Zawadzki et al. (Zawadzki et al., 1992) during which subjects 
ingested 112 g carbohydrate immediately and 2 hr after strenuous exercise and the 
average glycogen synthesis rate was 5.5 µmol/g wet muscle•h-1. In the present study, the 
muscle glycogen synthesis rate during 4-hr recovery was significantly lower in the 
CHO/HAA treatment compared with the CHO treatment. We then assessed the 
phosphorylation status of GS, which is the key enzyme regulating glycogen synthesis. GS 
is normally activated by dephosphorylating at Ser641,645 by GSK-3 via the 
insulin/Akt/PKB signaling pathway (Cohen, 1999; Cross et al., 1995). In the present 
study, we found no significant differences in GS phosphorylation at Ser641 among all three 
treatments immediately post 2 hr strenuous exercise or post 4 hr recovery, suggesting that 
amino acid mixture had no effect on GS activation. The blood insulin response was 
significantly higher in the CHO/HAA treatment. Moreover, the phosphorylation of 
Akt/PKB at Ser473 was significantly increased in the CHO/HAA at the end of 4 hr 
recovery compared with those immediately post exercise, but this did not occur in the 
other two treatments. These results indicate that the insulin signaling pathway was better 
activated in the CHO/HAA treatment compared with the CHO treatment. Furthermore, 
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increased insulin, as well as leucine, also may stimulate the phosphorylation of mTOR, 
which leads to the phosphorylation and the subsequent activation of p70S6k (Armstrong 
et al., 2001; Kimball et al., 2002; Peyrollier et al., 2000). It has been reported that 
activated p70S6k may induce inactivation of GSK-3, which in turn triggers activation of 
GS (Armstrong et al., 2001; Sutherland and Cohen, 1994; Sutherland et al., 1993). In the 
present study, we also found a significantly higher phosphorylation of mTOR at Ser2448 in 
the CHO/HAA treatments after 4 hr recovery, but this did not occur in the CHO and 
CHO/LAA treatments. In addition, the phosphorylation of mTOR was significantly 
higher in the CHO/HAA compared with the CHO treatment at the end of 4 hr recovery, 
although it did not differ between treatments immediately post 2-hr strenuous exercise. 
As a result, the insulin-activated stimuli on GS, via two distinct signaling pathways, may 
be stronger in the CHO/HAA treatment than the CHO treatment. However, these stimuli 
may not be sufficient to activate GS and increase muscle glycogen synthesis in the 
CHO/HAA treatment. By contrast, Morifuji et al. (Morifuji et al., 2009) found that 1 
mM leucine-isoleucine dipeptide from whey protein hydrolysates caused a significant 
stimulation in glucose uptake rate and glycogen storage in isolated epitrochlearis muscles. 
Leucine has been identified as a strong activator for mTOR while isoleucine has been 
shown not to have an effect (Anthony et al., 2000; Kimball and Jefferson, 2006). 
Activated mTOR/p70S6K signaling pathway causes transient inhibition of GSK-3 and 
subsequent activation of GS, which in turn stimulates muscle glycogen synthesis 
(Armstrong et al., 2001; Kimball et al., 2002; Peyrollier et al., 2000; Sutherland and 
Cohen, 1994; Sutherland et al., 1993). Therefore, the increased glycogen storage in the 
muscle incubated with leucine-isoleucine dipeptide may be due to the activated mTOR 
signaling by leucine, not isoleucine. In support of this, Doi et al. (Doi et al., 2003) found 
that 2 mM leucine caused a significant increase in D--[U-14C]-glucose incorporation into 
intracellular glycogen in C2C12 myotubes, which did not occur with 2 mM isoleucine. 
Moreover, an oral administration of 1.35 g/kg isoleucine in food-deprived rats 
significantly decreased the plasma glucose concentration and increased glucose uptake in 
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the muscle of rats (Doi et al., 2005); however, isoleucine did not increase D-[U-14C]-
glucose incorporation into glycogen in the skeletal muscle of rats compared with controls.  
In the present study, the muscle glycogen synthesis rate during 4 hr recovery is 
significantly lower in the CHO/HAA treatment compared with the CHO treatment. This 
may suggest that the increased glucose flux of the skeletal muscle in the CHO/HAA 
treatment is directed to glycolysis rather than converted to muscle glycogen, if in fact the 
lower blood glucose level during the CHO/HAA treatment was due to an increase in 
muscle glucose uptake. With glycolysis, G-6-P formed from glucose is converted into 
pyruvate, which can then either be converted to lactate and released from the cell or enter 
the tricarboxylic acid (TCA) cycle to be oxidized in mitochondria. In the present study, 
the plasma lactate concentration increased immediately post 2 hr strenuous exercise and 
steadily decreased during 4 hr recovery and then increased again post Wingate test in all 
three supplements. Furthermore, there was no significant difference in blood lactate 
between the treatments at any time point. This may suggest that an increased glucose flux 
in glycolysis with the CHO/HAA supplement is directed more to pyruvate oxidation 
rather than lactate formation. Insulin has been shown to activate pyruvate dehydrogenase 
complex (PDHC), which plays a central role in pyruvate oxidation (Bogardus et al., 1984; 
Mandarino et al., 1987; Patel and Roche, 1990; Wieland, 1983). One may assume that the 
significantly higher insulin response in the CHO/HAA treatment may activate PDHC to a 
greater extent compared with the CHO treatment, resulting in a higher glucose flux 
entering TCA cycle. Bonadonna et al. (Bonadonna et al., 1993) assessed the effects of 
insulin on the rates of total glycolysis, glucose oxidation, glycogen synthesis, and glucose 
recycling in healthy postabsorptive human subjects. They found that physiological 
hyperinsulinemia (~70 µIU/ml) stimulated glycogen synthesis above baseline more than 
glycolysis. Considering the higher insulin response in the CHO/HAA treatment without a 
corresponding higher muscle glycogen synthesis, the effect of insulin on glucose 
oxidation might have been minimal.  
Furthermore, Doi et al. (Doi et al., 2007) reported that isoleucine administration 
stimulates glucose uptake in the muscle, which was mainly oxidized immediately after 
exercise. In their study, oral administration of isoleucine (0.45g/kg body weight) with a 
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bolus intravenous administration of 2-DG significantly decreased the plasma glucose 
level by 20% and enhanced skeletal muscle glucose uptake by 71% in rats without a 
significant elevation of the plasma insulin level compared with controls. They then oral 
gavaged rats with the same amount of isoleucine or saline again and injected a bolus of 
30 µCi/kg body wt of [U-14C]glucose. The rats were placed in acryl metabolic cages and 
normal air was drawn through the cages at 8 l/min. The expired CO2 over a 30-min period 
was collected periodically after glucose infusion. They found that expiratory excretion of 
14CO2 from [U-14C]glucose was increased by 19% in isoleucine-administered rats 
compared with controls. Haesler et al. and Tappy et al. (Haesler et al., 1994; Tappy et al., 
1992) also reported that amino acid infusion increases glucose oxidation in healthy lean 
humans during exogenous infusion of glucose. In support of the stimulatory effect of 
isoleucine on glucose oxidation, Doi et al. (Doi et al., 2005) reported that oral 
administration of isoleucine caused a significant decrease in AMP content and AMP:ATP 
ratio in the skeletal muscle of rats compared with control. Correspondingly, they also 
found that isoleucine significantly decreased AMP-activated protein kinase (AMPK) 
isoform α2 activity, which is dependent on the cellular AMP content (Stapleton et al., 
1996; Stein et al., 2000). AMPKα2 is expressed predominantly in the liver and skeletal 
muscle. The activity of another isoform of AMPK, α1, which is widely expressed, was 
unchanged in rats administered isoleucine compared with the controls. Doi’s work 
indicates that isoleucine may increase the availability of ATP independent of activation of 
AMPK in skeletal muscle of rats (Doi et al., 2005). Therefore, isoleucine may increase 
glucose uptake in the skeletal muscle with the glucose mainly oxidized to improve the 
cellular energy state in the muscle. The signaling pathway underlying the stimulatory 
effect of isoleucine on glucose oxidation is still unknown. Further investigations are 
required to elucidate the mechanism behind this effect. Based on the results from Doi et 
al. (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007), we speculated that isoleucine 




Time-dependent exercise-induced activation of proteins controlling glucose transport 
and glycogen synthesis 
It is worth mentioning that AS160 phosphorylation was significantly decreased 
and GS phosphorylation was significantly increased in all three treatments after 4 hr 
recovery compared with immediately post exercise values. To our knowledge, this is the 
first study to demonstrate that exercise-stimulated AS160 phosphorylation decreased at 
the end of 4 hr recovery with carbohydrate supplementation. The underlying mechanism 
of decreased AS160 phosphorylation in the present study is not clear. AS160 serves as a 
converging point for both insulin- and muscle contraction-dependent signaling pathways 
on glucose uptake in skeletal muscle (Dreyer et al., 2008). AS160 phosphorylation allows 
the conversion of an inactive GDP-bound Rab protein to its activated GTP-bound form, 
enabling GLUT4 translocation to cell membrane (Watson and Pessin, 2006). In the 
present study, the blood glucose concentration returned back to fasting level in all three 
treatments at the end of 4 hr recovery, suggesting that postprandial blood glucose was 
completely disposed in the body. However, the blood insulin concentration was still 
significantly higher at the end of 4 hr recovery compared with the preexercise level in 
both CHO and CHO/HAA treatments, indicating that the decreased AS160 
phosphorylation was not due to a reduction in insulin. A prior bout of moderate-intensity 
exercise has been shown to immediately phosphorylate AS160 in lean subjects, and this 
effect was sustained for up to 3 hr in the postexercise period (Howlett et al., 2008; 
Sriwijitkamol et al., 2007). However, a decrease in AS160 phosphorylation was observed 
after 4 hr recovery in the present study, suggesting a decline in glucose transport 
previously stimulated by muscle contraction. This may imply the glycogen status in the 
skeletal muscle plays a role in regulating glucose uptake process. Exercise-depleted 
muscle glycogen is replenished over time, resulting in the stimulus for glucose uptake to 
wear off. To support this hypothesis, an inverse relationship between muscle glycogen 
concentration and both insulin- (Cartee and Holloszy, 1990; Jensen et al., 1997) and 
contraction-stimulated (Hespel and Richter, 1990) glucose transport has been reported. In 
addition, GS phosphorylation was significantly increased after 4 hr recovery regardless of 
the supplement ingested in the present study, which means inactivation of GS. GS is a 
rate-determining enzyme for glycogen synthesis with a hierarchal multisite 
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phosphorylation mechanism, with dephosphorylation increasing GS activity. 
Dephosphorylation of GS is stimulated by both insulin and muscle contraction 
(Aschenbach et al., 2001). However, the increase in GS phosphorylation at the end of 4 
hr recovery was most likely not a result of a fall in blood insulin as insulin levels still 
remained significantly elevated above basal. Similar to AS160, insulin- and contraction-
stimulated GS activation is strongly influenced inversely by glycogen content (Jensen et 
al., 2006; Lai et al., 2007). These results suggest that the muscle glycogen content may 
inversely regulate both glucose uptake and glycogen synthesis, which helps to prevent 
either insufficient glycogen storage or glycogen overload in the exercised muscle.  
 
Amino acid mixture has no effects on muscle damage markers and subsequent 
anaerobic exercise performance 
In the present study, we measured serum myoglobin during the 4 hr recovery and 
serum CK at 24 hrs post exercise to assess muscle damage. The increases in serum CK 
and myoglobin levels indicate structural damage to the muscle cell resulting in the 
leakage of proteins out of the cell and into the circulation (Peake et al., 2005). In our 
study, serum CK increased significantly 24 hr post exercise in all three treatments. Serum 
myoglobin levels were elevated immediately post 2 hr strenuous exercise and continued 
to increase during the first 2 hours in all three treatments. Immediately after WAnT, 
serum myoglobin declined slightly regardless of the treatment ingested. These results 
indicate that prolonged intense exercise causes muscle damage. Moreover, no differences 
in serum myoglobin and CK occurred among treatments at any time point tested. This 
may indicate that the amino acid mixture post exercise has no benefit with regards to 
exercise-induced muscle damage. Previous studies found that daily supplementation or 
acute ingestion of BCAA may prevent muscle damage that occurs as a result of a 
prolonged, intense endurance exercise or strength training (Blomstrand and Newsholme, 
1992; Coombes and McNaughton, 2000; Greer et al., 2007; Jackman et al., 2010; Negro 
et al., 2008; Shimomura et al., 2010; Skillen et al., 2008). Discrepancy between our 
results and previous findings might exist due to administration of the amino acid mixture. 
First, previous studies examined the effect of BCAA supplementation on muscle damage, 
which were mainly composed of leucine (Shimomura et al., 2010). Secondly, previous 
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studies evaluated the chronic effect of daily BCAA supplementation with 
supplementation lasting 14 days (Coombes and McNaughton, 2000; Skillen et al., 2008). 
Thirdly, supplementation was provided before and during exercise and not just post 
exercise (Greer et al., 2007). In the present study, we examined the acute effect of an 
amino acid mixture, mainly composed of isoleucine, provided with carbohydrate and 
given immediately and 2 hr post exercise. The different experimental designs may 
explain the different findings in the present study compared with previous studies.   
After 4 hr recovery, subjects underwent an WAnt test. There were no differences 
identified in anaerobic power, anaerobic capability, fatigue index, and total work 
accomplished between the three treatments. This is consistent with our muscle damage 
results. Exercise-induced muscle damage (EIMD) could cause an immediate and 
prolonged reduction in muscle function, including reductions in muscle force production 
and power generation. WAnT has been shown to be a highly reliable and applicable test 
for predicting performance in both individual and team sporting events (Nottle and 
Nosaka, 2007; Sinnett et al., 2001). Because the external load during WAnT remains 
constant, a reduction in peak power is the direct result of an inability to achieve a high 
pedal frequency against a constant resistance. No differences in muscle damage markers 
and WAnT measures were found between treatments in the present study. This suggests 
that the amino acid mixture had no significant effect on muscle damage repair or 
subsequent anaerobic performance. WAnT is composed of a 30 sec all-out cycling sprint 
and evaluates anaerobic performance. Anaerobic power is the peak power reached 
relative to body mass and is the output of the ATP-PC energy system, which is ideally 
measured during the first 5 second interval of WAnT. Anaerobic capacity is the average 
power output during the entire test relative to body mass and is the combined ability of 
ATP-CP and glycolytic systems. Previous studies showed that WAnt metabolism is 
highly anaerobic, with 80% of the energy turnover derived from glycolysis (Beneke et al., 
2002). In the present study, no significant difference was found in blood lactate at the end 
of WAnt between all three treatments, indicating that the amino acid mixture had no 
significant effect on the anaerobic glycolytic system. 
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High dosage of amino acid mixture is more effective on blood glucose regulation and 
activation of insulin-signaling proteins 
In the present study, we tested the effects of two different doses of amino acid 
mixture given immediately and 2 hr post exercise. The CHO/LAA consisted of 0.046 g 
cystine 2HCl, 0.023 g methionine, 0.045 g valine, 6.342 g isoleucine and 0.044 g leucine 
per person and CHO/HAA was twice CHO/LAA. There was no gastrointestinal distress 
reported for any treatments although amino acids have been reported to cause problems in 
some individuals. Both CHO/HAA and CHO/LAA decreased glucose response compared 
with CHO treatment. The hypoglycemic effect was greater in CHO/HAA than 
CHO/LAA treatment [CHO/HAA vs. CHO (p = .016), CHO/LAA vs. CHO (p = .047)]. 
The CHO/HAA treatment significantly increased the insulin response and decreased 
muscle glycogen storage rate compared with the CHO treatment while no significant 
differences were identified between CHO/LAA and CHO treatments. Moreover, the 
CHO/HAA treatment had a significant effect on mTOR and Akt/PKB phosphorylation 
compared with CHO treatment. However, there was no difference in protein 
phosphorylation between CHO/LAA and CHO treatments. As a result, the CHO/LAA 
treatment was efficient in regulating glucose homeostasis. A higher dosage of amino acid 
mixture had greater impact in lowering the glucose response to a carbohydrate bolus, but 
this may have been due to a combined effect of increased insulin response and amino acid 
mixture itself.  
In summary, an amino acid mixture, composed of isoleucine and 4 additional 
amino acids, lowered the glucose response to carbohydrate supplement given 
immediately and 2 hr post strenuous exercise. A higher insulin response was observed 
with the CHO/HAA treatment. Insulin and isoleucine may be responsible for the smaller 
increase in blood glucose concentration during the CHO/HAA and CHO/LAA treatments 
by inhibiting hepatic glucose uptake and increasing muscle glucose uptake. The lower 
muscle glycogen storage rate in the CHO/HAA treatment suggests that increased glucose 
flux in skeletal muscle were directed to oxidation rather than glycogen synthesis. There 
were no significant differences in AS160 and GS phosphorylation between treatments 
immediately post 2 hr strenuous exercise or post 4 hr recovery. Phosphorylation of 
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mTOR was significantly higher in the CHO/HAA than the CHO treatment after 4 hr 
recovery. There were no differences in blood lactate, CK, or myoglobin between the three 
treatments at any time point tested. Moreover, there were no differences in WAnT 
measures between treatments. This study suggests that a small dosage of amino acid 
mixture may be effective in controlling blood glucose. A higher dosage of amino acid 
































 Age (yr) Mass (kg) Height (cm) VO2max   
(L·kg-1·min-1) 
Mean, n=10 27.5 + 2.03 71.63 + 2.80 175.2 + 2.59 50.23 + 1.60 
Males, n=7 26.43 + 2.15 74.36 + 3.38 177.29 + 3.13 51.88 + 1.63 
Females, n=3 30 + 5.03 65.27 + 2.90 170.33 + 3.93 46.38 + 3.03 
Values are expressed as means + SE. 
 







































CHO 553.7+23.0 846.4+43.0 7.8+0.2 11.9+0.4 15.2+1.5 16611.8+689.5 
CHO/LAA 550.2+20.6 828.2+44.9 7.8+0.2 11.7+0.4 14.8+1.4 16508.5+619.0 
CHO/HAA 556.2+23.7 861+47.5 7.8+0.2 12.1+0.4 15.1+1.4 16684.6+710.4 
Treatments were CHO, CHO/LAA, and CHO/HAA supplements provided immediately 
after and 2 hr after exercise. N=10. Values are expressed as means + SE.  
 










































5 x 1-min  
Intervals 
(85% & 45% VO2max) 





PERIOD 2 h at 70% VO2max  plus Sprints 
Cycling Bout  Wingate 
Test 
         



















 Blood collection 
 Supplement  
 250ml water 




FIGURE 4.2A. BLOOD GLUCOSE POST EXERCISE AND DURING 4 HR RECOVERY. Treatments 
were with CHO (○), CHO/LAA (▵), and CHO/HAA (●) supplements provided 
immediately after and 2 hr after exercise. Values are means + SE. *, CHO/HAA vs. CHO 





FIGURE 4.2B. BLOOD GLUCOSE AREA UNDER THE CURVE (AUC) DURING 4 HR RECOVERY.  
Treatments were CHO, CHO/LAA, and CHO/HAA supplements provided immediately 
after and 2 hr after exercise. AUC was calculated with baseline (pre). Values are means + 







FIGURE 4.3A. BLOOD INSULIN POST EXERCISE AND DURING 4 HR RECOVERY. Treatments 
were CHO (○), CHO/LAA (▵), and CHO/HAA (●) supplements provided immediately 
after and 2 hr after exercise. Values are means + SE. *, CHO/HAA vs. CHO (p < .05). §, 
CHO/HAA vs. CHO/LAA (p< .05). 
 
 
FIGURE 4.3B. BLOOD INSULIN AREA UNDER THE CURVE (AUC) DURING 4 HR RECOVERY.  
Treatments were CHO, CHO/LAA, and CHO/HAA supplements provided immediately 
after and 2 hr after exercise. AUC was calculated with baseline (pre). Values are means + 










FIGURE 4.4. BLOOD LACTATE DURING EXERCISE AND 4 HR RECOVERY. Treatments were 
CHO (○), CHO/LAA (▵), and CHO/HAA (●) supplements provided immediately after 





FIGURE 4.5. TOTAL MUSCLE GLYCOGEN STORAGE IN THE VASTUS LATERALIS DURING 4 HR 
RECOVERY FROM INTENSE CYCLING. Treatments were CHO, CHO/LAA, and CHO/HAA 
supplements provided immediately after and 2 hr after exercise.  Values are means + SE. 











FIGURE 4.6. AS160 THR642 PHOSPHORYLATION immediately post 2 hr intense cycling (Ex-
End) and post 4 hr recovery (4hrs Post). Treatments were CHO, CHO/LAA, and 
CHO/HAA supplements provided immediately after and 2 hr after exercise. The 
phosphorylation status of AS160 was assessed as an indirect measurement of its activity 
level. The amount of phosphorylated AS160 on the membrane was normalized to α-



















FIGURE 4.7. GLYCOGEN SYNTHASE (GS) SER641 PHOSPHORYLATION immediately post 2 hr 
intense cycling (Ex-End) and post 4 hr recovery (4hrs Post). Treatments were CHO, 
CHO/LAA, and CHO/HAA supplements provided immediately after and 2 hr after 
exercise. The phosphorylation status of GS was assessed as an indirect measurement of 
its activity level. The amount of phosphorylated GS on the membrane was normalized to 
α-tubulin as a control between samples. Values are means + SE. ¶, 4hrs Post vs. Ex-End 





















FIGURE 4.8. MTOR SER2448 PHOSPHORYLATION immediately post 2 hr intense cycling (Ex-
End) and post 4 hr recovery (4hrs Post). Treatments were CHO, CHO/LAA, and 
CHO/HAA supplements provided immediately after and 2 hr after exercise. The 
phosphorylation status of mTOR was assessed as an indirect measurement of its activity 
level. The amount of phosphorylated mTOR on the membrane was normalized to α-
tubulin as a control between samples. Values are means + SE. *, CHO/HAA vs. CHO (p 





















FIGURE 4.9. AKT/PKB SER473 PHOSPHORYLATION immediately post 2 hr intense cycling 
(Ex-End) and post 4 hr recovery (4hrs Post). Treatments were CHO, CHO/LAA, and 
CHO/HAA supplements provided immediately after and 2 hr after exercise. The 
phosphorylation status of Akt/PKB was assessed as an indirect measurement of its 
activity level. The amount of phosphorylated Akt/PKB on the membrane was normalized 
to α-tubulin as a control between samples. Values are means + SE. ¶, 4hrs Post vs. Ex-

















FIGURE 4.10A. SERUM CREATINE KINASE CONCENTRATION BEFORE INTENSIVE CYCLING 
AND POST 24 HR RECOVERY. Treatments were CHO, CHO/LAA, and CHO/HAA 
supplements provided immediately after and 2 hr after exercise. Values are means + SE. ¶, 





FIGURE 4.10B. SERUM MYOGLOBIN CONCENTRATION DURING EXERCISE AND 4 HR 
RECOVERY. Treatments were CHO (○), CHO/LAA (▵), and CHO/HAA (●) supplements 







FIGURE 4.11. TOTAL WORK DURING THE WINGATE ANAEROBIC TEST. Treatments were 
CHO, CHO/LAA, and CHO/HAA supplements provided immediately after and 2 hr after 




















Chapter V: General Discussion 
 
Recent research suggests that amino acids, such as leucine and isoleucine, may 
lower the blood glucose level by accelerating glucose uptake in peripheral tissues 
(Bernard et al., 2011; Doi et al., 2003; Doi et al., 2005; Doi et al., 2007; Kalogeropoulou 
et al., 2008; Kleinert et al., 2011; Morifuji et al., 2009; Nishitani et al., 2002).  
Nishitani et al. (Nishitani et al., 2002) reported that 2 mM leucine promoted 
glucose uptake in soleus muscles isolated from normal rats under insulin-free conditions. 
Doi et al. (Doi et al., 2003) evaluated the effects of leucine and isoleucine (0.3 g/kg body 
weight) in normal rats during the oral glucose tolerance test. Isoleucine significantly 
reduced plasma glucose response to the glucose bolus, whereas leucine did not cause a 
significant decrease. The measurement of plasma concentration of individual amino acid 
showed that plasma isoleucine concentration was elevated to 0.89 mM, over threefold 
that of leucine, which was only 0.27 mM. This may explain the lack of effect of leucine 
on glucose response in this study. These results indicate that isoleucine is more potent 
than leucine in lowering blood glucose, which is also supported by the findings that a 
significant increase in 2-DG uptake occurred when C2C12 myotubes was incubated with 
isoleucine ranging between 1-10 mM but only happened when incubated with leucine 
greater than 5 mM. Some investigators have explored the possible underlying pathway 
for the hypoglycemic effect of amino acids in animal (Doi et al., 2003; Nishitani et al., 
2002). It was found that stimulation of glucose uptake by leucine/isoleucine in vitro was 
mediated by PI3K and PKC, but independent of mTOR. The significant hypoglycemic 
effect of leucine/isoleucine was identified in C2C12 myotubes (Doi et al., 2003), L6 
myotubes, and isolated epitrochlearis muscle (Morifuji et al., 2009; Nishitani et al., 2002) 
in the absence of insulin, and was also shown in normal rats without apparent increase in 
plasma insulin (Doi et al., 2003; Doi et al., 2005; Doi et al., 2007). The ability of amino 
acids to attenuate the blood glucose response to a glucose challenge independently of 
insulin holds great clinical significance for individuals with insulin resistance. 
A series of studies have been carried on in our laboratory to explore the effect of 
an amino acid mixture, composed of isoleucine, leucine, cystine 2HCl, methionine, and 
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valine, on glucose metabolism and underlying signaling mechanism. A previous study 
showed that the amino acid mixture is more potent than isoleucine or leucine alone in 
regulating blood glucose (unpublished). Bernard et al. (Bernard et al., 2011) gavaged 
Sprague-Dawley rats with either glucose (CHO) or glucose plus the amino acid mixture 
(CHO-AA). Glucose uptake was significantly higher in CHO-AA compared with CHO in 
both fast-twitch red and white muscles with no difference in insulin between treatments. 
A follow-up in vitro study confirmed that the amino acid mixture increased 2-DG uptake 
in the isolated rat epitrochlearis muscle in the absence of insulin (Kleinert et al., 2011). 
Furthermore, when the amino acid mixture was combined with a maximal insulin 
concentration, 2-DG uptake was further increased significantly. These results suggest that 
the amino acid mixture lowers blood glucose by increasing skeletal muscle glucose 
uptake independently of insulin. When the signaling proteins were examined, we found 
that amino acid mixture significantly elevated phosphorylation of AS160 in Sprague-
Dawley rat skeletal muscles during an oral glucose challenge (Bernard et al., 2011). 
Concurrently, amino acid mixture increased phosphorylation of AS160 in isolated rat 
epitrochlearis muscle in the absence or presence of insulin (Kleinert et al., 2011). 
Moreover, the phosphorylation of Akt/PKB was not affected by the amino acid mixture 
itself or when the mixture was added to submaximal concentration of insulin. AS160 is 
one potential candidate of downstream targets of Akt/PKB and has been suggested to 
regulate GLUT-4 translocation in response to either insulin or contractile activity (Bruss 
et al., 2005; Eguez et al., 2005; Larance et al., 2005; Treebak et al., 2006). These data 
suggest that the amino acid mixture may increase glucose uptake in the absence of insulin 
via AS160 signaling. 
The animal studies support the hypoglycemic effect of an amino acid mixture 
independent of insulin. However, there has not been a comprehensive investigation of the 
impact of amino acid ingestion on glucose homeostasis in humans. Therefore, one 
primary objective of this dissertation was to investigate the effects of an amino acid 
mixture on blood glucose regulation in different populations, including overweight/obese 
adults and trained athletes. 
Once glucose enters muscle cells, it is rapidly phosphorylated and enters 
glycolysis or glycogen synthetic pathways depending on the prevailing conditions 
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(Mandarino et al., 1993). The storage form of glucose in the muscles, glycogen, is an 
important fuel source for moderate to high intensity exercise. It has been clearly 
demonstrated that aerobic endurance is directly related to the initial muscle glycogen 
stores (Bergstrom et al., 1967; Bergstrom and Hultman, 1966) and that strenuous exercise 
cannot be maintained once these stores are depleted (Bergstrom et al., 1967; Bergstrom 
and Hultman, 1966; Hermansen et al., 1967). Therefore, amino acid supplementation 
during the recovery period may be beneficial for rapid and effective replenishment of 
muscle glycogen and subsequent exercise performance, taking  account of the 
hypoglycemic effects of amino acids. 
Another important aspect of endurance exercise recovery is muscle damage 
repair. This damage does not just occur during exercise, but can continue after exercise 
for many hours. Muscle damage occurs when there is a negative net protein balance, 
which normally happens immediately after prolonged exercise if no supplement is 
provided. The ingestion of carbohydrate and protein or amino acids following exercise 
has been reported to promote protein synthesis and hasten recovery post-exercise, taking 
advantage of an enhanced insulin response, energy availability, and substrates for protein 
synthesis (Biolo et al., 1997; Koopman et al., 2005; Levenhagen et al., 2001; Tipton et 
al., 1999). Based on these studies in which an anabolic response was promoted by 
carbohydrate-protein/amino acids supplementation, it could be predicted that such 
supplementation would also reduce exercise-induced muscle damage. Muscle damage 
could affect force production and result in a reduction in the subsequent anaerobic 
exercise performance. Therefore, anaerobic performance during a subsequent exercise 
bout maybe affected by carbohydrate-protein/amino acids supplementation.  
Therefore, the secondary objective of this dissertation was to investigate the 
effects of an amino acid mixture on muscle glycogen synthesis, markers of muscle 
damage, and subsequent anaerobic performance in athletes. In addition, we examined 
whether this amino acid mixture can better activate cellular signaling proteins that 
regulate glucose transport and glycogen synthesis.  
Because it has been reported that amino acids cause gastrointestinal distress in 
some individuals, the third objective of these dissertation studies was to test two different 
dosages of amino acid mixture and evaluates whether the lower dosage would have a 
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similar effect on glucose homeostasis as the higher dosage but without gastrointestinal 
distress.  
STUDY 1 
In Study 1, the primary aim was to determine if an amino acid mixture lowers the 
blood glucose response to an oral glucose challenge in healthy overweigh adults. The 
overweight/obese population is chosen because that weight is considered the single 
strongest predictor of type 2 diabetes. A summary of results for study 1 is listed in Table 
5.1. 
Briefly, in Study 1, twenty-two healthy overweight/obese men and women 
between 20 and 45 years old completed two oral glucose tolerance tests (OGTT) after 
consuming two different beverages using a double-blinded, random ordered experimental 
design. The CHO/AA beverage consisted of an amino acid mixture in a 355 ml (12 oz) 
orange-flavored solution. The amino acid mixture consisted of 0.088 g cystine 2HCl, 
0.043 g methionine, 0.086 g valine, 12.094 g isoleucine and 0.084 g leucine per 355 ml 
solution. The CHO beverage consisted of a 355 ml orange-flavored placebo drink. Before 
each trial, both beverages were mixed with a 296 ml (10 oz) orange-flavored drink 
containing 100 g dextrose to make a drink totaling 651 ml. All subjects were instructed to 
finish the drinks within a total of 15 min. Subjects rested quietly in a room with dimmed 
lighting during each trial. Venous blood samples (7 ml) were drawn 10 min before the 
start of ingesting the drinks. Once the drinks were ingested, subsequent blood samples (7 
ml) were taken at 15, 30, 60, 120 and 180min. 
There were no significant differences in fasting blood glucose levels among the 
treatment groups. After the completion of experimental drinks, the blood glucose 
response peaked at 30 min for both treatments, and returned to the fasting level after 120 
min during the CHO/AA treatment, but during the CHO treatment this required 180 min. 
The blood glucose response and glucose AUC for the CHO/AA treatment were 
significantly lower than that of the CHO treatment. Moreover, the blood glucose during 
the CHO/AA treatment was lower than the CHO treatment at 30, 60, 120, and 180 min 
after supplement ingestion. These data suggests that the amino acid mixture lowers blood 
glucose response to a glucose bolus in healthy overweight/obese subjects. 
 93 
Insulin is one of major hormones regulating blood glucose. Therefore, the plasma 
insulin response during the OGTT was determined to assess if it is contributing to the 
lower glucose response observed with CHO/AA treatment. Plasma c-peptide response 
was also determined since it serves as an important linker between two chains of insulin 
and released as equimoler amount as insulin to the portal circulation. The mean fasting 
plasma insulin values were similar between the two treatments. After ingestion of the 
beverage, both blood insulin and c-peptide increased immediately and remained higher 
than the fasting value for the next 180 minutes regardless of treatment received. 
Furthermore, there was no significant difference in plasma insulin responses between the 
CHO and CHO/AA treatments, nor was there a significant difference in the insulin AUC 
between the two treatments Similar to the plasma insulin response, plasma c-peptide 
concentrations did not differ between the treatments at any time point. These data 
suggests that the amino acid mixture lowers blood glucose response to a glucose bolus, 
which was not likely due to an increased plasma insulin response. Our results are 
consistent with previous in vivo and in vitro animal studies.   
Glucagon is another important hormone regulating blood glucose. The mean 
fasting plasma glucagon values were not significantly different between the two 
treatments. However, the blood glucagon concentration was significantly higher at 60 
min post CHO than that post the CHO treatment. There was also a significant difference 
in the glucagon AUC between the two treatments. The relative higher glucagon response 
in CHO/AA, as compared to the CHO treatment, may be due to the reduced glucose 
concentration caused by the amino acid mixture. The significantly higher plasma 
concentration of glucagon at 60 min post CHO/AA corresponded with significantly lower 
blood glucose concentration in CHO/AA treatment. Moreover, amino acids have been 
found to stimulate glucagon secretion, which may be partly responsible for the higher 
glucagon response with CHO/AA treatment. It is worth mentioning that the blood 
glucose concentration was significantly lower in CHO/AA compared with the CHO 
treatment, although the plasma glucagon level was higher in CHO/AA and it raises blood 
glucose levels. These results, therefore, further support the hypoglycemic effect of the 
amino acid mixture. 
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There were no significant differences in plasma FFA, TG, or lactate responses 
between the two treatments at any time point, suggesting that the amino acid mixture has 
little effect on plasma FFA or TG metabolism and anaerobic glycolysis. 
In conclusion, study 1 demonstrated that an amino acid mixture, composed of 
isoleucine and 4 additional amino acids, lowered the glucose response to an OGTT in 
healthy overweight/obese subjects. Insulin was not likely responsible for the 
hypoglycemic effect of amino acid mixture. This study suggests that a mixture of amino 
acids may be effective in improving the control of blood glucose in individuals at risk of 
developing type 2 diabetes.   
 
STUDY 2 
The primary aim of Study 2 was to study the effects of two different doses of 
amino acid mixture on blood glucose homeostasis and recovery in athletes after strenuous 
exercise. In addition, we investigated whether the amino acid mixture activates cellular 
signaling proteins that regulate glucose transport and glycogen synthesis.  
Ten healthy active adults between 18 and 35 years old volunteered for the study. 
Maximum oxygen uptake (VO2max) was measured in all subjects and the average VO2max 
was 51.9±1.6 ml•kg-1•min-1 in men and 46.4±3.0 ml•kg-1•min-1 in women. Each subject 
completed three experimental trials, during which they had a glycogen-depleting cycling 
bout, consisting of cycling at 70% VO2max for 2 hr, followed by five 1-min sprints at 
maximal effort at 85% VO2max. Blood sampling and a muscle biopsy were performed 
immediately on cessation of exercise. After the muscle biopsy, subjects were given the 
first of two supplement doses. Subjects received either a 1.2 g CHO/kg body weight 
(CHO), 1.2 g CHO/kg body weight/6.5 g amino acid mixture (CHO/LAA) or 1.2 g 
CHO/kg body weight/13 g amino acid mixture (CHO/HAA). Carbohydrate was obtained 
as 100 g dextrose in a 10 oz orange flavored drink and provided 1.2 g CHO/kg body 
weight. CHO/LAA consisted of 0.046 g cystine 2HCl, 0.023 g methionine, 0.045 g valine, 
6.342 g isoleucine and 0.044 g leucine per dose and was added to the dextrose drink. 
CHO/HAA was twice CHO/LAA. The timing for recovery was started immediately after 
complete ingestion of the first supplement. At 120 min into the recovery period, subjects 
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were given the second dose of the supplement. A second muscle biopsy was performed 
after 240 min of recovery to assess muscle glycogen resynthesis. Within 30 min of the 
second muscle biopsy, subjects performed a Wingate Anaerobic Test (WAnT) to assess 
anaerobic exercise performance. Twenty hours after WAnT, each subject returned to the 
lab for the last blood draw. A summary of results for study 2 is listed in Table 5.2. 
Blood glucose significantly increased within 30 min after ingestion of the first 
dosage regardless of the treatments. The blood glucose response and glucose AUC for the 
CHO/HAA treatment were significantly lower than that of the CHO treatments during 
the 4hr recovery. No significant treatment effect was detected between the CHO and the 
CHO/LAA treatments. However, the glucose AUC for the CHO/LAA treatment was 
significantly lower than for the CHO treatment. Moreover, the blood glucose during the 
CHO/HAA treatment was significantly lower than the CHO treatment at 150 and 240 min 
during the recovery. Also, the blood glucose during the CHO/LAA treatment was 
significantly lower than the CHO treatment at 240 min during the 4 hr recovery. These 
data suggest that amino acid mixture lowers blood glucose response to a glucose bolus 
post exercise in athletes, with higher dosage more potent than lower dosage.  
There were no significant differences in the mean fasting blood insulin or the blood 
insulin immediately post 2 hr exercise between the three treatments. There was no 
significant treatment effect between the CHO and the CHO/LAA treatments, nor was 
there a significant difference in the insulin AUC. This result suggests that CHO/LAA 
lowers blood glucose response independent of insulin, which is consistent with Study 1.  
However, the CHO/HAA treatment caused a significantly higher blood insulin 
response than that of the CHO and CHO/LAA treatments during the 4 hr recovery. The 
higher insulin response in the CHO/HAA may be partially responsible for the lower 
glucose response observed. Both leucine and isoleucine are insulin-secretagogues. 
However, the amino acid mixture in the CHO/HAA supplement is mainly composed of 
isoleucine and leucine is only a small portion. Therefore, the higher insulin response 
during the CHO/HAA treatment should be due to the insulin-secretion effect of 
isoleucine but not leucine.  
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In Study 2, significantly higher insulin concentrations were identified at 30 min 
after first dose and second dose in the CHO/HAA compared with CHO treatment. These 
results are different with Study 1, which gave subjects the same amount of amino acid 
mixture (one dose) and did not produce different insulin response between treatments. 
The different insulin response to amino acid mixture between Study 1 and the current 
study may be due to the experimental design. In Study 1, the peak insulin reached 1000-
1300 pmol/L at 30 min, but in Study 2, it only reached 300-400 pmol/L at 30 min after 
the first supplement and reached 400-600 pmol/L at 30 min after the second supplement 
of CHO/HAA. The insulin-secretagogue effect of isoleucine may be limited when the 
circulating insulin level is getting physiologically high. 
The increased insulin response observed in CHO/HAA treatment may increase 
muscle glucose uptake and suppress hepatic glucose output, which in turn contributes to 
the lower blood glucose. Moreover, isoleucine has also been found to inhibit hepatic 
gluconeogenesis in isolated hepatocytes under insulin-free conditions (Doi et al., 2007). 
Whether isoleucine has a similar effect in humans needs further investigation. 
Furthermore, previous studies found that isoleucine stimulates glucose uptake in skeletal 
muscles and the phosphorylation of AS160. However, in Study 2, we did not find any 
significant differences in AS160 phosphorylation between treatments immediately post 2 
hr strenuous exercise or post 4 hr recovery. The reason for the lack of effect of amino acid 
mixture and insulin on AS160 phosphorylation is not clear. One might be that AS160 
phosphorylation was significantly increased and then reversed in the CHO/HAA 
treatment before the end of 4 hr recovery. In the present study, the insulin level was 
significantly higher in the CHO/HAA at 120 and 150 min of recovery, indicating that a 
greater phosphorylation of AS160 may happen in the same time points since AS160 is 
regulated by insulin. As a result, it is possible that isoleucine lowers blood glucose during 
a glucose challenge via both insulin-dependent and -independent pathways, which may 
operate synergistically in stimulating muscle glucose uptake and suppressing hepatic 
glucose output.   
In Study 2, the muscle glycogen synthesis rate during 4 hr recovery was 
significantly lower in the CHO/HAA treatment compared with the CHO treatment. 
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Moreover, no significant difference in GS phosphorylation at Ser641 was found between 
all three treatments, suggesting amino acid mixture has no effect on GS activation. In 
contrast, both Akt/PKB and mTOR were better activated in CHO/HAA compared with 
CHO treatment. Isoleucine has been shown to have no effect on mTOR. However, the 
significantly higher insulin response and leucine in the CHO/HAA treatment could 
theoretically stimulate mTOR phosphorylation, which in turn could activate p70S6k and 
subsequently inactivate GSK-3, resulting in activation of GS. However, these stimuli 
from insulin and leucine were apparently insufficient to activate GS during the 
CHO/HAA treatment.  
The lower blood glucose levels and muscle glycogen storage during 4 hr recovery 
in the CHO/HAA treatment may indicate a higher glycolysis in the muscle. In Study 2, 
there was no significant difference in blood lactate between the treatments at any time 
point. This may suggest that an increased glucose flux in glycolysis with the CHO/HAA 
supplement is directed more to pyruvate oxidation rather than lactate formation. Insulin 
has been shown to activate pyruvate dehydrogenase complex (PDHC), which plays a 
central role in pyruvate oxidation (Bogardus et al., 1984; Mandarino et al., 1987; Patel 
and Roche, 1990; Wieland, 1983). However, insulin was reported to affect glycogen 
synthesis more than glycolysis. Considering the higher insulin response in the CHO/HAA 
treatment without corresponding higher muscle glycogen synthesis, the contribution of 
insulin to possibly increased glucose oxidation in Study 2 may be minimal. Some studies 
suggested that isoleucine administration stimulates glucose oxidation in rats and healthy 
lean humans. Moreover, isoleucine has been found to decrease AMP:ATP ratio and 
increase availability of ATP in rats muscle, which is independent of AMPK activation. 
Therefore, it is possible that isoleucine may increase glucose uptake in the skeletal muscle 
with the incorporated glucose mainly oxidized to improve the cellular energy state in the 
muscle. The signaling pathway underlying the stimulatory effect of isoleucine on glucose 
oxidation is still unknown, further investigations are required to elucidate the mechanism 
behind this effect.  
In Study 2, we measured serum myoglobin during the 4 hr recovery and serum 
CK at 24 hrs post the 2 hr strenuous exercise to assess muscle damage. No differences in 
 98 
serum myoglobin and CK occurred at any time point tested among treatments. After 4 hr 
recovery, WAnT was performed in all subjects to assess anaerobic exercise performance. 
Similar to muscle damage markers, there were no differences identified in anaerobic 
power, anaerobic capability, fatigue index, and total work accomplished within 30 sec 
sprint between all three treatments. This may indicate that the amino acid mixture post 
exercise has no additional benefit on exercise-induced muscle damage recovery and the 
subsequent anaerobic exercise performance. WAnT is composed of a 30 sec all-out 
cycling sprint and is highly anaerobic, with 80% of the energy turnover is derived from 
glycolysis. In the present study, no significant difference was found in blood lactate at the 
end of WAnt between all three treatments. This may indicate that the amino acid mixture 
has no significant effect on anaerobic metabolism. 
In Study 2, we tested the effects of two different doses of amino acid mixture 
given immediately and 2 hr post exercise. The amount of amino acid mixture in 
CHO/HAA was twice CHO/LAA. There was no any gastrointestinal distress reported in 
subjects after all treatments. Both CHO/HAA and CHO/LAA decreased glucose response 
compared with CHO treatment, with the hypoglycemic effect greater in CHO/HAA than 
CHO/LAA treatment. The CHO/HAA treatment significantly increased the insulin 
response and decreased muscle glycogen storage rate compared with CHO treatment 
while no significant differences were identified between CHO/LAA and CHO treatments. 
Moreover, the CHO/HAA had a significant effect on mTOR and Akt/PKB 
phosphorylation compared with CHO treatment. However, there was no difference in 
protein phosphorylation between CHO/LAA and CHO treatments. As a result, the 
CHO/LAA was efficient in regulation of glucose homeostasis. The higher dosage of amino 
acid mixture had a greater impact in lowering glucose response to a carbohydrate bolus, 
which may be due to a combined effect of increased insulin response and amino acid 
mixture itself.  
In conclusion, an amino acid mixture, composed of isoleucine and 4 additional 
amino acids, lowers the glucose response to carbohydrate supplement given immediately 
and 2 hr post strenuous exercise. A higher insulin response was observed with the 
CHO/HAA treatment. Insulin and isoleucine may be responsible for the smaller increase 
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in blood glucose concentration during the CHO/HAA and CHO/LAA treatments by 
inhibiting hepatic glucose uptake and increasing muscle glucose uptake. The lower 
muscle glycogen storage rate in the CHO/HAA treatment indicates that increased glucose 
flux in skeletal muscle may be directed to oxidation rather than glycogen synthesis. There 
were no significant differences in AS160 and GS phosphorylation between treatments 
immediately post 2 hr strenuous exercise or post 4 hr recovery. Phosphorylation of 
mTOR was significantly higher in the CHO/HAA than the CHO treatment after 4 hr 
recovery. There were no differences in blood lactate, CK, or myoglobin between the three 
treatments at any time point tested. Moreover, there were no differences in WAnT 
measures between treatments. This study suggests that a small dosage of amino acid 
mixture may be effective in controlling blood glucose. A higher dosage of amino acid 
mixture may have more effect on stimulating insulin secretion and maintaining energy 
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Table 5.1 Summary for Study 1 Results. All of the measures are compared with CHO treatment. 
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Table 5.2 Summary for Study 2 Results.  All of the measures are compared with CHO treatment if not specially mentioned. 
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FUTURE DIRCTIONS 
This series of studies demonstrated the beneficial effects of an amino acid mixture 
on glucose tolerance in both healthy overweight/obese adults and trained athletes. These 
studies have also addressed some possible mechanisms underlying the hypoglycemic 
effect of amino acid mixture. Moreover, these studies evaluated the acute effect of the 
amino acid mixture on exercise-induced muscle damage and subsequent anaerobic 
exercise performance. However, several areas warrant further investigation. 
The most elusive aspect of these investigations is to fully understand the exact 
mechanism(s) through which amino acid mixture lowers blood glucose response. Study 2 
suggests the hypoglycemic effects of amino acid mixture may be due to the dual 
regulation of insulin and isoleucine on hepatic glucose output and/or muscle glucose 
uptake. The use of stable isotope methodology to track the movement of glucose in the 
body may clarify the mechanism. Furthermore, it was suggested that increased glucose 
flux in the muscle cell by isoleucine may be directed more to glycolysis rather than 
glycogen synthesis. A combination of oxygen consumption measurement and stable 
isotope methodology may provide evidence to support this assumption. If the amino acid 
mixture does have effects on hepatic glucose output and glucose oxidation, then it would 
be important to investigate the underlying mechanism responsible for them. 
AS160 is the key protein regulating GLUT4 translocation in response to insulin 
and contraction. Several animal studies have found the involvement of AS160 in 
isoleucine-induced glucose uptake. However, we did not found any difference in AS160 
phosphorylation between treatments in Study 2. One possibility may be that we missed 
the time phosphorylation of AS160 was elevated. We performed muscle biopsies 
immediately postexercise and 4 hrs after the first dose of supplement. The 
phosphorylation of AS160 may be increased after amino acid administration, but quickly 
reversed within 4 hrs. Therefore, a future study could be designed to examine the effects 
of amino acid mixture on AS160 phosphorylation at more frequent intervals, which could 
be done in an animal model.   
In addition, Study 2 did not find any benefits with the acute amino acid mixture 
supplement on exercise-induced muscle damage and subsequent anaerobic exercise 
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performance. However, daily ingestion of amino acids for at least 14 days has been 
shown to reduce muscle soreness and muscle damage markers. Therefore, chronic 
administration of the amino acid mixture may show a significant effect. Moreover, it 
would be interesting to see whether the chronic administration of amino acid mixture has 
a better control on blood glucose than an acute dosage.  
The amino acid mixture is mainly composed of isoleucine, which has been shown 
to have no effect on Akt/PKB and mTOR. Insulin-stimulated Akt/PKB and mTOR 
signaling pathways could inhibit GSK-3 and in turn activate GS, causing an increase in 
muscle glycogen synthesis. Leucine is potent in insulin secretion stimulation and mTOR 
activation. However, leucine only accounts for a small portion of our amino acid mixture. 
Therefore, increasing the leucine proportion in the mixture may cause a greater muscle 
glycogen synthesis, combined with hypoglycemic effect of isoleucine. A future study 
could be designed to examine the effectiveness of the amino acid mixture with a higher 
leucine concentration on muscle glycogen replenishment and subsequent endurance 
performance.        
These studies translated findings from animal studies to healthy humans and 
determined the effectiveness of amino acid mixture on blood glucose control. However, 
whether this supplement has a similar effect on impaired glucose tolerance and insulin-
resistant populations is not currently known. This could be possibly elucidated by 
applying the amino acid mixture on these populations during an OGTT. If the amino acid 
mixture did work in those populations, then it would serve as a non-pharmacological 






Appendix A: Blood Collection and Sample Preparation 
 
Study 1 Immediately upon collection, each blood sample was transferred into two 
12 x 75 mm polypropylene culture test tubes cooled on ice, containing 
ethylenediaminetetraacetic acid solution (EDTA, 24 mg/ml, pH 7.4). From all blood 
samples, 0.3 ml of the anticoagulated blood was transferred to tubes containing 0.6 ml 
10% perchloric acid (PCA). All tubes were centrifuged for 10 min at 3,000 rpm at 4ºC 
with a HS-4 rotor in a Sorvall RC-6 centrifuge (Thermo Fisher Scientific Inc. Waltham, 
MA). Following centrifugation, the PCA extracts were transferred to 12 x 75 test tubes 
and stored for later analysis of blood lactate. The plasma was transferred to five new 12 x 
75 test tubes. Three tubes received 0.6 ml plasma each and stored for later analysis of 
insulin, c-peptide, and glucagon. A protease inhibitor, Trasylol (aprotinin), was added to 
the glucagon test tubes to prevent proteolysis. A fourth test tube received 0.5 ml plasma 
and was stored for later analysis of glucose, free fatty acids (FFA), and triglycerides. The 
remaining plasma was placed in a fifth test tube and saved as a backup. All test tubes 
were immediately stored at -80° C. Each subject’s samples were analyzed in duplicate 
and concurrently after completion of all trials.  
Study 2 Immediately upon collection, five milliliters of each blood sample was put 
into one 5ml gold top vacutainer tube containing clot activator and gel for serum 
separation. A 0.5 ml sample was transferred to another 12x75 mm chilled culture tube 
containing 1 ml of 10% PCA. Vacutainer tubes were centrifuged for 15 min at 1,300 g and 
culture tubes were centrifuged for 10 min at 3,000 rpm at 4ºC with a HS-4 rotor in a 
Sorvall RC-6 centrifuge (Thermo Fisher Scientific Inc. Waltham, MA). Serum and the 
PCA extracts were transferred to separate eppendorf microcentrifuge tubes and were 
stored at -80℃. Each subject’s samples were analyzed concurrently after completion of 
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all trials. Serum extracts were used for analysis of glucose, insulin, CK and myoglobin. 


























Appendix B: Substrate Measurement 
(Glucose, Lactate, Free Fatty Acids, Triglycerides) 
Glucose Assay 
Plasma glucose was determined using Glucose Color Reagent Kits (Cliniqa 
Corporation, San Marcos, CA), which employs glucose oxidase (GOD) and a modified 
Trinder color reaction (Trinder, 1969). The modified Trinder reagent contains the enzyme 
peroxidase (HPOD), 4-aminoantipyrine (4-AAP) and p-hydroxybenzene sulfonate (p-
HBS). Glucose is oxidized to D-gluconate by GOD with production of equal amount of 
hydrogen peroxide. Catalyzed by HPOD, 4-AAP and p-HBS are oxidized by hydrogen 
peroxide and form a quinoneimine dye, intensely colored in red. The absorbance of the 
reaction solution was measured using a Beckman DU 640 spectrophotometer (Beckman 
Coulter, Inc., Fullerton, CA) at a wavelength of 500 nm. The intensity of the color in the 
reaction solution is proportional to the concentration of glucose in the blood sample. 
Normal resting, fasted blood glucose levels ranged between 70 and 105 mg/dL. 
Three different concentrations of glucose were used as standards and controls to 
monitor the performance of assay procedures, providing a continued screening of the 
instrument, reagents and technique. Within and between assay variations was performed 
on three standards containing varying concentrations of glucose. Data (% CV) shown are 
from two duplicate determinations of each sample in seven separate assays. 
 
Sample No. Mean mg/dL Within % CV Between % CV 
1 50 1.9 9.3 
2 100 3.7 7.3 
3 200 3.8 2.1 
 
Lactate Assay 
Blood lactate was determined spectrophotometrically as described by Hohorst 
(Hohorst, 1965). Coupled with β-NAD and hydrazine, lactate is oxidized by lactate 
dehydrogenase (LDH) to generate pyruvate hydrazone and β-NADH. The reaction can be 
monitored by the changes in the fluorescence of NADH, which was measured using a 
Beckman DU 640 spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) at a 
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wavelength of 340nm. All samples were measured in duplicate. Normal resting, fasted 
blood lactate levels ranged between 0.8 and 1.5 mM. The protocol is below: 
Chemicals: 
NAD                       Sigma N-7004 
LDH                       Sigma L-3916 
Hydrazine               Sigma H-9507 
Glycine                    Fisher G-7126 
Perchloric Acid       Fisher A-229 
GLycine-hydrazine Buffer (1000ml): 
0.33M glycine          25.02g 
0.27M hydrazine      23.94ml 
Mix and bring up to 1000ml with dH2O, pH to 9.2. 
Procedure: 
1. Prepare reagent cocktail 
For each sample: 
1ml glycine-hydrazine buffer 
 0.83mg NAD 
5U LDH (need 5µl if use 1000U/ml stock) 
2. Add 1ml reagent cocktail into test tubes. 
3. Add 50µl 10% PCA to test tubes for blank 
4. Add 50µl two lactate acid standards to standard test tubes 
5. Add 50µl blood samples to sample test tubes 
6. Vortex and incubate tubes at 37℃ for 45 minutes in shaking water bath (speed 50 
RPM). 
7. Warm the spectrophotometer for 30 minutes, read the samples at 340nM. 
8. Calculations: 
Lactate concentration = (Absorbance/6.22) x 1.05/0.05 x 3/1 
Absorbance/6.22 = Absorbance/Absorption Coefficient of NADH (ε = 6.22 cm-1 
mmol-1) 
1.05/0.05 = cuvette dilution 
3/1 = blood dilution (0.5ml blood in 1ml 10% PCA) 
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FFA Assay 
FFA was measured using a modified colorimetric method stemming from those 
devised by Ayers (Ayers, 1956) and Iwayama (Iwayama, 1959). FFA is extracted from 
plasma samples with CHM extraction reagent (choloroform, hepatane, and methanol). 
Copper nitrate and triethanolamine (TEA) are added to the test solution to form copper 
soaps of FFA. After centrifugation and separation, color reagent, diethyldithiocarbamate 
solution dissolved in butanol, was added to the chloroform layer. The color developed 
was measured using a Beckman DU 640 spectrophotometer (Beckman Coulter, Inc., 
Fullerton, CA) at a wavelength of 436nm. All samples were measured in duplicate. 
Normal resting, fasted blood FFA levels ranged from 0.3-0.8 µmol/mL. 
Four different concentrations of FFA were used as standards and controls to 
monitor the performance of assay procedures, providing a continued screening of the 
instrument, reagents and technique. Within and between assay variation was performed 
on four standards containing varying concentrations of FFA. Data (% CV) shown are 
from two duplicate determinations of each sample in 4 separate assays.  
Sample No. Mean µmol/mL Within % CV Between % CV 
1 0.25 5.5 5.7 
2 0.5 5.6 5.9 
3 1 4.9 2.7 
4 2 5.1 2.1 
 
Triglycerides Assay 
Triglycerides were measured using triglyceride GPO reagent (Cliniqa corporation, 
San Marcos, CA). The triglyceride GPO reagent contained adenosine-5’-triphosphate 
(ATP), 4-Aminoantpyrine (4-AAP), 3, 5-dichloro-2-hydroxybenzene sulfonate (DHBS), 
lipases, glycerol kinase (GK), glycerol phosphate oxidase (GPO), and peroxidase 
(HPOD). TG was hydrolyzed by lipase to glycerol and free fatty acids. Glycerol was 
phosphorylated by ATP to glycerol-1-phosphate (G-1-P), which was then oxidized to 
dihydroxyacetone phosphate (DAP) by GPO while producing equal amounts of hydrogen 
peroxide. Coupled by hydrogen peroxide, 4-AAP and DHBS were oxidized by HPOD 
and formed a quinoneimine dye, intensely colored in red. The absorbance of the reaction 
solution was measured using a Cary 50 MPR microplate reader (Varian Australia Pty Ltd, 
Victoria, Australia) at a wavelength of 520nm. The absorbance of quinoneimine dye in 
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the reaction solution was proportional to the concentration of TG in the blood sample. 



























Appendix C: Blood Hormone Measurement 
(Insulin, C-peptide, Glucagon) 
Plasma insulin, glucagon, and C-peptide were measured using commercially 
available 125I radioimmunoassay (RIA) kits. Industry standards and controls are included 
in the kit. All samples were measured in duplicate. In a radioimmunoassay, the plasma 
hormone competes with its 125I-labeled counterpart for a limited and constant number of 
binding sites on the antibody. The amount of antibody-bound 125I-labeled hormone 
decreases as the concentration of the plasma hormone increases. After incubation, 
antibody-bound was separated from free 125I-labeled hormones by precipitation and 
centrifugation. The radioactivity of antibody-bound 125I-labeled hormone was counted in 
a Wallac 1470 Wizard™ automatic gamma counter (Perkin Elmer life sciences, Turku, 
Finland). . After determining the average counts per sample, the percentage of radioactive 
insulin bound to the antibody (%B/Bo) was calculated by the following formula: 
%B/Bo = (CPM of standard or sample/ CPM of 0 µIU/mL) x 100 
The concentrations of plasma hormones were then calculated using the equation 
of the standard curve.  
 
Insulin Assay 
Plasma insulin was measured using ImmuChemTM Coated Tube  125I  RIA  Kit 
(MP biomedicals, LLC. Solon, OH). Insulin levels from healthy, fasting individuals 
obtained utilizing the ImmuChemTM Insulin RIA kit yielded the following range: 4.3-19.9 
µIU/mL (mean = 9.6, n = 24) 
Within and between assay variation was shown in the table below.  
  Intra-Assay Variation(m=1) Inter-Assay Variation(m=12) 
Control n mean SD CV% Mean SD CV% 
Pool-1 12 18.19 1.50 8.25 19.07 1.68 8.81 
Pool-2 12 36.49 1.54 4.22 35.89 3.04 5.66 
Pool-3 12 91.42 4.93 5.39 8.81 8.47 6.36 





Expected Physiological Insulin Ranges (µIU/mL) 
 
Yalow. R.S. and Berson, S.A., J. Clin. Invest., 39:1157, 1960. 
Oral administration of Glucose 
 Average 
Fasting 
0.5 hr. 1 hr. 2 hr. Average 
Nondiabetic 21 143 139 106 117 
Diabetic 27 97 156 243 147 
 
Merimee, T.J. and Pulkkinen, A.J., J. Clin. Endocrinol. Metab., 45/2, 232, 1977 
Oral administration of glucose (100g) 
Nondiabetic Average 
Fasting 
0.5 hr. 1 hr. 2 hr. 
Women 12+2 71+7 77+13 59+8.0 
Men 11+3 68+14 57+7 51+7.9 
 
 McReynolds, C.R., et al. Annals of Clin. Lab Sci., 3/6, 454, 1973 
 Oral administration of glucose (100g) 
 Average 
Fasting 
0.5 hr. 1.5 hr. 2 hr. 3 hr. 
Nondiabetic 13 54 54 47 28 
Adult onset 
diabetic 








Plasma glucagon was measured using Millipore Glucagon RIA Kit (Millipore, St. 
Charles, Missouri. Protocol attached). Normal resting, fasted blood glucagon levels 
ranged between 50 and 150 pg/mL. 
Within and between assay variation was shown in the table below.  
Sample No. Mean pg/mL Within % CV Between % CV 
1 60 6.8 13.5 
2 65 4.0 12.7 
3 90 4.6 13.4 









Plasma C-peptide was measured using Millipore Human C-Peptide RIA Kit 
(Millipore, St. Charles, Missouri. Protocol attached). Normal resting, fasted blood C-
peptide levels ranged between 0.5 and 1.5 ng/mL. 
Within and between assay variation was shown in the table below.  
Sample No. Mean ng/mL Within % CV Between % CV 
1 0.4 3.4 9.3 
2 0.9 4.4 4.4 
3 1.8 6.4 4.2 
4 2.1 4.2 3.2 

































Appendix D: Blood Muscle Damage Markers Measurement 
(Creatine Kinase, Myoglobin) 
Creatine Kinase Assay 
Serum creatine kinase (CK) was measured spectrophotometrically using Creatine 
Kinase Reagent Set (Pointe Scientific, Inc. Canton, MI). CK catalyzes the reversible 
phosphorylation of ADP to form ATP and creatine in the presence of creatine phosphate.  
Coupled with the formed ATP, glucose is phosphorylated by hexokinase(HK) to generate 
ADP and glucose-6-phosphate (G-6-P). The G-6-P is then oxidized by G6PDH to form 6-
phosphogluconate with the concomitant production of NADH.  
   CPK 
  ADP + Creatine Phosphate             Creatine + ATP 
          HK 
              ATP + Glucose             ADP + Glucose-6-Phosphate 
    G6PDH 
              G-6-P + NAD+          6-Phosphogluconate + NADH + H+ 
This reaction can be monitored by the changes in the fluorescence of NADH, 
which was measured using a Beckman DU 640 spectrophotometer (Beckman Coulter, 
Inc., Fullerton, CA) at a wavelength of 340nm. All samples were measured in duplicate. 
According to the manufacturer’s specifications, within % CV is reported to be 0.9 for 152 
determinations, and between %CV is 1.0 for 155 assays. 
Calculations 
One international Unit (U/L) is defined as the amount of enzyme that catalyzes 
the transformation of one micromole of substrate per minute under defined conditions. 
U/L = ΔAbs./min. x 1.025 x 1000 / (1 x 6.22 x 0.025) 
       = ΔAbs./min. x 6592 
Where: ΔAbs./min. = Average absorbance change per minute 
             1.025 = Total reaction volume 
             1000  = Conversion of U/ml to U/L 
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             1        = Light path in cm 
             6.22   = Millimolar absorptivity of NADH 
             0.025 = Sample volume in ml 
SI Units: To convert to SI Units (nkat/L) multiple U/L by 16.67 
Expected Values 
Expected values are based on measurement performed at 37℃. The values for males are 
up to 160 U/L, and for females are up to 130 U/L.  
 
Myoglobin Assay 
Myoglobin was measured spectrophotometrically using Myoglobin Enzyme 
Immunoassay Test Kit (Bio Check, Inc., Foster City, CA). This test is based on the 
principle of a solid phase enzyme-linked immunosorbent assay (ELISA). ELISA utilizes 
a unique monoclonal antibody directed against a distinct antigenic determinant on the 
myoglobin molecule. Mouse monoclonal anti-myoglobin antibody is used for solid phase 
immobilization on the microtiter wells, while a goat anti-myoglobin antibody is used in 
the antibody-enzyme conjugate solution. The myoglobin molecules are sandwiched 
between the solid phase and enzyme-linked antibodies when the test samples react 
simultaneously with the two antibodies. After incubating at room temperature for 45 
minutes, the wells are washed with distilled water to remove unbound labeled antibodies. 
Then, the wells are incubated with a TMB (Tetrabethyl-benzidine) reagent for 20 
minutes, resulting in the development of a blue color. A Stop Solution is added to stop 
the color development, which changes the color to yellow. The absorbance of the reaction 
solution was measured using a Bio-Tek ELx800 microplate reader (Bio-Tek Inc., 
Winooski, VT) at a wavelength of 450 nm. The intensity of the color in the reaction 
solution is proportional to the concentration of myoglobin in the blood sample. Normal 
serum myoglobin levels ranged between 12 and 100 ng/ml. 
All samples were measured in duplicate. According to the manufacturer’s 
specifications, the lowest detectable level of myoglobin by this assay is estimated to be 5 
ng/ml. The within-run and between-run precisions were determined by replicate 




Sample 1 2 3 4 5 
# Reps. 20 20 20 20 20 
Mean Myo 
(ng/ml) 55.6 214.3 294.9 505.9 1,437 
S.D. 2.2 12.9 16.2 26.3 94.0 




Sample 1 2 3 4 5 
# Reps. 35 35 35 35 35 
Mean Myo 
(ng/ml)   59.2 244.4 330.5 568.3 1451.7 
S.D. 4.6 12.8 38.9 52.7 104.7 





















Appendix E: Muscle Biopsy Procedure 
On the day before each trial, the biopsy needles were placed in self-seal 
sterilization pouches (McKesson Corporation, Richmond VA) and sterilized by 
subjecting them to high pressure steam at 120 °C for 30 minutes using an autoclave 
(Market Forge Industries, INC). Muscle biopsies (~50 mg wet wt) were taken according 
to Bergstrom (Bergstrom et al., 1967) from the vastus lateralis, which is a muscle highly 
recruited during cycling. The thigh was cleansed with 10% betadine solution and then 1.8 
ml of a local anesthesia (1% Lidocaine Hydrochloride Injection, Elkins-Sinn, Inc., Cherry 
Hill, NJ) injected to anesthetize the site of the muscle biopsy using a 25-guage 
hypodermic needle. A 5-8 mm incision was made through the skin and fascia, 2 inches 
from the midline of the thigh on the lateral side and 4 inches above the patella. Once the 
bleeding was stopped, the muscle biopsy was taken using a 3.5 to 5 mm sterile biopsy 
needle with accompanying suction and pressure was reapplied to the incision to stop 
bleeding. The biopsy samples were trimmed of adipose and connective tissue and frozen 
in liquid nitrogen at -80° C for subsequent analysis. Once bleeding stops, the incision was 
closed with a Band-Aid and a pressure pack was affixed firmly over the incision and 
taped in place with athletic tape and adhesive wrap. The subjects were given verbal and 
written instructions on how to care for the biopsy site and were required to return for a 








Appendix F: Homogenization for Glycogen Measurement and Western 
Blotting  
Muscle biopsies (~50 mg wet wt) were taken immediately after exercise and after 
4-h of recovery from the vastus lateralis. The biopsy samples were immediately frozen in 
liquid nitrogen and stored at -80 ℃ for subsequent determination of glycogen and protein 
according to Ferguson-Stegall (Ferguson-Stegall et al., 2011). On the day of assay, the 
muscle samples were weighed and homogenized in 9X volume of ice-cold homogenization 
buffer (pH 7.4), using 3 x 5 sec bursts with a Caframo RZR1 homogenizer at speed 3-4. 
The homogenization buffer was made as described below: 
 









HEPES H-3375 238.3 20 0.4766 
EGTA E-4378 380.4 2 0.0761 
NaF S-7920 41.9 50 0.209 
KCl P-217 74.6 100 0.746 
EDTA ED-2SS 292.2 0.2 0.0074 
β-Glycerophosphate  
disodium salt hydrate 
G-6251 216.0 50 1.08 
DTT D-0632 154.3 1 0.015 
PMSF 
(Phenylmethanesulfonyl fluride) 
P-7626 174.2 0.1 0.00174 
Benzamidine B-6506 156.6 1 0.01566 




The muscle homogenate was then centrifuged at 1,000 rpm for 2 min at 4℃ to 
collect the entire sample. Half of the homogenate was used for muscle glycogen analysis 
immediately. For another half of the homogenate, centrifuge at 14,000 G for 10 min and 
aliquot the supernatant into 4 x 0.5 mL microcentrifuge tubes per sample. Each aliquot 
contains ~30 µl of sample supernatant. Freeze them in liquid nitrogen immediately and 
quickly store in -80OC freezer. Freeze pellet separately at -80O. These are saved for 






















Appendix G: Muscle Glycogen Measurement 
SOLUTIONS:  
 
1 N KOH (for 500 mL): 
Add 28.01 g KOH (Fisher P-250) into 400 ml ddH2O, stir on a magnetic plate and bring 
volume to 500ml with ddH2O.   
 
0.3 M sodium acetate, pH 4.8 (for 500 mL): 
Add 12.3 g sodium acetate (Sigma S-8750) into 300 mL ddH2O, stir on a magnetic plate, 
pH to 4.8, bring volume to 500ml with ddH2O.   
 
50% glacial acetic acid (for 200 mL): 
Mix 100 mL glacial acetic acid (Sigma A-9967) with 100 ml ddH2O, stir on a magnetic 
plate.	  	  
 
10 mg/ml amyloglucosidase in sodium acetate (for 40 mL): 
Add 40 mg amyloglucosidase (Sigma 10115) into 4 mL 0.3 M sodium acetate, pH 4.8 
(Sigma S-8750) 
 
1 N NaOH (for 200 mL): 
Add 8 g NaOH (Fisher S318-3) into 150 ml ddH2O, stir on a magnetic plate and bring 




1. Add 1 ml of ice-cold 1N KOH into each muscle homogenate tube. 
2. Incubate the homogenate tube at 60oC for 30 min (shaking speed 40 RPM), 
vortexing vigorously using hand at 20 minute.  
3. Transfer 100 µl aliquot of the KOH-digested homogenate to 250 µl of 0.3 M sodium 
acetate, pH 4.8, and vortex.  
4. Add 10µl of 50% of glacial acetate acid to each of the tubes. 
5. Add 250 µl of 0.3 M sodium acetate, pH 4.8, containing 10 mg/ml amyloglucosidase 
to each tube and vortex.  
6. Seal tubes with parafilm and incubate overnight at room temperature. 
7. The following day, add 25 µl of 1 N NaOH to each sample tube and vortex to 
terminate reaction. 
8. Set up 12 x 75 mm test tubes for Trinder assay (Trinder, 1969) for determination of 
liberated glucose.  
9. Prepare Raichem color reagent according to product insert and pipet 1.5 mL of 
reagent into each tube, including two standards and samples in duplicate and a 
blank. 
10. Pipet 100 µl of muscle samples into test tubes for the Trinder reaction to begin. Use 
2 duplicate glucose standards (4.5 mg and 9.0 mg glucose/dL dH2O) to run in 
parallel with the muscle samples.   
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1. (Ab sample / Ab standard) × (standard conc. = 4.5 mg/dl) = mg/dl 
2. Dilution factors 
DF1: (1000 µl + half volume in µl of muscle homogenate)/half volume = % 
DF2: [(0.25 ml + 0.01 ml + 0.25 ml + 0.025 ml) + 0.1 ml]/0.1 ml = 6.35 
DF3: volume in cuvette, same in standard = 1 
3. Final Calculation: 
[(mg/dl) × half volume in dl of muscle homogenate × DF1 × DF2 × DF3] / half 
muscle weight (g) = mg glycogen/g wet muscle  
























Appendix H: Determination of Muscle Protein Concentration 
(Modified Lowry Assay) 




0.1 N NaOH (1L) 
Add 4 g NaOH (Fisher S-318-3) into 900 ml ddH2O, stir on a magnetic plate and bring 
volume to 1000ml with ddH2O.   
 
2% Sodium carbonate (1L) 
Add 20 g Sodium carbonate into 900 ml 0.1 N NaOH, stir on a magnetic plate and bring 
volume to 1000ml with 0.1 N NaOH.   
 
2% Sodium potassium tartrate (200ml) 
Add 4 g sodium potassium tartrate (Fisher S-387) into 150 ml ddH2O, stir on a magnetic 
plate and bring volume to 200ml with ddH2O.   
 
1% Cupric sulfate (200ml) 
Add 2 g cupric sulfate (Fisher C-489) into 150 ml ddH2O, stir on a magnetic plate and 





1. Thaw 1 aliquot of 5 mg/mL BSA (bovine serum albumin) stock and samples on ice. 
2. Dilute samples 1:30 by adding 10 µl of supernatant to labeled microcentrifuge tube 
containing 290 µl ddH2O and vortex. Keep on ice. 
3. Perform serial dilution: 
 ddH2O (ml) Std protein (ml) [protein] (mg/ml) 
Blank 1.0 0 0 
A 1.8 0.2 of BSA Stock .5 
B 0.2 0.8 of A .4 
C 0.5 0.5 of B .2 
D 0.5 0.5 of C .1 
E 0.5 0.5 of D .05 
F 0.5 0.5 of E .025 
 
4. Make Solution A (1 mL per tube needed) in a 125 mL Erlenmeyer flask: 
 
48 mL 2% Sodium carbonate  Stir with stir bar 
1 mL 2% Sodium potassium tartrate  Gently layer 
1 mL 1% Cupric sulfate  Gently layer 
 
4. Add 0.1 mL of each standard or sample to the corresponding tube and duplicates. 
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5. Add 1.0 mL of Solution A to each tube including blank. Vortex each tube after 
Solution A is added to all.  
6. Incubate at room temperature for 10 min.  
7. Dilute Folin & Ciocalteu’s Phenol Reagent (Sigma F-9252) 1:2 with ddH2O. Stir 
briefly.  
8.  Pipet 0.1 ml of diluted Folin & Ciocalteu’s Phenol Reagent directly into the center of 
each tube while vortexing each tube without touching sides of tube.  
13. Incubate 30 min at room temperature.  
14. Turn on spectrophotometer at start of incubation. Select setting a:/Low_Pro at 750 
nm. 





1. Generate a standard curve from absorbances of the 6 standards.  
2. Using the equation from the standard curve, calculate the concentration of each 
sample.  
3. Multiply the calculated concentration by the dilution factor (30) for the final protein 



























Appendix I: SDS-PAGE Procedure 
(Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis)  




30% acrylamide and 1% bisacrylamide mixture (200 ml): 
58 g acrylamide (Sigma A-8887) 
2 g bisacrylamide (Sigma M-7279) 
Add reagents into 150 ml ddH2O in the order listed, stir on a magnetic plate and bring 
final volume to 200 ml with ddH2O. 
Filter mixture through Whatman No. 1 filter paper. Store in a dark bottle at  4oC. 
 
1.5 M Tris, pH 8.8 (500 ml): 
Add 90.82 g Trisbase (Sigma T-6066) into 300 ml ddH2O, pH to 8.8 with concentrated 
HCl, stir on a magnetic plate and bring final volume to 500 ml with ddH2O. Store at  4oC. 
 
1.0 M Tris, pH 6.8 (500 ml): 
Add 60.57 g Trisbase (Sigma T-6066) into 300 ml ddH2O, pH to 6.8 with concentrated 
HCl, stir on a magnetic plate and bring final volume to 500 ml with ddH2O. Store at  4oC. 
 
10% Sodium dodecyl sulfate (SDS) (100 ml): 
Add 10 g SDS (Sigma L-3771) into 80 ml ddH2O, stir on a magnetic plate and bring final 
volume to 100 mL with ddH2O. Filter through Whatman No. 1 filter paper. Store at room 
temperature. 
 . 
20% Sodium dodecyl sulfate (SDS) (100 ml): 
Add 20 g SDS (Sigma L-3771) into 80 ml ddH2O, stir on a magnetic plate and bring final 
volume to 100 mL with ddH2O. Filter through Whatman No. 1 filter paper. Store at room 
temperature. 
 
10% Ammonium persulfate (APS) (1 ml): 




Sigma T-9281. Store at 4oC. 
 
10x Running buffer (1 L): 
30.28 g Trisbase (Sigma T-6066) 
144.2 g Glycine (Sigma G-8898) 
Add reagents into 800 ml ddH2O, stir on a magnetic plate and bring final volume to 1000 





1x Running buffer (1 L): 
100 ml 10x Running buffer 
5 ml 20% SDS 
900 ml ddH2O 
 
0.25% Bromophenol blue (5 ml): 
Add 0.0125 g bromophenol blue (Sigma B-5525) into 5 ml ddH2O, stir on a magnetic 
plate. 
 
2x Sample buffer (50 ml):  
5 ml 1.25 M Tris, pH 6.8 
10 ml 20% glycerol      
5 ml 20% SDS     
2.25 ml β-mercaptoethanol (Sigma M-6250) (add under fume hood) 
1.6 ml 0.25% bromophenol blue solution  (add 0,0125g into 5ml ddH2O to make 0.25%) 
Add reagents to 26.15 ml ddH2O, stir on a magnetic plate. 
	  
Resolving Gel (10%) 
 For 2 gels (ml) For 4 gels (ml) 
ddH2O 5.9 11.8 
30% Acrylamide mix 5.0 10.0 
1.5 M Tris, pH 8.8 3.8 7.6 
10% SDS 0.15 0.3 
10% APS (make fresh) 0.15 0.3 
TEMED 0.006 0.012 
 
Stacking Gel (5%) 
 For 2 gels (ml) For 4 gels (ml) 
ddH2O 3.4 6.8 
30% Acrylamide mix 0.83 1.7 
1.0 M Tris, pH 6.8 0.63 1.25 
10% SDS 0.05 0.1 
10% APS (make fresh) 0.05 0.1 




1. Assemble gel apparatus in casting stands according to manufacturer’s 
instructions. 
2. Prepare resolving gel solution (10%) for the number of gels to be cast. 
3. Gently swirl solution to avoid bubbles.  
4. Use 1ml pipette to fill the caster ~3/4 full. Overlay resolving gel with 200 µl 
butanol to amooth out the top surface of the resolving gel.  
5. Allow 1 hr for gel to polymerize. 
6. Wash butanol off the resolving gel with ddH2O. Dry between casting plates as 
much as possible with a KimWipe. 
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7. Prepare stacking gel solution for the number of gels to be cast. 
8. Gently swirl solution. Use pipette to fill up the rest of the caster to the top with the 
stacking gel solution. Carefully insert 15-well comb into place, avoiding any 
bubble formation. 
9. Allow ~45 min for stacking gel to polymerize. 
10. During stacking gel polymerization, prepare samples with 2x sample buffer.  
a. Thaw samples on ice.  
b. Dilute the samples 1:1 with 2x sample buffer in 0.5 ml microcentrifuge 
tubes. 
c. Vortex tubes then place them in a tube holder in boiling water (~95oC) for 
5 min. 
d. Centrifuge tubes in microcentrifuge for ~5 seconds to allow all solution 
collect in the bottom of the microcentrifuge tube. 
11. After stacking gels have polymerized, carefully remove the 15-well combs and 
assemble the gel apparatus and electrophoresis chamber according to the 
manufacturer’s instructions. Fill inner chamber with 1x Running buffer and the 
outer chamber to ~1/3 full with 1x Running buffer (~500 ml for each chamber). 
12. Load 100 µg muscle homogenate (~10 – 20 µl sample + buffer), rat muscle 
standard and moleculare weight marker into gel wells.  
13. Electrophoresis at 160 V for 2hr, may extend for 10-20 more min, make sure the 
50 kDa band not running out.  
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Transfer Buffer (2 L): 
1400 ml ddH2O 
28.8 g Glycine (Sigma G-8898) 
6.04 g Trisbase (Sigma T-6066) 
0.75 g SDS (Sigma L-3771) (or use 3.75 ml 20% SDS) 
300 m Methanol (Fisher A-411-4) 
 






1. Soak filter papers (2 for each gel) in transfer buffer for 20 min. 
2. Prepare nitrocellulose membrane, cut to ~6 cm x 9.5 cm each, mark in pencils 
in the left edge for identification 
3. Soak nitrocellulose membranes in transfer buffer on a shake for 15 min. 
4. Carefully remove the gel from the electrophoresis apparatus. Make cuts in the 
gel corners for identification. Place gel in transfer buffer on a shaker for 15 
min. 
5. Soak four spongy pads in transfer buffer for a few minutes 
6. Making the gel “sandwich”: 
a. Place cassette in a container filled with transfer buffer. Black side 
down, clear side up and facing away from you. 
b. Place a spongy pad on the surface of black side 
c. Place a filter paper on the top of spongy pad 
d. Place gel on the top of the filter paper. Use finger to direct the gel 
and let it lie on the middle surface of filter paper 
e. Place nitrocellulose membrane to cover the gel. Use the fingertip 
to touch down the membrane slightly and let it fully contact with 
the gel. 
f. Place another filter paper on the top of the membrane. Roll out 
bubbles with wetted glass tube. 
g. Add another spongy pad on the top of the filter paper 
h. Close cassette. Make sure everything is aligned correctly.  
i. Place the cassette in transfer apparatus with the black sides lining 
up. 
j. Repeat steps a-i with the second gel 
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k. Place an ice cube in transfer apparatus 
7. Loading the transfer apparatus and start the transfer 
a. Place the transfer apparatus in a large plastic container and fill the 
container with ice water to cover half of the transfer apparatus 
b. Fill the transfer apparatus with transfer buffer up to the edge. 
c. Place the top cover with electrodes to the apparatus 
d. Set voltage to 90 volts. Start and run for 2 hrs. 
 
8. After transfer, turn off the voltage 
a. Take out the “sandwich” and place black side up. 
b. Remove spongy filter, filter paper.  
c. Carefully remove the gel and place it in container with some 




















Appendix K: Immunoblotting Procedures 
SOLUTIONS: 
 
10 x Tris-buffered saline (TBS; pH 7.5) (1 L): 
60.05 g Trisbase (Sigma T-6066) 
87.6 g NaCl (Fisher S271-3) 
 
ADD reagents into 800 ml ddH2O, stir on a magnetic plate, pH to 7.5 with concentrated 
HCl, bring final volume to 1000 ml with ddH2O. 
 
1x Tris-buffered saline + 0.06% Tween-20 (1 xTTBS) (1 L): 
100 ml 10 x Tris-buffered saline (TBS; pH 7.5) 
900 ml ddH2O 
0.6 ml Tween-20 (Sigma P-1379) 
 
Blocking solution (30 ml for each membrane):  
7% Non-fat dry milk (NFDM) in 1x TTBS  
Stir gently on a magnetic plate 
 
Primary Antibody (diluted in 2% NFDM-TTBS): 
 
 Dilution ratio Probe site Catalog # 
p-mTOR 1:900 Ser-2448 Cell Signaling, 2971S 
p-AS160 1:800 Thr-642 Cell Signaling, 4288S 
p-GS 1:1000 Ser-641 Cell Signaling, 3891S 
p-Akt/PKB 1:1000 Ser-473 Cell Signaling, 9271S 
α-Tubulin 1:1000 Total Cell Signaling, 2144S 
 
Secondary Antibody: 
Goat Anti-rabbit IgG (Cell Signaling 7074), diluted to 1:800 in 2% NFDM-TTBS 
 
Stripping buffer,  pH 6.7 (1 L): 
20 g 2% sodium dodecyl sulphate (SDS) (Sigma L-3771)  
7.5 g Trisbase (Sigma T-6066) 
Add reagents into 850 ml ddH2O, stir on a magnetic plate 
Add 7 ml of 100 mM 2-mercaptoethanol (perform this step under fume hood) 
Adjust pH to 6.7 




1. Block nitrocellulose membrane in 7% blocking solution (above) for 30 min at 
room temperature with gentle shaking. 
2. Wash membrane in ddH2O for 2 min 
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3. Wash membrane in 30 ml TTBS 3X for 5 min each on a shaker 
4. Cut nitrocellulose membranes in sections according to molecular weight 
markers to probe individually for proteins of interest. 
5. Incubate each membrane section in 10 ml of the respective primary antibody 
solutions overnight on a rocking platform at low speed (1.5) in 4oC refrigerator. 
6. Next morning, recycle the primary antibody and keep in the -20 oC  refrigerator 
7. Wash membrane in 15 ml TTBS 3X for 5 min each on a shaker  
8. Incubate each membrane section in 10 ml of secondary antibody solutions for 1 
hr with gentle shaking at room temperature. 
9. Recycle the primary antibody and keep in the -20 oC  refrigerator 
10. Wash membrane in 15 ml TTBS 3X for 5 min each on a shaker 
11. Visualize bands using ECL detection (ECL Western Lighting Plus kit, Perkin 
Elmer) with a Bio-Rad ChemiDoc detection system according to the 
manufacturer’s instructions.  
12. Analyze bands (intensity x mm2) using Quantity One Analysis software.  
13. Wash membrane sections in 15 ml TTBS for 5 min on a shaker 
14. Dry membranes with thick transfer papers and store between two transfer 
papers in in 4oC. 
15. If stripping to reprobe, wash membranes in 15 ml TTBS 2X for 5 min each on 
a shaker  
16. Incubate membranes in 30 ml stripping buffer for 1 hr in 70oC shaking water 
bath at 65 rpm. 
17. Wash membranes in 15 ml TTBS 2X for 5 min on a shaker 






















Study 1 Subject Characteristics 
Subject # Initials Gender Age (yr) Weight (kg) Height (cm) BMI (kg/m2) Waist (cm) Screen Fasting Blood Glucose  
(mmol/L) 
1 ADO F 22 92.99 158.5 36.7 107 5.88 
2 LWD F 38 80.40 162.6 30.4 94 6.16 
3 PGD M 24 116.57 180.4 35.8 108 5.74 
4 SDG F 39 89.24 163.4 33.4 99.5 6.38 
5 JHS F 23 103.65 169.4 36.1 122.5 5.16 
6 G-A F 22 87.66 163.1 33 103 5.55 
7 EAS F 41 72.67 169.1 25.4 90 5.77 
8 N-W F 27 88.34 158.75 34.8 93 5.55 
9 K-C F 24 83.69 150.1 37.1 99 5.63 
10 BCW M 23 99.00 182.1 29.8 104 4.16 
11 DLM M 28 94.35 180.1 29 105 4.86 
12 JLP F 37 89.02 160.8 34.4 96 4.88 
13 MLL F 35 113.17 148 51.6 121 4.91 
14 YMA F 29 96.50 157.6 38.8 114 6.27 
15 M-C F 40 106.14 182.5 31.8 102 5.22 
16 ANE F 21 96.30 161.7 36.8 118 4.52 
17 AHC F 40 83.14 162.2 31.6 103 5.16 
18 MMW1 F 27 99.79 165.1 36.6 112 5.99 
19 MMW2 F 35 94.80 164.4 33.5 119 5.16 
20 TDT F 43 67.81 140.5 34.3 99 5.52 
21 M-L F 36 80.97 158.3 32.3 109 4.80 
22 CRT F 25 103.19 166.6 37.2 105 6.27 
AVG   30.86 92.70 163.88 34.56 105.59 5.44 




Study 1 Plasma Glucose Concentration (mmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 4.56 5.25 6.89 5.89 5.64 4.65 
2 LWD 4.12 5.61 5.60 3.67 3.45 4.18 
3 PGD 3.84 6.29 6.78 4.98 4.10 3.88 
4 SDG 4.21 4.70 5.00 5.24 4.58 4.21 
5 JHS 4.12 4.81 5.94 4.71 4.03 3.55 
6 G-A 4.24 4.66 6.49 6.94 6.13 4.90 
7 EAS 4.18 4.87 5.28 4.52 2.88 3.33 
8 N-W 4.01 5.98 6.55 5.06 3.98 3.97 
9 K-C 4.61 6.21 8.11 8.04 5.53 5.51 
10 BCW 4.02 5.38 6.39 4.37 4.32 3.09 
11 DLM 3.55 5.06 5.97 4.10 3.47 3.42 
12 JLP 4.09 5.62 6.86 4.87 3.22 3.64 
13 MLL 4.46 4.63 5.91 6.93 7.05 5.57 
14 YMA 4.63 5.14 6.69 8.59 6.55 4.99 
15 M-C 4.33 5.05 5.37 6.46 5.67 4.74 
16 ANE 3.65 4.37 5.06 4.34 4.21 3.83 
17 AHC 4.20 4.70 5.57 6.22 5.89 4.87 
18 MMW 3.81 4.38 5.43 5.96 3.77 3.57 
19 MMW2 4.56 5.29 7.77 9.70 7.88 5.39 
20 TDT 4.13 5.55 7.58 5.07 4.08 4.86 
21 M-L 4.03 4.89 6.91 9.10 7.84 5.16 
22 CRT 4.28 5.30 6.38 6.13 3.40 4.63 
AVG  4.16 5.17 6.30 5.95 4.89 4.36 
SE  0.06 0.12 0.19 0.36 0.32 0.16 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 4.04 4.55 5.39 5.62 5.24 4.95 
2 LWD 4.13 5.10 4.63 2.76 2.45 2.79 
3 PGD 4.48 6.16 7.29 5.75 3.80 3.50 
4 SDG 4.41 4.29 4.39 3.72 3.32 3.70 
5 JHS 4.07 6.61 4.50 3.16 4.10 3.68 
6 G-A 4.08 4.36 5.77 4.68 4.92 4.16 
7 EAS 3.78 4.36 4.28 4.40 4.73 4.78 
8 N-W 3.89 4.05 3.69 4.76 4.11 3.34 
9 K-C 4.41 5.09 6.29 5.11 4.92 4.46 
10 BCW 4.89 5.65 5.53 4.97 3.53 3.19 
11 DLM 3.82 4.34 5.29 3.12 2.84 2.98 
12 JLP 3.84 5.26 5.83 4.18 3.73 3.62 
13 MLL 4.20 4.46 5.61 5.40 4.49 4.16 
14 YMA 4.53 5.00 6.42 7.04 4.85 4.18 
15 M-C 4.06 4.52 3.95 3.97 3.83 3.92 
16 ANE 3.93 4.67 4.17 2.46 3.16 3.20 
17 AHC 4.09 4.58 6.10 4.08 4.54 3.79 
18 MMW 3.75 4.58 4.88 4.36 3.52 2.87 
19 MMW2 4.79 5.84 7.54 8.30 6.32 4.19 
20 TDT 4.32 5.25 5.65 3.51 3.93 3.89 
21 M-L 3.87 5.00 5.58 5.41 6.15 5.72 
22 CRT 4.62 4.95 5.74 6.78 4.05 4.07 
AVG  4.18 4.94 5.39 4.71 4.21 3.87 
SE  0.07 0.14 0.22 0.31 0.21 0.15 
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Study 1 Plasma Insulin Concentration (pmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 248.28 707.00 2010.37 2677.99 1823.76 885.97 
2 LWD 114.45 475.11 529.83 478.86 255.30 287.38 
3 PGD 101.19 793.05 1210.17 538.17 181.33 125.36 
4 SDG 92.30 239.39 297.94 474.76 305.16 300.02 
5 JHS 174.46 752.07 1828.06 1474.08 611.37 405.80 
6 G-A 132.51 559.14 1313.37 1753.68 1493.59 1011.54 
7 EAS 115.91 259.88 501.36 799.23 381.56 292.87 
8 N-W 171.96 809.86 1739.58 1810.91 1129.12 731.10 
9 K-C 242.17 830.83 1557.62 1489.08 1213.22 853.33 
10 BCW 92.09 421.08 539.56 731.66 317.46 103.97 
11 DLM 140.22 672.28 1553.04 951.19 233.42 339.12 
12 JLP 93.06 601.85 1193.29 982.86 469.76 356.90 
13 MLL 330.44 601.78 1176.76 1173.01 2278.86 1483.45 
14 YMA 214.46 418.92 305.51 1273.78 2289.21 1157.66 
15 M-C 218.14 446.08 977.23 1575.06 1383.58 1039.04 
16 ANE 137.02 734.29 1983.63 1445.12 1082.24 725.68 
17 AHC 112.93 620.33 656.65 889.65 792.49 454.76 
18 MMW 173.90 337.04 664.57 1293.09 1007.79 511.01 
19 MMW2 180.57 334.19 1052.65 1132.52 795.55 540.46 
20 TDT 85.98 645.75 1312.12 804.02 440.24 130.36 
21 M-L 286.97 662.34 704.78 2098.57 3253.04 1893.00 
22 CRT 144.59 249.95 292.32 491.01 149.73 238.91 
AVG  163.80 553.28 1063.66 1197.19 994.90 630.35 
SE  14.53 40.68 118.94 121.13 175.37 99.63 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 234.67 607.90 1783.48 2538.12 2270.11 1402.20 
2 LWD 122.93 590.19 964.24 328.64 233.00 238.21 
3 PGD 100.91 511.36 1193.71 797.70 286.55 132.16 
4 SDG 128.41 322.11 465.04 503.03 276.41 271.13 
5 JHS 170.92 255.02 2706.26 1037.79 1838.48 923.27 
6 G-A 232.80 479.14 1407.82 1155.58 1103.98 524.07 
7 EAS 71.46 270.99 326.55 321.76 637.76 419.06 
8 N-W 120.84 449.90 1125.51 1343.86 753.67 443.99 
9 K-C 290.51 1568.88 2758.00 1595.06 1825.08 2078.85 
10 BCW 146.12 737.21 1582.00 466.08 406.98 133.48 
11 DLM 170.85 421.28 946.40 1364.97 473.93 640.88 
12 JLP 115.63 552.06 1253.36 1396.92 616.51 467.26 
13 MLL 261.97 708.46 1819.17 1442.62 1048.90 1435.60 
14 YMA 266.34 526.36 721.79 1916.82 1971.69 665.61 
15 M-C 201.47 1607.49 1973.42 1080.02 805.20 461.56 
16 ANE 109.24 1147.31 2552.98 787.29 604.35 248.63 
17 AHC 104.80 596.30 697.28 610.33 768.95 374.34 
18 MMW 144.04 332.18 778.26 831.11 959.38 596.30 
19 MMW2 134.18 388.78 840.14 1057.65 1898.97 677.83 
20 TDT 102.58 632.27 1322.88 607.76 424.48 228.49 
21 M-L 220.43 711.86 1385.32 1341.64 1981.13 2665.21 
22 CRT 98.41 275.99 175.36 1032.51 494.41 360.51 
AVG  161.34 622.41 1308.13 1070.78 985.45 699.48 
SE  13.66 79.19 155.00 114.64 140.69 138.31 
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Study 1 Plasma C-peptide Concentration (nmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 1.31 2.10 3.65 4.23 3.92 2.95 
2 LWD 0.61 1.48 1.75 2.12 1.12 1.48 
3 PGD 0.40 1.75 1.98 1.70 0.90 0.56 
4 SDG 0.48 0.81 1.09 1.82 1.83 1.49 
5 JHS 0.65 1.52 3.22 3.18 2.33 1.81 
6 G-A 0.64 1.03 2.40 3.20 3.20 2.68 
7 EAS 0.42 0.78 1.31 2.17 1.42 1.47 
8 N-W 0.81 1.74 2.69 3.03 2.61 2.00 
9 K-C 0.76 1.43 2.00 2.42 2.21 1.79 
10 BCW 0.20 0.74 1.42 1.99 1.28 0.31 
11 DLM 0.41 1.44 2.89 2.15 1.78 1.10 
12 JLP 0.31 1.19 1.69 1.85 1.19 1.02 
13 MLL 1.07 1.61 2.45 2.55 3.35 2.88 
14 YMA 0.93 1.19 1.59 2.78 3.22 2.54 
15 M-C 0.74 1.13 2.02 3.19 2.89 2.27 
16 ANE 0.65 1.28 3.13 2.96 2.58 2.03 
17 AHC 0.75 1.62 2.38 3.21 3.04 2.40 
18 MMW 0.68 1.00 1.66 2.97 2.63 1.73 
19 MMW2 0.79 1.10 2.30 2.66 2.76 2.44 
20 TDT 0.43 1.61 2.72 2.97 2.24 1.36 
21 M-L 0.80 1.35 2.42 3.08 3.51 3.04 
22 CRT 0.74 0.91 1.48 2.17 1.21 1.57 
AVG  0.66 1.31 2.19 2.66 2.33 1.86 
SE  0.05 0.08 0.14 0.13 0.19 0.16 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 1.05 1.83 3.12 4.16 3.99 3.87 
2 LWD 0.80 1.82 2.80 2.18 1.74 1.42 
3 PGD 0.48 1.32 2.12 2.28 1.19 0.66 
4 SDG 0.54 1.01 1.47 1.91 1.34 1.36 
5 JHS 0.67 0.58 3.88 2.81 3.57 2.43 
6 G-A 0.84 1.21 2.68 2.89 2.85 1.93 
7 EAS 0.36 0.77 0.95 1.01 2.16 1.84 
8 N-W 0.58 1.07 2.28 3.04 2.50 1.94 
9 K-C 0.87 2.12 3.18 2.63 3.02 3.15 
10 BCW 0.43 1.42 2.31 1.64 1.73 0.50 
11 DLM 1.00 1.18 2.01 2.89 1.85 2.23 
12 JLP 0.32 0.99 1.97 2.64 1.52 1.20 
13 MLL 1.06 1.75 2.75 3.07 2.94 3.01 
14 YMA 0.95 1.35 2.04 3.11 3.60 2.51 
15 M-C 0.62 2.29 3.08 2.55 2.21 1.90 
16 ANE 0.59 1.96 3.59 2.26 2.09 1.22 
17 AHC 0.63 1.50 1.36 2.43 3.29 2.40 
18 MMW 0.59 0.99 1.85 2.43 2.43 2.27 
19 MMW2 0.77 1.15 1.85 2.48 3.96 2.88 
20 TDT 0.47 1.29 2.72 2.44 2.13 1.39 
21 M-L 0.78 1.70 2.43 2.43 3.22 3.76 
22 CRT 0.60 0.95 1.44 2.78 2.30 1.59 
AVG  0.68 1.38 2.36 2.55 2.53 2.07 
SE  0.05 0.10 0.16 0.13 0.18 0.19 
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Study 1 Plasma Glucagon Concentration (ng/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 47.25 54.00 35.69 40.38 43.28 45.47 
2 LWD 39.80 34.40 25.90 24.29 29.31 24.05 
3 PGD 73.33 51.24 46.97 53.42 48.69 54.28 
4 SDG 69.16 71.07 68.72 84.03 71.73 71.68 
5 JHS 122.45 104.77 111.50 93.26 86.91 96.87 
6 G-A 43.01 60.87 63.15 44.06 40.25 35.09 
7 EAS 30.95 33.65 28.90 42.28 41.80 43.62 
8 N-W 69.72 68.03 67.66 58.61 54.64 57.85 
9 K-C 86.69 56.72 42.86 33.30 47.28 46.24 
10 BCW 34.21 46.25 39.31 34.66 33.74 47.51 
11 DLM 52.88 41.33 40.50 51.19 43.04 42.68 
12 JLP 51.45 60.17 50.99 48.83 55.35 49.48 
13 MLL 64.10 51.14 41.28 58.67 60.00 48.50 
14 YMA 148.97 138.64 110.04 110.52 112.95 109.88 
15 M-C 46.03 53.50 47.75 39.94 35.92 38.03 
16 ANE 73.09 41.94 42.80 42.05 36.28 55.84 
17 AHC 54.71 47.71 38.77 45.82 46.63 48.93 
18 MMW 87.40 68.50 66.77 59.49 64.47 61.77 
19 MMW2 63.49 66.74 66.37 52.12 52.45 29.87 
20 TDT 122.76 130.27 134.25 120.94 117.96 134.31 
21 M-L 40.74 34.99 24.79 31.83 28.55 32.68 
22 CRT 67.23 52.49 39.14 48.45 72.56 67.53 
AVG  67.70 62.20 56.10 55.37 55.63 56.46 
SE  6.51 6.00 6.17 5.35 5.18 5.68 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 58.53 58.10 41.29 37.40 24.94 36.42 
2 LWD 35.04 35.40 39.64 34.84 37.42 33.39 
3 PGD 69.69 57.12 49.08 53.19 51.65 62.70 
4 SDG 70.67 58.00 63.60 80.18 84.79 80.28 
5 JHS 98.22 97.00 102.63 92.49 92.32 100.64 
6 G-A 58.32 55.64 50.40 38.23 34.26 26.17 
7 EAS 48.19 33.76 35.00 62.89 51.66 53.83 
8 N-W 66.22 56.55 59.38 60.08 61.41 66.96 
9 K-C 68.37 63.34 47.57 41.65 49.32 49.80 
10 BCW 47.63 49.66 39.10 42.69 43.81 55.15 
11 DLM 44.14 47.80 38.90 45.07 45.20 44.72 
12 JLP 44.22 50.82 55.82 70.56 54.34 54.28 
13 MLL 54.05 69.96 61.03 51.15 38.21 44.57 
14 YMA 146.84 153.84 146.86 152.32 139.51 136.97 
15 M-C 44.65 58.56 54.00 47.08 42.96 36.78 
16 ANE 40.28 29.64 44.68 67.01 51.59 58.90 
17 AHC 54.23 49.50 40.57 51.94 53.81 45.52 
18 MMW 66.66 80.61 80.48 81.62 78.53 64.01 
19 MMW2 47.77 65.72 51.11 50.76 42.83 39.89 
20 TDT 127.29 128.81 133.18 134.82 131.80 129.31 
21 M-L 44.61 40.52 27.61 28.62 29.90 33.67 
22 CRT 68.96 75.46 48.72 78.58 74.99 73.40 
AVG  63.84 64.35 59.58 63.78 59.78 60.33 
SE  5.91 6.31 6.53 6.60 6.40 6.24 
 
 135 
Study 1 Plasma Lactate Concentration (mmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 1.257 1.285 1.393 1.719 1.313 1.075 
2 LWD 0.431 0.511 0.700 0.890 0.762 0.721 
3 PGD 0.742 0.828 0.980 1.107 0.943 0.867 
4 SDG 0.675 0.652 0.719 1.066 0.941 0.902 
5 JHS 0.807 0.778 0.781 1.277 1.408 1.181 
6 G-A 1.217 1.262 1.469 2.231 1.559 1.103 
7 EAS 1.187 0.981 1.023 1.290 1.046 1.046 
8 N-W 1.097 1.111 1.371 1.797 1.475 1.278 
9 K-C 0.981 0.843 1.198 1.350 1.110 1.032 
10 BCW 0.691 0.696 0.686 1.033 1.244 0.932 
11 DLM 0.975 0.934 1.177 1.554 1.149 0.932 
12 JLP 0.860 0.551 0.694 1.044 0.932 0.829 
13 MLL 0.991 0.869 0.910 1.259 1.281 1.083 
14 YMA 1.331 1.698 1.162 1.474 1.252 1.176 
15 M-C 1.097 1.035 0.968 1.568 1.673 1.355 
16 ANE 0.730 0.794 0.887 0.325 1.449 1.087 
17 AHC 1.146 1.066 1.198 1.719 1.106 0.836 
18 MMW 0.632 0.568 0.612 0.995 0.926 0.744 
19 MMW2 1.051 0.892 1.166 1.494 1.084 0.799 
20 TDT 0.513 0.559 0.781 1.167 0.865 0.668 
21 M-L 1.166 0.904 1.022 1.001 1.419 0.904 
22 CRT 0.500 0.512 0.526 0.840 0.810 0.717 
AVG  0.913 0.879 0.974 1.282 1.170 0.967 
SE  0.057 0.062 0.057 0.086 0.055 0.040 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 1.140 1.167 1.293 1.420 1.056 0.953 
2 LWD 1.139 0.711 1.140 1.207 0.819 0.829 
3 PGD 1.031 0.932 1.002 1.213 1.045 0.672 
4 SDG 0.991 0.902 0.907 1.096 1.115 1.186 
5 JHS 1.067 0.889 1.186 1.316 1.530 1.565 
6 G-A 1.149 1.019 1.240 1.531 1.276 1.084 
7 EAS 1.095 0.967 0.921 1.275 1.052 1.108 
8 N-W 1.362 1.238 1.406 1.781 1.569 1.131 
9 K-C 0.921 0.926 1.120 1.414 1.159 1.091 
10 BCW 0.886 0.978 1.308 1.589 1.184 0.973 
11 DLM 1.211 1.378 1.021 1.225 1.050 0.914 
12 JLP 1.254 0.644 0.735 1.193 1.216 1.117 
13 MLL 0.704 0.836 0.905 1.432 1.124 1.100 
14 YMA 0.945 0.906 0.921 1.466 1.266 1.018 
15 M-C 0.999 0.897 1.283 1.484 1.547 1.586 
16 ANE 0.877 0.898 1.008 1.365 1.351 0.674 
17 AHC 0.783 0.877 0.915 1.276 1.136 0.921 
18 MMW 0.712 0.531 0.612 1.198 1.060 0.944 
19 MMW2 0.806 0.856 0.747 1.424 1.130 1.044 
20 TDT 0.778 0.796 1.072 1.385 1.041 0.870 
21 M-L 0.768 0.610 0.723 1.055 0.999 0.912 
22 CRT 0.503 0.605 0.503 1.083 0.975 0.735 
AVG  0.960 0.889 0.999 1.338 1.168 1.019 
SE  0.045 0.043 0.051 0.038 0.041 0.049 
 
 136 
Study 1 Plasma Free Fatty Acids Concentration (mmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 0.2853 0.2793 0.2543 0.0942 0.1089 0.0536 
2 LWD 0.1555 0.1278 0.1239 0.0597 0.0589 0.0600 
3 PGD 0.2353 0.2266 0.1739 0.1494 0.0992 0.1652 
4 SDG 0.2112 0.2347 0.1946 0.0646 0.0226 0.0764 
5 JHS 0.2527 0.2400 0.1527 0.0475 0.0356 0.0296 
6 G-A 0.3919 0.2664 0.2402 0.1123 0.0825 0.0579 
7 EAS 0.3357 0.2115 0.2243 0.1263 0.1257 0.0747 
8 N-W 0.2240 0.2367 0.1464 0.0634 0.0829 0.0443 
9 K-C 0.2064 0.2064 0.1560 0.0335 0.0467 0.0514 
10 BCW 0.2685 0.2976 0.2206 0.0800 0.1380 0.0989 
11 DLM 0.3246 0.2322 0.1725 0.1461 0.0879 0.1066 
12 JLP 0.3943 0.3881 0.2020 0.0702 0.0799 0.0962 
13 MLL 0.2498 0.1448 0.1510 0.0883 0.0660 0.0803 
14 YMA 0.2237 0.3723 0.2519 0.0991 0.0222 0.0156 
15 M-C 0.2935 0.5042 0.3274 0.1002 0.0356 0.0306 
16 ANE 0.1850 0.2320 0.1514 0.0536 0.0099 0.0139 
17 AHC 0.3091 0.3610 0.2283 0.1120 0.0658 0.0765 
18 MMW 0.1779 0.1188 0.1022 0.0652 0.0961 0.0710 
19 MMW2 0.2289 0.2394 0.2281 0.1013 0.0862 0.0566 
20 TDT 0.2606 0.2105 0.1181 0.0569 0.0273 0.0097 
21 M-L 0.2393 0.3084 0.1978 0.1201 0.1307 0.1174 
22 CRT 0.2070 0.2075 0.1107 0.0300 0.0190 0.0274 
AVG  0.2573 0.2566 0.1876 0.0852 0.0694 0.0643 
SE  0.0136 0.0191 0.0120 0.0072 0.0082 0.0081 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 0.2447 0.2241 0.2054 0.1214 0.1284 0.0909 
2 LWD 0.1681 0.1278 0.1183 0.0796 0.0804 0.0714 
3 PGD 0.2570 0.1857 0.2034 0.1284 0.1110 0.1367 
4 SDG 0.0964 0.1112 0.0762 0.0427 0.0468 0.0360 
5 JHS 0.1614 0.0690 0.0773 0.0520 0.0623 0.0512 
6 G-A 0.3105 0.1950 0.1746 0.1112 0.0853 0.0780 
7 EAS 0.2707 0.3108 0.3331 0.3359 0.1557 0.1543 
8 N-W 0.3092 0.2262 0.2381 0.0619 0.0601 0.0941 
9 K-C 0.2710 0.1756 0.1489 0.0328 0.0287 0.0145 
10 BCW 0.1022 0.0785 0.0545 0.0487 0.0655 0.0708 
11 DLM 0.2003 0.1860 0.1570 0.0645 0.0661 0.1093 
12 JLP 0.2794 0.2381 0.2266 0.0842 0.0546 0.0753 
13 MLL 0.2549 0.2160 0.2146 0.0644 0.0369 0.0368 
14 YMA 0.2661 0.2448 0.2914 0.0948 0.0205 0.0059 
15 M-C 0.2224 0.1788 0.1222 0.0758 0.0296 0.0349 
16 ANE 0.1501 0.1322 0.1399 0.1172 0.0250 0.0070 
17 AHC 0.2653 0.2851 0.0592 0.0447 0.0217 0.0489 
18 MMW 0.1611 0.0907 0.0849 0.0590 0.0527 0.0426 
19 MMW2 0.3029 0.4165 0.3749 0.1729 0.1244 0.1350 
20 TDT 0.2443 0.2080 0.1001 0.0559 0.0498 0.0489 
21 M-L 0.2244 0.2316 0.2125 0.1332 0.1113 0.0769 
22 CRT 0.1575 0.1771 0.0948 0.0712 0.0600 0.0624 
AVG  0.2236 0.1958 0.1685 0.0933 0.0671 0.0674 
SE  0.0137 0.0171 0.0189 0.0138 0.0081 0.0087 
 
 137 
Study 1 Plasma Triglycerids Concentration (mmol/L) 
CHO 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 1.639 1.495 1.470 1.558 1.637 1.430 
2 LWD 0.586 0.734 0.758 0.635 0.579 0.360 
3 PGD 0.976 0.860 0.699 0.817 0.625 0.667 
4 SDG 0.700 0.660 0.732 0.763 0.770 0.651 
5 JHS 0.413 0.472 0.396 0.566 0.539 0.491 
6 G-A 1.102 1.072 1.458 1.415 0.994 0.958 
7 EAS 0.408 0.389 0.391 0.471 0.436 0.343 
8 N-W 0.957 0.951 1.164 1.140 0.884 0.816 
9 K-C 1.434 1.315 1.362 1.674 1.433 1.168 
10 BCW 0.618 0.584 0.756 0.671 0.503 0.430 
11 DLM 0.880 1.071 1.319 1.117 1.317 1.677 
12 JLP 0.688 0.654 0.641 0.817 0.703 0.651 
13 MLL 0.285 0.552 0.541 0.715 0.480 0.490 
14 YMA 1.703 1.711 1.740 1.806 1.916 2.051 
15 M-C 0.646 0.738 0.809 0.747 0.546 0.567 
16 ANE 0.574 0.601 0.685 0.821 0.654 0.534 
17 AHC 1.994 2.046 1.979 1.959 1.684 1.943 
18 MMW 0.864 1.015 0.902 0.977 0.858 0.686 
19 MMW2 1.517 1.367 1.624 1.702 1.600 1.818 
20 TDT 0.484 0.509 0.590 0.585 0.524 0.395 
21 M-L 0.833 0.743 0.944 0.928 0.957 1.073 
22 CRT 0.836 0.730 0.832 0.791 0.754 0.715 
AVG  0.915 0.921 0.991 1.031 0.927 0.905 
SE  0.099 0.092 0.096 0.096 0.098 0.116 
 
CHO/AA 
Subject # Initials Pre 15min 30min 60min 120min 180min 
1 ADO 2.396 2.107 2.324 2.401 2.066 1.915 
2 LWD 0.611 0.598 0.603 0.588 0.573 0.607 
3 PGD 0.735 0.640 0.654 0.900 0.678 0.775 
4 SDG 0.779 0.918 0.733 0.769 0.806 0.914 
5 JHS 0.503 0.206 0.474 0.548 0.544 0.498 
6 G-A 0.900 0.880 1.106 1.060 0.964 0.891 
7 EAS 0.409 0.345 0.385 0.543 0.409 0.378 
8 N-W 0.684 0.588 0.703 0.677 0.580 0.568 
9 K-C 0.748 0.778 1.018 1.217 0.887 0.854 
10 BCW 0.271 0.274 0.337 0.297 0.269 0.308 
11 DLM 1.658 1.271 1.256 1.120 1.024 1.185 
12 JLP 0.710 0.717 0.877 0.811 0.781 0.706 
13 MLL 0.490 0.407 0.589 0.558 0.452 0.368 
14 YMA 1.586 1.650 1.413 1.717 1.617 1.464 
15 M-C 0.800 0.754 0.764 0.861 0.734 0.806 
16 ANE 0.674 0.746 0.841 0.937 0.899 0.902 
17 AHC 1.345 1.165 1.641 1.610 1.375 1.517 
18 MMW 0.877 0.898 0.868 0.933 0.739 0.666 
19 MMW2 1.283 1.335 1.143 1.237 1.415 1.635 
20 TDT 0.681 0.567 0.595 0.633 0.681 0.648 
21 M-L 0.835 0.791 1.229 0.946 0.918 0.947 
22 CRT 0.924 0.648 0.807 0.884 0.666 0.682 
AVG  0.904 0.831 0.925 0.966 0.867 0.874 




Study 2 Subject Characteristics 














001 JB M 22 168 66.9 2.957 44.20 140 170 80 
002 DGL M 24 175 76.2 3.867 50.75 185 230 110 
003 JSW F 36 165 61.7 2.900 47.00 135 170 75 
004 JLM F 34 168 63.1 3.237 51.30 170 210 100 
005 JWB M 24 180 62.4 3.391 54.35 160 190 90 
006 HMZ F 20 178 71 2.900 40.85 140 175 80 
007 BTI M 21 192 82.2 4.410 53.65 220 270 130 
008 ASD M 26 182 87.3 4.540 52.00 225 280 140 
009 JFC M 37 169 77.4 3.878 50.10 190 240 115 
010 BDK M 31 175 68.1 3.957 58.10 195 235 110 
AVG   27.5 175.2 71.63 3.604 50.23 176 217 103 











Study 2 Ratings of Perceived Exertion (RPE) and Heart Rate (HR, bpm) 
CHO 


























001 JB 15 17 17 18 20 19 56 150 147 150 158 170 167 
002 DGL 13 14 14 17 20 19 53 156 154 154 156 171 178 
003 JSW 13 13 14 14 19 20 59 147 158 156 158 183 213 
004 JLM 12 12 12.5 13 17 17.5 57 135 134 134 140 174 175 
005 JWB 12 12 13 13 19.5 19.5 61 135 130 130 143 174 169 
006 HMZ 13 13 14 15 20 19 62 151 154 153 159 175 165 
007 BTI 13 14 14 15 16 17.5 61 138 146 153 161 170 173 
008 ASD 13 15 17 19 20 20 65 142 145 151 134 155 166 
009 JFC 14 14 14 14 18 17.5 50 128 123 128 129 166 156 
010 BDK 14 14 14 15 18 20 62 129 129 131 128 146 160 
AVG  13.20 13.80 14.35 15.30 18.75 18.90 58.60 141.10 142.00 144.00 146.60 168.40 172.20 
SE  0.29 0.47 0.47 0.65 0.45 0.33 1.45 3.05 3.85 3.67 4.19 3.36 5.00 
   
CHO/LAA 


























001 JB 14 16 17 19 20 17 68 151 150 153 130 162 166 
002 DGL 13 13 14 16 19 19 50 144 146 155 145 170 179 
003 JSW 12.5 12 13 13 19 17 55 140 142 144 158 183 164 
004 JLM 13 13 13.5 14 18.5 17 61 141 150 143 146 183 182 
005 JWB 12 12 13 14 19 19.5 51 128 129 130 137 174 174 
006 HMZ 13 13 14 14 19 19.5 59 141 141 145 149 174 164 
007 BTI 13 14 14 15 17 15 71 137 145 148 153 171 172 
008 ASD 13 14 15 16 20 20 70 133 136 139 143 173 164 
009 JFC 14.5 15 15 15.5 17 18.5 80 138 142 145 146 162 155 
010 BDK 13 14 15 15 17 17 59 133 131 137 132 147 164 
AVG  13.10 13.60 14.35 15.15 18.55 17.95 62.40 138.60 141.20 143.90 143.90 169.90 168.40 
SE  0.22 0.40 0.38 0.53 0.37 0.50 3.05 2.04 2.29 2.34 2.79 3.39 2.59 
 140 
Study 2 Ratings of Perceived Exertion (RPE) and Heart Rate (HR, bpm) 
CHO/HAA 


























001 JB 14 16 16 17 19 18 61 148 148 155 160 177 166 
002 DGL 13 13 14 16 19 19 60 149 157 148 153 175 180 
003 JSW 12.5 13 14.5 15 20 19.5 51 146 159 164 176 181 187 
004 JLM 12.5 12.5 13 13 17 17.5 63 132 138 144 141 174 184 
005 JWB 12 13 13 15 19 19.5 68 139 135 141 140 166 178 
006 HMZ 13 14 13 13 19 19 69 149 150 144 151 182 175 
007 BTI 13 13 14 14 16 17 83 147 155 151 166 182 171 
008 ASD 15 16 17 17 20 20 101 151 151 151 148 170 164 
009 JFC 13.5 15 16 17 17 17 51 143 135 153 156 173 156 
010 BDK 13 14 15 14 17 20 67 122 125 125 128 173 173 
AVG  13.15 13.95 14.55 15.10 18.30 18.65 67.40 142.60 145.30 147.60 151.90 175.30 173.40 












Study 2 Wingate Anaerobic Test 
CHO 






























001 JB 505 672 389 0.1 124 153 112 0.4 7.6 10.1 9.5 15140.2 
002 DGL 618 986 418 0.1 136 171 99 1.7 8.1 13 19 18536.3 
003 JSW 468 738 320 0.1 136 166 103 1.3 7.8 12.3 14 14029.3 
004 JLM 517 725 404 0.1 140 154 119 4.5 8.4 11.7 10.8 15512.6 
005 JWB 523 839 350 0.1 142 173 108 1.4 8.5 13.6 16.4 15682.5 
006 HMZ 465 796 323 0.1 115 156 86 0.5 6.6 11.3 15.8 13954 
007 BTI 667 768 536 0.1 129 149 116 0.2 8 9.3 7.8 20015.5 
008 ASD 656 1114 394 0.1 127 171 93 1.1 7.5 12.8 24.1 19686.7 
009 JFC 556 936 405 0.1 122 166 93 0.6 7.2 12.1 17.8 16692.7 
010 BDK 562 890 399 0.1 139 177 108 1.1 8.3 13.1 16.4 16868.5 
AVG  553.70 846.40 393.80 0.10 131.00 163.60 103.70 1.28 7.80 11.93 15.16 16611.83 
SE  22.95 43.03 19.28 0.00 2.83 3.10 3.43 0.39 0.19 0.43 1.53 689.50 
 
CHO/LAA 






























001 JB 546 691 422 0.1 133 153 114 0.5 8.2 10.4 9 16384.1 
002 DGL 618 933 449 0.1 135 168 105 0.7 8.1 12.3 16.2 18536.2 
003 JSW 443 668 311 0.1 126 145 100 2.1 7.4 11.2 12 13281.7 
004 JLM 508 628 395 0.1 134 143 119 9.6 8.2 10.1 7.8 15245 
005 JWB 536 867 376 0.1 146 177 111 1.3 8.7 14.1 16.4 16090.7 
006 HMZ 485 806 344 0.1 121 164 88 0.9 6.9 11.4 15.4 14558.6 
007 BTI 560 830 402 0.1 112 150 89 0.5 6.7 10 14.3 16798.3 
008 ASD 674 1108 436 0.1 133 190 95 0.8 7.8 12.7 22.5 20224.2 
009 JFC 570 854 359 0.1 125 167 95 0.4 7.4 11.1 16.6 17113.6 
010 BDK 562 897 373 0.1 139 177 107 1.2 8.3 13.2 17.5 16852.3 
AVG  550.20 828.20 386.70 0.10 130.40 163.40 102.30 1.80 7.77 11.65 14.77 16508.47 
 142 
SE  20.63 44.88 13.53 0.00 3.06 4.89 3.36 0.88 0.21 0.44 1.36 619.02 
 
Study 2 Wingate 
CHO/HAA 






























001 JB 501 716 371 0.1 123 144 102 1 7.5 10.7 11.5 15019.5 
002 DGL 617 980 447 0.1 136 173 104 1 8.1 12.9 17.8 18515.9 
003 JSW 451 673 316 0.1 130 158 101 1 7.5 11.2 12 13520.7 
004 JLM 511 667 407 0.1 138 153 118 2.5 8.3 10.8 8.7 15325.6 
005 JWB 537 878 381 0.1 145 172 116 1.4 8.7 14.2 16.6 16111 
006 HMZ 487 891 336 0.1 122 166 87 0.7 6.9 12.6 18.5 14618.5 
007 BTI 678 910 549 0.1 130 137 118 0.7 8.2 11 12 20330.6 
008 ASD 656 1162 447 0.2 128 179 95 1.1 7.5 13.4 24 19676.5 
009 JFC 579 880 439 0.1 124 155 99 0.7 7.5 11.4 14.7 17377.3 
010 BDK 545 853 387 0.1 134 174 108 0.6 8 12.5 15.6 16350.8 
AVG  556.20 861.00 408.00 0.11 131.00 161.10 104.80 1.07 7.82 12.07 15.14 16684.64 










Study 2 Serum Glucose Concentration (mmol/L) 
CHO 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 5.51 4.04 10.08 6.53 7.43 5.16 3.96 
2 DGL 4.29 2.58 6.99 4.70 6.20 4.48 3.25 
3 JSW 4.78 5.55 8.45 3.84 5.65 2.87 4.20 
4 JLM 4.08 4.26 5.72 4.50 7.39 4.36 2.71 
5 JWB 4.40 4.80 5.85 3.00 5.82 5.27 4.33 
6 HMZ 4.22 5.65 7.37 6.46 6.96 5.87 4.62 
7 BTI 4.39 4.36 7.29 3.65 6.19 3.21 2.91 
8 ASD 4.91 2.92 6.17 6.31 6.24 4.27 2.54 
9 JFC 4.52 5.06 6.77 6.48 5.65 4.64 3.86 
10 BDK 4.74 4.37 8.69 3.54 5.54 4.01 2.81 
AVG  4.58 4.36 7.34 4.90 6.31 4.42 3.52 
SE  0.13 0.32 0.44 0.45 0.23 0.29 0.24 
         
CHO/LAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 4.73 2.57 7.53 4.53 7.03 3.46 3.03 
2 DGL 4.43 2.79 6.39 5.49 6.01 4.51 3.04 
3 JSW 6.12 5.80 6.64 3.54 5.94 2.86 3.93 
4 JLM 4.22 4.86 5.46 5.18 3.80 3.40 3.56 
5 JWB 4.45 4.89 7.76 3.62 4.41 2.23 3.11 
6 HMZ 4.78 5.50 7.39 5.35 5.38 4.54 3.83 
7 BTI 5.48 4.16 7.76 4.53 5.13 3.07 2.99 
8 ASD 4.46 4.22 5.71 3.22 4.20 3.06 2.19 
9 JFC 4.55 4.77 6.69 6.05 6.37 4.45 4.52 
10 BDK 5.00 3.64 7.87 5.40 6.12 4.81 2.89 
AVG  4.82 4.32 6.92 4.69 5.44 3.64 3.31 
SE  0.18 0.34 0.28 0.30 0.33 0.28 0.21 
         
CHO/HAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 4.59 3.45 8.30 4.78 6.11 4.09 2.19 
2 DGL 4.57 2.35 6.21 5.69 6.24 4.19 4.75 
3 JSW 5.02 5.10 7.65 4.13 6.41 3.38 3.92 
4 JLM 4.76 4.18 5.16 4.87 6.62 4.52 3.41 
5 JWB 4.96 4.50 7.33 3.01 5.76 3.32 2.80 
6 HMZ 4.64 5.74 7.51 4.96 5.08 3.97 4.34 
7 BTI 4.51 4.43 7.87 2.86 5.08 2.33 3.19 
8 ASD 4.73 4.52 6.82 4.76 4.01 3.31 1.97 
9 JFC 4.52 3.88 5.86 6.66 5.21 4.46 4.35 
10 BDK 4.86 3.88 6.42 4.28 5.60 4.03 3.67 
AVG  4.72 4.20 6.91 4.60 5.61 3.76 3.46 





Study 2 Serum Insulin Concentration (pmol/L) 
CHO 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 149.94 45.63 430.38 274.88 746.03 357.95 151.12 
2 DGL 89.45 43.13 157.30 63.55 260.51 174.39 102.92 
3 JSW 104.66 62.99 277.17 88.48 217.73 64.93 48.41 
4 JLM 80.56 52.99 196.40 70.21 351.49 84.94 54.73 
5 JWB 122.30 94.87 346.56 108.20 514.49 256.83 122.30 
6 HMZ 125.64 83.13 458.37 248.63 613.38 479.48 184.18 
7 BTI 188.00 80.98 352.67 162.72 531.01 177.79 102.86 
8 ASD 71.46 40.84 110.36 156.89 326.14 148.14 103.69 
9 JFC 86.74 58.87 342.51 246.48 228.35 128.71 105.79 
10 BDK 69.51 62.57 182.70 85.25 218.35 150.94 113.86 
AVG  108.83 62.60 285.44 150.53 400.75 202.41 108.99 
SE  12.04 5.82 37.72 25.47 59.49 40.69 12.63 
         
CHO/LAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 103.69 30.07 226.48 114.25 390.38 165.50 125.29 
2 DGL 120.98 36.81 205.71 198.07 342.53 110.36 71.46 
3 JSW 371.00 60.28 263.63 73.20 208.14 52.78 50.56 
4 JLM 104.31 64.59 250.99 188.42 191.13 111.68 72.16 
5 JWB 106.12 68.13 476.98 127.09 348.01 118.62 81.88 
6 HMZ 144.39 105.22 737.00 271.34 773.74 223.56 135.36 
7 BTI 97.65 89.87 553.86 223.77 834.65 207.72 104.87 
8 ASD 88.90 52.78 232.17 95.84 295.58 128.48 59.31 
9 JFC 96.05 82.40 249.44 262.94 469.06 271.06 150.01 
10 BDK 100.86 65.56 179.53 88.32 306.65 146.58 94.52 
AVG  133.39 65.57 337.58 164.32 415.99 153.63 94.54 
SE  26.86 7.25 58.91 23.36 69.68 20.40 10.63 
         
CHO/HAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 115.70 40.49 471.50 402.32 921.05 298.22 95.77 
2 DGL 101.81 39.38 201.89 206.75 303.57 183.97 211.41 
3 JSW 97.37 40.70 382.67 83.62 165.85 81.26 68.82 
4 JLM 111.81 40.70 193.28 160.43 452.12 150.36 82.65 
5 JWB 114.52 67.23 622.97 122.93 876.32 146.75 102.92 
6 HMZ 121.75 105.63 870.63 367.53 1375.60 213.98 193.14 
7 BTI 174.11 145.22 858.75 286.48 1526.51 175.29 142.30 
8 ASD 146.33 47.71 364.96 169.25 329.68 204.81 79.94 
9 JFC 67.05 70.63 201.50 303.67 486.91 262.28 252.70 
10 BDK 66.67 66.39 160.06 62.03 152.44 87.12 136.61 
AVG  111.71 66.41 432.82 216.50 659.00 180.40 136.63 




Study 2 Plasma Lactate Concentration (mmol/L) 
CHO 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 1.14 7.56 1.84 1.37 1.40 1.37 7.39 
2 DGL 0.97 5.37 1.53 0.94 0.91 1.28 4.92 
3 JSW 1.11 12.01 2.07 1.23 1.16 1.10 8.61 
4 JLM 1.46 6.53 1.35 1.06 0.97 0.78 4.47 
5 JWB 0.76 10.09 1.88 0.93 1.00 0.87 5.30 
6 HMZ 0.61 8.02 2.38 0.82 0.87 1.05 2.77 
7 BTI 1.61 4.29 2.31 1.57 1.29 0.96 5.09 
8 ASD 0.66 2.81 1.77 0.94 0.92 0.97 3.53 
9 JFC 0.89 11.41 2.67 1.27 1.05 0.84 2.43 
10 BDK 1.15 4.41 1.56 1.21 1.39 1.47 7.09 
AVG  1.04 7.25 1.93 1.14 1.10 1.07 5.16 
SE  0.10 1.00 0.13 0.07 0.06 0.07 0.64 
         
CHO/LAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 0.93 4.67 1.77 1.12 1.15 1.13 6.13 
2 DGL 0.96 5.62 1.60 1.26 1.01 1.09 5.15 
3 JSW 1.31 10.54 2.57 1.18 1.34 1.12 5.49 
4 JLM 1.42 10.35 2.70 1.31 1.06 1.10 7.00 
5 JWB 1.62 11.68 3.27 2.58 1.84 1.87 6.94 
6 HMZ 0.72 9.10 1.68 1.09 1.03 1.09 3.90 
7 BTI 1.46 4.75 1.98 1.64 1.46 1.56 3.40 
8 ASD 0.75 8.54 1.78 1.42 0.84 0.89 11.16 
9 JFC 0.56 7.24 1.90 1.32 0.99 0.88 2.58 
10 BDK 0.93 4.94 1.79 1.70 1.44 1.32 7.88 
AVG  1.07 7.74 2.10 1.46 1.22 1.21 5.96 
SE  0.11 0.84 0.17 0.14 0.09 0.10 0.79 
         
CHO/HAA 
Subject # Initials Pre Ex-End R30 R120 R150 R240 Wingate 
1 JB 0.99 8.19 1.99 1.67 1.54 1.26 5.25 
2 DGL 1.23 5.08 1.51 0.95 1.02 1.07 4.22 
3 JSW 0.97 11.35 2.24 1.17 1.41 0.92 7.74 
4 JLM 1.84 6.49 1.53 1.28 1.23 1.23 7.90 
5 JWB 0.69 8.30 1.52 1.08 1.08 0.94 4.73 
6 HMZ 0.67 10.14 2.10 1.22 0.94 0.91 10.09 
7 BTI 1.48 7.83 2.04 1.28 1.32 1.15 5.84 
8 ASD 1.06 9.32 1.85 1.20 1.09 1.10 6.89 
9 JFC 0.63 7.22 2.26 1.13 0.83 0.80 2.28 
10 BDK 0.85 5.69 2.31 1.20 1.19 1.27 8.67 
AVG  1.04 7.96 1.93 1.22 1.16 1.06 6.36 






Study 2 Serum Creatine Kinase Concentration (nkat/L) 
 CHO CHO/LAA CHO/HAA 
Subject # Initials Pre 24hrs Pre 24hrs Pre 24hrs 
1 JB 2307.66 4648.29 4521.92 6585.99 2448.69 7893.67 
2 DGL 1333.32 1734.41 1192.29 3102.52 1633.68 2139.17 
3 JSW 1217.93 2036.60 1483.50 1934.04 1749.06 2373.59 
4 JLM 1300.35 2109.86 1725.25 2595.20 1611.70 1899.24 
5 JWB 1291.19 1890.08 1410.24 1617.19 1152.00 1597.05 
6 HMZ 1983.49 3913.87 652.01 1164.82 749.07 1137.35 
7 BTI 1864.44 3531.09 1672.14 3494.46 1655.66 3457.83 
9 JFC 2239.90 3536.58 1655.66 1767.38 1569.58 4948.65 
10 BDK 1741.73 1987.15 1384.60 3406.55 1362.62 2049.42 
AVG  1697.78 2820.88 1744.18 2852.02 1548.01 3055.11 





















Study 2 Serum Myoglobin Concentration (ng/ml) 
CHO 
Subject # Initials Pre Ex-End R120 Win 
1 JB 18.29 49.45 77.81 75.53 
2 DGL 33.97 37.39 63.12 64.32 
3 JSW 46.66 78.42 65.53 62.72 
4 JLM 47.76 57.99 82.30 89.80 
5 JWB 41.92 36.28 70.27 61.97 
6 HMZ 33.34 35.62 76.17 53.52 
7 BTI 13.17 23.51 41.61 33.70 
8 ASD 14.53 48.34 45.28 61.61 
9 JFC 20.35 23.48 47.10 60.63 
10 BDK 25.43 25.60 36.33 37.88 
AVG  29.54 41.61 60.55 60.17 
SE  4.13 5.50 5.27 5.15 
      
CHO/LAA 
Subject # Initials Pre Ex-End R120 Win 
1 JB 36.23 62.80 105.50 86.79 
2 DGL 33.97 40.89 85.37 68.79 
3 JSW 39.84 62.32 83.61 53.76 
4 JLM 56.28 40.78 43.37 56.74 
5 JWB 29.79 27.55 39.58 32.04 
6 HMZ 22.51 20.65 31.72 30.75 
7 BTI 7.59 26.18 156.10 106.51 
8 ASD 40.91 37.60 41.92 35.30 
9 JFC 12.99 13.74 19.57 19.57 
10 BDK 24.31 32.94 83.64 58.99 
AVG  30.44 36.55 69.04 54.92 
SE  4.52 5.13 13.21 8.58 
      
CHO/HAA 
Subject # Initials Pre Ex-End R120 Win 
1 JB 25.86 62.18 254.52 220.79 
2 DGL 30.95 30.62 38.09 49.24 
3 JSW 19.36 33.10 61.39 50.24 
4 JLM 35.33 42.32 49.24 51.11 
5 JWB 25.65 24.39 43.93 41.58 
6 HMZ 17.57 23.14 20.96 39.91 
7 BTI 22.06 43.24 53.29 38.72 
8 ASD 24.39 35.95 36.94 33.34 
9 JFC 12.24 30.98 213.55 168.21 
10 BDK 20.47 20.47 45.93 29.08 
AVG  23.39 34.64 81.78 72.22 






Study 2 Muscle Glycogen Concentration (µmol/g wet muscle) 
  CHO  CHO/LAA  CHO/HAA 
Subject # Initials Pre Post Difference  Pre Post Difference  Pre Post Difference 
1 JB 26.41 38.44 12.03  17.33 32.80 15.46  13.68 26.22 12.55 
2 DGL 10.87 38.50 27.63  6.13 21.51 15.39  10.35 33.01 22.66 
3 JSW 50.79 75.84 25.05  48.84 65.71 16.87  35.68 52.55 16.86 
4 JLM 49.12 68.44 19.32  56.29 68.83 12.53  73.86 80.90 7.04 
5 JWB 12.54 32.48 19.94  36.13 52.93 16.80  21.71 39.63 17.92 
6 HMZ 14.04 37.57 23.53  33.82 60.24 26.42  29.70 45.57 15.87 
7 BTI 17.87 41.46 23.59  30.81 54.39 23.58  26.59 53.38 26.79 
8 ASD 18.49 42.08 23.59  27.06 37.50 10.45  32.38 40.87 8.49 
9 JFC 28.32 50.68 22.36  48.71 62.85 14.14  8.97 25.16 16.20 
10 BDK 34.78 52.78 18.00  30.07 59.70 29.64  32.12 41.86 9.74 
AVG  26.32 47.83 21.50  33.52 51.65 18.13  28.50 43.92 15.41 
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